[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, a synonym for Acrokeratosis paraneoplastica is Bazex's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. A synonym for Acrokeratosis paraneoplastica is Bazex's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "A synonym for Acrokeratosis paraneoplastica is Bazex's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome is similar to Sotos syndrome in that both are characterized by childhood overgrowth, advanced bone age, and developmental delay. However, Weaver syndrome has its own distinctive facial gestalt, which sets it apart from Sotos syndrome. Additionally, recent studies have shown that intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome, with a minority of cases having large deletions of the NSD1 gene. Weaver syndrome is also associated with NSD1 mutations, but these are typically found in a smaller proportion of cases compared to Sotos syndrome. Therefore, while Weaver syndrome shares some similarities with Sotos syndrome, it has distinct differences in terms of its facial appearance and genetic causes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Both Weaver syndrome and Sotos syndrome are characterized by childhood overgrowth, advanced bone age, and developmental delay.\n2. Weaver syndrome has distinctive facial features that set it apart from Sotos syndrome.\n3. Intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome.\n4. Large deletions of the NSD1 gene are a cause of Sotos syndrome but in a minority of cases.\n5. Weaver syndrome is associated with NSD1 mutations, but in a smaller proportion of cases than Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Both Weaver syndrome and Sotos syndrome are characterized by childhood overgrowth, advanced bone age, and developmental delay.",
      "Weaver syndrome has distinctive facial features that set it apart from Sotos syndrome.",
      "Intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome.",
      "Large deletions of the NSD1 gene are a cause of Sotos syndrome but in a minority of cases.",
      "Weaver syndrome is associated with NSD1 mutations, but in a smaller proportion of cases than Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Weaver syndrome is associated with mutations in the EZH2 gene, not the NSD1 gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of JASPAR database are:\n1. JASPAR Release 1 (2004): This was the first release of the JASPAR database, which contained a collection of transcription factor binding site profiles for 12 organisms, including humans.\n2. JASPAR Release 2 (2006): This release expanded the database to include profiles for an additional 10 organisms, bringing the total number of organisms covered to 22.\n3. JASPAR Release 3 (2010): This release introduced a new format for the binding site profiles, which improved the accuracy and efficiency of the data. Additionally, the database was expanded to include profiles for an additional 15 organisms, bringing the total number of organisms covered to 37.\n4. JASPAR Release 4 (2013): This release introduced a new web interface for browsing and searching the database, as well as a suite of programming tools for genome-wide and comparative genomic analysis of regulatory regions.\n5. JASPAR Release 5 (2016): This release expanded the database to include profiles for an additional 10 organisms, bringing the total number of organisms covered to 47.\n6. JASPAR Release 6 (2019): This release introduced a new format for the binding site profiles, which improved the accuracy and efficiency of the data. Additionally, the database was expanded to include profiles for an additional 15 organisms, bringing the total number of organisms covered to 62.\nIt is important to note that the JASPAR database is continuously updated and new releases are made available as new data becomes available.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Database Release 1 was in 2004 with transcription factor binding site profiles for 12 organisms.\n2. JASPAR Database Release 2 was in 2006 and included profiles for an additional 10 organisms.\n3. JASPAR Database Release 3 was in 2010, it updated the format for binding site profiles and expanded to include profiles for 15 additional organisms.\n4. JASPAR Database Release 4 was in 2013 and introduced a new web interface and suite of programming tools.\n5. JASPAR Database Release 5 was in 2016 and added profiles for 10 additional organisms.\n6. JASPAR Database Release 6 was in 2019, updated the binding site profile format, and included profiles for 15 more organisms.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Database Release 1 was in 2004 with transcription factor binding site profiles for 12 organisms.",
      "JASPAR Database Release 2 was in 2006 and included profiles for an additional 10 organisms.",
      "JASPAR Database Release 3 was in 2010, it updated the format for binding site profiles and expanded to include profiles for 15 additional organisms.",
      "JASPAR Database Release 4 was in 2013 and introduced a new web interface and suite of programming tools.",
      "JASPAR Database Release 5 was in 2016 and added profiles for 10 additional organisms.",
      "JASPAR Database Release 6 was in 2019, updated the binding site profile format, and included profiles for 15 more organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n6. UNKNOWN\n\nThe reason for the \"UNKNOWN\" responses is that while the first statement regarding the initial release of the JASPAR database in 2004 can be confirmed through historical records related to the database's inception, the subsequent releases' details provided in statements 2 through 6 require specific information about the database's release history that is not common knowledge and not provided in the passage. Therefore, without additional context or access to historical records of the JASPAR database releases, the truth of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the viral KP4 protein is to down-regulate major histocompatibility complex (MHC) class I surface expression by increasing the rate of endocytosis. The K3 protein of a human tumor-inducing herpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), accelerates the endocytosis of MHC class I molecules, redirects them to the trans-Golgi network (TGN), and targets them to the lysosomal compartment. The N-terminal zinc finger motif and the central sorting motif are involved in triggering internalization of MHC class I molecules, while the C-terminal diacidic cluster region is engaged in targeting MHC class I molecules to the lysosomal compartment. These actions of K3 ensure viral escape from host immune effector recognition.",
    "llama-2-7b-chat-hf_fact_raw": "1. The function of the viral KP4 protein is to down-regulate major histocompatibility complex (MHC) class I surface expression.\n2. The KP4 protein increases the rate of endocytosis of MHC class I molecules.\n3. The K3 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) redirects MHC class I molecules to the trans-Golgi network (TGN).\n4. The K3 protein targets MHC class I molecules to the lysosomal compartment.\n5. The N-terminal zinc finger motif and the central sorting motif of the K3 protein are involved in the internalization of MHC class I molecules.",
    "llama-2-7b-chat-hf_fact": [
      "The function of the viral KP4 protein is to down-regulate major histocompatibility complex (MHC) class I surface expression.",
      "The KP4 protein increases the rate of endocytosis of MHC class I molecules.",
      "The K3 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) redirects MHC class I molecules to the trans-Golgi network (TGN).",
      "The K3 protein targets MHC class I molecules to the lysosomal compartment.",
      "The N-terminal zinc finger motif and the central sorting motif of the K3 protein are involved in the internalization of MHC class I molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific literature or context provided for the KP4 protein, it is not possible to determine the accuracy of this statement.\n2. UNKNOWN: Without additional context or references, the specific function of the KP4 protein on endocytosis of MHC class I molecules cannot be validated.\n3. TRUE: This statement is consistent with known research. The K3 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is known to redirect MHC class I molecules to the trans-Golgi network, thereby evading the immune response.\n4. FALSE [correction]: It's the K5 protein, not the K3 protein, of Kaposi's sarcoma-associated herpesvirus (KSHV) that is known to target MHC class I molecules for lysosomal degradation.\n5. TRUE: This statement is accurate as the N-terminal zinc finger motif and the central sorting motif of the K3 protein are indeed key domains for the downregulation of MHC class I molecules by mediating their internalization and rerouting.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, DITPA is a thyroid hormone analog that has been used in experimental and clinical studies. It is an analog of thyroid hormone (TH) that enters cells independently of the TH transporter, monocarboxylate transporter 8 (MCT8), and has thyromimetic action. In this study, DITPA was given to Mct8-deficient (Mct8KO) mice to determine its effect on thyroid tests in serum and metabolism. The results showed that administration of DITPA brought serum T3 levels and metabolic parameters to levels observed in untreated wild-type (Wt) animals, and ameliorated the hypermetabolism in liver and muscles, but did not fully ameliorate the brain hypothyroidism. Therefore, DITPA is suitable for the treatment of the hypermetabolism in patients with MCT8 deficiency, as suggested in limited preliminary human trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA enters cells independently of the thyroid hormone transporter, monocarboxylate transporter 8 (MCT8).\n3. In a study, DITPA was administered to Mct8-deficient (Mct8KO) mice.\n4. The administration of DITPA to Mct8KO mice resulted in serum T3 levels and metabolic parameters similar to those observed in untreated wild-type animals.\n5. Preliminary human trials suggest DITPA may be suitable for treating hypermetabolism in patients with MCT8 deficiency.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA enters cells independently of the thyroid hormone transporter, monocarboxylate transporter 8 (MCT8).",
      "In a study, DITPA was administered to Mct8-deficient (Mct8KO) mice.",
      "The administration of DITPA to Mct8KO mice resulted in serum T3 levels and metabolic parameters similar to those observed in untreated wild-type animals.",
      "Preliminary human trials suggest DITPA may be suitable for treating hypermetabolism in patients with MCT8 deficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The administration of DITPA to Mct8KO mice resulted in improvements of serum T3 levels and metabolic parameters, which suggests effectiveness in the absence of the MCT8 transporter, but they may not be identical to untreated wild-type animals.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the COUGER tool is likely a device used for sharpening dental instruments, specifically tartar scrapers, curettes, excavators, and elevators. The article emphasizes the importance of sharp instruments in providing quality and efficient dental care, and the COUGER tool is likely a tool used to maintain the sharpness of these instruments.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects. The study suggests that pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects against neuroinfection induced by subsequent inoculation with either Langat virus or TBE virus. This implies that the use of a live vaccine against TBE in individuals with immunity defects is dangerous and could potentially lead to affection of the central nervous system.\nTherefore, the answer to the user's question is that there are no drugs available to treat TBE in individuals with immunity defects, and the use of a live vaccine against TBE in such individuals is not recommended due to the risk of adverse effects on the central nervous system.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects.\n2. Pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects from neuroinfection induced by subsequent inoculation with Langat virus or TBE virus.\n3. Use of a live vaccine against TBE in individuals with immunity defects is dangerous.\n4. A live vaccine against TBE in individuals with immunity defects could potentially lead to affection of the central nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "There are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects.",
      "Pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects from neuroinfection induced by subsequent inoculation with Langat virus or TBE virus.",
      "Use of a live vaccine against TBE in individuals with immunity defects is dangerous.",
      "A live vaccine against TBE in individuals with immunity defects could potentially lead to affection of the central nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There are no specific antiviral drugs available to treat tick-borne encephalitis; treatment is supportive.\n2. UNKNOWN: Without specific information from the context, it is unclear whether pre-treatment with an inactivated vaccine against TBE protects mice with immunity defects from neuroinfection.\n3. TRUE: Generally, live vaccines are considered dangerous for individuals with immune system deficiencies due to the risk of vaccine-induced disease.\n4. TRUE: Since live vaccines contain weakened forms of the virus, there is a risk that individuals with immune deficiencies could develop an infection, potentially affecting the central nervous system.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Genome Browser Database that is available for DNA shape annotations is the University of California Santa Cruz (UCSC) Genome Browser Database. This database is an up-to-date source for genome sequence data integrated with a large collection of related annotations, and it is optimized for fast interactive performance with the web-based UCSC Genome Browser. The annotations for a given genome are displayed in the browser as a series of tracks aligned with the genomic sequence, and the data can also be viewed in a text-based tabular format or downloaded as tab-delimited flat files. The Genome Browser Database, browsing tools, and downloadable data files can all be found on the UCSC Genome Bioinformatics website.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UCSC Genome Browser Database provides DNA shape annotations.\n2. The database integrates genome sequence data with related annotations.\n3. It offers a web-based UCSC Genome Browser for fast interactive performance.\n4. Annotations are displayed as a series of tracks aligned with the genomic sequence.\n5. The Genome Browser Database and tools can be accessed on the UCSC Genome Bioinformatics website.",
    "llama-2-7b-chat-hf_fact": [
      "The UCSC Genome Browser Database provides DNA shape annotations.",
      "The database integrates genome sequence data with related annotations.",
      "It offers a web-based UCSC Genome Browser for fast interactive performance.",
      "Annotations are displayed as a series of tracks aligned with the genomic sequence.",
      "The Genome Browser Database and tools can be accessed on the UCSC Genome Bioinformatics website."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the syndromes associated with mutations in the EZH2 gene are:\n1. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN): Mutations in the EZH2 gene are frequently observed in patients with MDS/MPN, occurring in approximately 10-13% of cases.\n2. Myelodysplastic syndrome (MDS): EZH2 mutations are specifically identified in MDS-derived cells, indicating that these mutations play a role in the development of this disease.\n3. Myeloproliferative neoplasms (MPN): EZH2 mutations are also observed in MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.\nIt is important to note that the study only analyzed a cohort of 41 patients with EZH2 mutations, and further research is needed to confirm these findings and identify additional syndromes associated with EZH2 mutations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with myelodysplastic/myeloproliferative neoplasms (MDS/MPN).\n2. Approximately 10-13% of MDS/MPN cases have mutations in the EZH2 gene.\n3. EZH2 mutations are identified in cells derived from myelodysplastic syndrome (MDS).\n4. Mutations in the EZH2 gene are observed in myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.\n5. The report or study referenced analyzed a cohort of 41 patients with EZH2 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with myelodysplastic/myeloproliferative neoplasms (MDS/MPN).",
      "Approximately 10-13% of MDS/MPN cases have mutations in the EZH2 gene.",
      "EZH2 mutations are identified in cells derived from myelodysplastic syndrome (MDS).",
      "Mutations in the EZH2 gene are observed in myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.",
      "The report or study referenced analyzed a cohort of 41 patients with EZH2 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Mutations in the EZH2 (Enhancer of Zeste Homolog 2) gene have been associated with various types of cancers, including myelodysplastic/myeloproliferative neoplasms.\n2. FALSE [correction]: The exact percentage of MDS/MPN cases with mutations in the EZH2 gene can vary, and without specific reference data provided, an accurate percentage cannot be confirmed. The statement contains a precise range (10-13%), which may be true in some studies but not universally; therefore, without a specific reference, the accuracy of these figures cannot be validated.\n3. TRUE: EZH2 mutations have indeed been identified in cells derived from myelodysplastic syndrome (MDS).\n4. TRUE: Mutations in the EZH2 gene have also been observed in myeloproliferative neoplasms (MPN), including conditions such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.\n5. UNKNOWN: The statement regarding an analyzed cohort of 41 patients with EZH2 mutations cannot be confirmed as true or false without access to the specific report or study referenced.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Human pregnancy zone protein (PZP): As mentioned in the document, PZP forms dimeric/tetrameric species with a molecular weight of 360/720 kDa. The binding of proteinases to PZP leads to a transition to a new conformational state.\n2. Alpha-2 macroglobulin (A2M): While not directly mentioned in the document, A2M is a human protein that also undergoes a dimer-to-tetramer transition. A2M is related to PZP and shares some structural features with it.\nIt is important to note that the document focuses on the conformational changes of PZP and its derivatives, and does not provide information on the dimer-to-tetramer transition of other human proteins. Therefore, this list may not be exhaustive, and other human proteins may also undergo similar conformational changes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Human pregnancy zone protein (PZP) can form dimeric or tetrameric species with molecular weights of 360 and 720 kDa, respectively.\n2. The binding of proteinases to PZP can lead to a conformational state transition.\n3. Alpha-2 macroglobulin (A2M) is a human protein that undergoes a dimer-to-tetramer transition.\n4. Alpha-2 macroglobulin (A2M) shares some structural features with PZP.",
    "llama-2-7b-chat-hf_fact": [
      "Human pregnancy zone protein (PZP) can form dimeric or tetrameric species with molecular weights of 360 and 720 kDa, respectively.",
      "The binding of proteinases to PZP can lead to a conformational state transition.",
      "Alpha-2 macroglobulin (A2M) is a human protein that undergoes a dimer-to-tetramer transition.",
      "Alpha-2 macroglobulin (A2M) shares some structural features with PZP."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Alpha-2 macroglobulin (A2M) is a human protein that is already a tetramer; it does not undergo a dimer-to-tetramer transition. A2M is itself a large protease inhibitor like PZP and can trap proteases in its structure.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is SERCA1a. The document mentions that SERCA1a, an isoform from skeletal muscle, has been structurally characterized in great detail, and that direct information about the conformation of PLN in complex with SERCA has been limited. However, the document goes on to state that chemical-shift assignments in all domains of a mutant form of PLN (AFA-PLN) provide direct evidence for the presence of two terminal alpha helices connected by a linker region of reduced structural order that differs from previous findings on free PLN. Additionally, the document mentions that ssNMR experiments on wild-type PLN (WT-PLN) show no significant difference in binding compared to AFA-PLN and do not support the coexistence of a significantly populated dynamic state of PLN after formation of the PLN/SERCA complex. These findings suggest that SERCA1a is the protein that interacts with PLN and is also an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. SERCA1a has been found to interact with phospholamban (PLN).\n2. SERCA1a is an anti-apoptotic protein.\n3. SERCA1a, an isoform from skeletal muscle, has been structurally characterized in great detail.\n4. Chemical-shift assignments in all domains of a mutant form of phospholamban (AFA-PLN) suggest the presence of two terminal alpha helices connected by a linker region.\n5. Solid-state NMR (ssNMR) experiments on wild-type PLN (WT-PLN) indicate no significant difference in binding to SERCA compared to AFA-PLN.",
    "llama-2-7b-chat-hf_fact": [
      "SERCA1a has been found to interact with phospholamban (PLN).",
      "SERCA1a is an anti-apoptotic protein.",
      "SERCA1a, an isoform from skeletal muscle, has been structurally characterized in great detail.",
      "Chemical-shift assignments in all domains of a mutant form of phospholamban (AFA-PLN) suggest the presence of two terminal alpha helices connected by a linker region.",
      "Solid-state NMR (ssNMR) experiments on wild-type PLN (WT-PLN) indicate no significant difference in binding to SERCA compared to AFA-PLN."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: SERCA1a, a type of sarco/endoplasmic reticulum Ca2+-ATPase, indeed has been shown to interact with phospholamban. Phospholamban regulates the activity of SERCA pumps, including SERCA1a, by acting as an inhibitor.\n2. FALSE [correction]: SERCA1a is not primarily known as an anti-apoptotic protein. It is a calcium pump found in the sarcoplasmic reticulum of skeletal muscle cells and is involved in muscle contraction by transferring Ca2+ from the cytosol to the sarcoplasmic reticulum. SERCA2a, however, has been implicated to have anti-apoptotic properties in cardiac muscles.\n3. TRUE: SERCA1a has indeed been characterized in great detail structurally. The high-resolution structures of SERCA1a have been instrumental in understanding the mechanism of calcium transport in muscle cells.\n4. UNKNOWN: The statement regarding chemical-shift assignments and the structural details of a mutant form of phospholamban (AFA-PLN) is very specific and would require access to the particular study or studies that detail these findings to determine its accuracy.\n5. UNKNOWN: Similar to statement 4, the results of solid-state NMR (ssNMR) experiments regarding the binding of wild-type PLN (WT-PLN) compared to AFA-PLN to SERCA would require access to specific scientific studies or data to verify.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no evidence to suggest that vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials. In fact, the USPSTF found adequate evidence to bound the harms of vitamin D supplementation as no greater than small to moderate, and recommended against vitamin D supplementation to prevent falls in community-dwelling adults 65 years or older. Therefore, it is unlikely that taking vitamin D supplements will reduce the risk of falls in older people.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitamin D supplementation has not been shown to reduce the incidence of falls in older people in clinical trials.\n2. The US Preventive Services Task Force (USPSTF) found the harms of vitamin D supplementation to be no greater than small to moderate.\n3. The USPSTF recommended against vitamin D supplementation to prevent falls in community-dwelling adults aged 65 years or older.",
    "llama-2-7b-chat-hf_fact": [
      "Vitamin D supplementation has not been shown to reduce the incidence of falls in older people in clinical trials.",
      "The US Preventive Services Task Force (USPSTF) found the harms of vitamin D supplementation to be no greater than small to moderate.",
      "The USPSTF recommended against vitamin D supplementation to prevent falls in community-dwelling adults aged 65 years or older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vitamin D supplementation has been shown to reduce the incidence of falls in some older people in clinical trials, but the evidence is mixed and context-dependent.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is an association between Jarid2 and miR-155 in Th17 cells. The study found that microRNA-155 (Mir-155) expression is elevated in CD4(+) T cells during experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. The study also showed that Mir-155(-/-) mice had a delayed course and reduced severity of disease and less inflammation in the central nervous system (CNS). Additionally, the study found that the T cell-intrinsic function of Mir-155(-/-) was demonstrated by the resistance of Mir-155(-/-) CD4(+) T cell-repleted Rag-1(-/-) mice to EAE. Furthermore, the study found that anti-Mir-155 treatment reduced clinical severity of EAE when given before and after the appearance of clinical symptoms. These findings suggest that Mir-155 confers susceptibility to EAE by affecting inflammatory T cell responses, and identify Mir-155 as a new target for therapeutic intervention in multiple sclerosis.\nTherefore, based on the information provided in the document, there is an association between Jarid2 and miR-155 in Th17 cells, as Mir-155 is involved in the regulation of inflammatory T cell responses and is a new target for therapeutic intervention in multiple sclerosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is an association between Jarid2 and miR-155 in Th17 cells.\n2. MicroRNA-155 (Mir-155) expression is elevated in CD4(+) T cells during experimental autoimmune encephalomyelitis (EAE).\n3. Mir-155(-/-) mice exhibit a delayed course and reduced severity of EAE and less inflammation in the central nervous system.\n4. The T cell-intrinsic function of Mir-155(-/-) was demonstrated in Mir-155(-/-) CD4(+) T cell-repleted Rag-1(-/-) mice, which showed resistance to EAE.\n5. Anti-Mir-155 treatment reduced the clinical severity of EAE when administered before and after the onset of clinical symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "There is an association between Jarid2 and miR-155 in Th17 cells.",
      "MicroRNA-155 (Mir-155) expression is elevated in CD4(+) T cells during experimental autoimmune encephalomyelitis (EAE).",
      "Mir-155(-/-) mice exhibit a delayed course and reduced severity of EAE and less inflammation in the central nervous system.",
      "The T cell-intrinsic function of Mir-155(-/-) was demonstrated in Mir-155(-/-) CD4(+) T cell-repleted Rag-1(-/-) mice, which showed resistance to EAE.",
      "Anti-Mir-155 treatment reduced the clinical severity of EAE when administered before and after the onset of clinical symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: JARID2 has been reported to augment the pro-inflammatory function of Th17 cells by stabilizing the expression of miR-155.\n2. TRUE: During experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, miR-155 expression has been found to be upregulated in CD4(+) T cells.\n3. TRUE: Mir-155 knockout (Mir-155(-/-)) mice have been shown to exhibit a less severe and delayed progression of EAE, along with reduced inflammation in the central nervous system.\n4. TRUE: The T cell-intrinsic function of miR-155 was demonstrated by a study where repletion of Mir-155(-/-) CD4(+) T cells into Rag1(-/-) mice resulted in resistance to EAE, indicating the critical role of miR-155 in T cells during the disease.\n5. TRUE: Therapeutic targeting of miR-155 with anti-miR-155 treatment has been shown to alleviate the clinical severity of EAE when administered either prophylactically (before disease onset) or therapeutically (after the onset of clinical symptoms).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human hoxD cluster contains approximately 21 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human hoxD cluster contains approximately 21 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human hoxD cluster contains approximately 21 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains approximately 9 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the phosphorylation consensus motifs for Casein Kinase 1 (CK1):\n1. Ser/Thr-Pro-Ser/Thr (STPS) sequence: This is a common consensus motif for CK1, as it is recognized by the enzyme in various studies.\n2. Ser/Thr-Pro-Gly-Ser/Thr (STPG) sequence: This motif is also recognized by CK1 and is found in various cytosolic proteins.\n3. Ser/Thr-Pro-Gly-Ala-Ser/Thr (STPGS) sequence: This motif is similar to the STPG motif but with an additional alanine residue.\n4. Ser/Thr-Pro-Gly-Pro-Ser/Thr (STPPPS) sequence: This motif is recognized by CK1 and is found in proteins involved in various cellular processes.\n5. Ser/Thr-Pro-Gly-Asp-Ser/Thr (STPDPS) sequence: This motif is recognized by CK1 and is found in proteins involved in cell signaling pathways.\nIt is important to note that these consensus motifs are not exclusive to CK1 and may be recognized by other protein kinases as well. Additionally, the specificity of CK1 for these motifs can vary depending on the context and the specific protein substrate.",
    "llama-2-7b-chat-hf_fact_raw": "1. The phosphorylation consensus motif Ser/Thr-Pro-Ser/Thr (STPS) is recognized by Casein Kinase 1 (CK1).\n2. Ser/Thr-Pro-Gly-Ser/Thr (STPG) is a phosphorylation consensus motif recognized by CK1.\n3. Ser/Thr-Pro-Gly-Ala-Ser/Thr (STPGS) is another phosphorylation consensus motif for CK1.\n4. The sequence Ser/Thr-Pro-Gly-Pro-Ser/Thr (STPPPS) is a consensus motif recognized by CK1.\n5. The motif Ser/Thr-Pro-Gly-Asp-Ser/Thr (STPDPS) is recognized by CK1 in cell signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "The phosphorylation consensus motif Ser/Thr-Pro-Ser/Thr (STPS) is recognized by Casein Kinase 1 (CK1).",
      "Ser/Thr-Pro-Gly-Ser/Thr (STPG) is a phosphorylation consensus motif recognized by CK1.",
      "Ser/Thr-Pro-Gly-Ala-Ser/Thr (STPGS) is another phosphorylation consensus motif for CK1.",
      "The sequence Ser/Thr-Pro-Gly-Pro-Ser/Thr (STPPPS) is a consensus motif recognized by CK1.",
      "The motif Ser/Thr-Pro-Gly-Asp-Ser/Thr (STPDPS) is recognized by CK1 in cell signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The consensus phosphorylation motif for Casein Kinase 1 (CK1) is generally defined as Ser/Thr-X-X-Ser/Thr (where \"X\" can be any amino acid), not Ser/Thr-Pro-Ser/Thr (STPS).\n2. TRUE: Ser/Thr-Pro-Gly-Ser/Thr (STPG) corresponds with the general consensus motif recognized by CK1, as the \"-Gly-\" acts as the variable amino acid (X) in the motif.\n3. UNKNOWN: While \"STPGS\" incorporates Ser/Thr-Pro-Gly which fits within CK1's motif, the addition of Ala-Ala-Ser/Thr is not standard and without additional context, its recognition by CK1 cannot be definitively confirmed or denied.\n4. FALSE [correction]: CK1 generally recognizes motifs with a Ser/Thr at the +1 or +3 position relative to another Ser/Thr, and Ser/Thr-Pro-Gly-Pro-Ser/Thr (STPPPS) has two Pro residues in between Ser/Thr which does not match the recognized CK1 consensus sequence.\n5. UNKNOWN: While the motif contains the basic elements of STP (Ser/Thr-Pro), the specific sequence Ser/Thr-Pro-Gly-Asp-Ser/Thr (STPDPS) is not a well-known consensus motif for CK1 and additional context or experimental evidence would be required to verify its recognition by CK1 in cell signaling pathways.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Aspartase: The gene encodes a protein with a molecular weight of 52,224 composed of 477 amino acid residues. The amino acid sequence of the protein predicted from the nucleotide sequence was consistent with those of the NH2- and COOH-terminal regions and also with the amino acid composition of the purified aspartase determined previously.\n2. AspH: The gene encodes a protein with a molecular weight of 52,224 composed of 477 amino acid residues. The amino acid sequence of the protein predicted from the nucleotide sequence was consistent with those of the NH2- and COOH-terminal regions and also with the amino acid composition of the purified aspartase determined previously.\n3. Asp-beta-hydroxylase: The gene encodes a protein that hydroxylates aspartate residues in the synthesis of amino acid neurotransmitters such as dopamine, norepinephrine, and serotonin.\n4. Aspartate aminotransferase: The gene encodes an enzyme that catalyzes the transfer of an amino group from aspartate to alpha-ketoglutarate, forming oxaloacetate and glutamate.\n5. Aspartate semialdehyde dehydrogenase: The gene encodes an enzyme that catalyzes the oxidation of aspartate semialdehyde to oxaloacetate.\nIt is important to note that the above information is based on the provided document and may not be applicable to other sources or organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes a protein named aspartase with a molecular weight of 52,224, which is composed of 477 amino acid residues.\n2. The gene also encodes a protein named AspH with an identical molecular weight and number of amino acid residues as aspartase.\n3. The ASPH gene encodes a protein known as Asp-beta-hydroxylase, which is involved in the hydroxylation of aspartate residues.\n4. The gene is responsible for encoding aspartate aminotransferase, an enzyme that facilitates the transfer of an amino group from aspartate to alpha-ketoglutarate.\n5. Another enzyme encoded by the ASPH gene is aspartate semialdehyde dehydrogenase, which catalyzes the oxidation of aspartate semialdehyde to oxaloacetate.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes a protein named aspartase with a molecular weight of 52,224, which is composed of 477 amino acid residues.",
      "The gene also encodes a protein named AspH with an identical molecular weight and number of amino acid residues as aspartase.",
      "The ASPH gene encodes a protein known as Asp-beta-hydroxylase, which is involved in the hydroxylation of aspartate residues.",
      "The gene is responsible for encoding aspartate aminotransferase, an enzyme that facilitates the transfer of an amino group from aspartate to alpha-ketoglutarate.",
      "Another enzyme encoded by the ASPH gene is aspartate semialdehyde dehydrogenase, which catalyzes the oxidation of aspartate semialdehyde to oxaloacetate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The given details such as molecular weight and the number of amino acid residues cannot be verified without specific scientific data or resources.\n2. FALSE [correction]: While the protein AspH might be encoded by the ASPH gene, it is unlikely that \"aspartase\" and \"AspH\" with identical molecular weights and amino acid counts would be separate proteins. It could be that \"aspartase\" is not the correct name or there is a misunderstanding.\n3. TRUE: AspH (Aspartyl/asparaginyl beta-hydroxylase) is indeed involved in the hydroxylation of aspartate residues among other functions, suggesting the statement is true.\n4. FALSE [correction]: Aspartate aminotransferase is encoded by the GOT1 and GOT2 genes, not the ASPH gene.\n5. FALSE [correction]: Aspartate semialdehyde dehydrogenase is encoded by the gene ALDH1L1/ALDH1L2, not the ASPH gene.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, empagliflozin was FDA approved in 2014. According to the document, the safety and tolerability of empagliflozin/linagliptin were evaluated in two Phase III studies, and the results were published in 2014. Therefore, the FDA approval of empagliflozin must have occurred around 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.\n2. The safety and tolerability of empagliflozin/linagliptin were evaluated in two Phase III studies.\n3. The results of the two Phase III studies evaluating empagliflozin/linagliptin were published in 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014.",
      "The safety and tolerability of empagliflozin/linagliptin were evaluated in two Phase III studies.",
      "The results of the two Phase III studies evaluating empagliflozin/linagliptin were published in 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the loss of the protein Lon1 in the plant Arabidopsis leads to significant changes in the steady-state proteome and its response to senescence. Specifically, the study found that the loss of Lon1 in the mutant strain sgr1 leads to:\n1. Differences in plastid soluble protein abundance: The study found that sgr1 has lower abundance of plastid soluble proteins compared to the wild-type plant Col-0.\n2. Changes in membrane located machinery for photosystem II (PSII): The study found that sgr1 has lower abundance of PSII components compared to Col-0.\n3. Differences in Calvin cycle components: The study found that sgr1 has lower abundance of Calvin cycle components compared to Col-0.\n4. Changes in redox control of the stromal compartment and ammonia assimilation: The study found that sgr1 has different levels of proteins involved in redox control of the stromal compartment and ammonia assimilation compared to Col-0.\n5. Enhanced loss of oxygen evolving complex (OEC) subunits from PSII: The study found that sgr1 has higher stability of PSII repair proteins compared to Col-0.\n6. Retention of light-harvesting chlorophyll-a/b binding protein (LHCB2) during later stages of senescence: The study found that sgr1 retains LHCB2 during the later stages of senescence, while Col-0 does not.\nOverall, the study suggests that the loss of Lon1 in Arabidopsis leads to significant changes in the steady-state proteome and its response to senescence, indicating that sgr1 is in fact significantly different from wild-type plants both before and during leaf senescence.",
    "llama-2-7b-chat-hf_fact_raw": "1. The loss of the protein Lon1 in the mutant strain sgr1 of Arabidopsis results in a lower abundance of plastid soluble proteins compared to the wild-type Col-0.\n2. sgr1 exhibits a lower abundance of photosystem II (PSII) components compared to wild-type Col-0.\n3. In the mutant strain sgr1, there is a lower abundance of Calvin cycle components compared to the wild-type Col-0.\n4. Proteins involved in redox control of the stromal compartment and ammonia assimilation have different levels in sgr1 compared to Col-0.\n5. The sgr1 strain retains light-harvesting chlorophyll-a/b binding protein (LHCB2) during the later stages of senescence, unlike Col-0.",
    "llama-2-7b-chat-hf_fact": [
      "The loss of the protein Lon1 in the mutant strain sgr1 of Arabidopsis results in a lower abundance of plastid soluble proteins compared to the wild-type Col-0.",
      "sgr1 exhibits a lower abundance of photosystem II (PSII) components compared to wild-type Col-0.",
      "In the mutant strain sgr1, there is a lower abundance of Calvin cycle components compared to the wild-type Col-0.",
      "Proteins involved in redox control of the stromal compartment and ammonia assimilation have different levels in sgr1 compared to Col-0.",
      "The sgr1 strain retains light-harvesting chlorophyll-a/b binding protein (LHCB2) during the later stages of senescence, unlike Col-0."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage or research data related to the statements about the Arabidopsis mutant strain sgr1 and the wild-type Col-0, it is not possible to accurately validate these claims. They are referring to highly specialized biological research findings that would need to be referenced directly to confirm their veracity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, a linker histone does not exist in the yeast genome. The document specifically states that the chromatin of Schizosaccharomyces pombe, a type of yeast, lacks linker histones. This suggests that the histones in yeast chromatin are more divergent in their sequences and have fewer lysine residues compared to higher eukaryotes, which may affect the way chromatin folds and interacts with other proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone does not exist in the yeast genome according to the provided document.\n2. The chromatin of Schizosaccharomyces pombe, a type of yeast, lacks linker histones.\n3. Yeast histones are more divergent in their sequences compared to those in higher eukaryotes.\n4. Yeast histones have fewer lysine residues than those in higher eukaryotes.\n5. The divergence in yeast histone sequences and the lower number of lysine residues may affect chromatin folding and interactions with other proteins.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone does not exist in the yeast genome according to the provided document.",
      "The chromatin of Schizosaccharomyces pombe, a type of yeast, lacks linker histones.",
      "Yeast histones are more divergent in their sequences compared to those in higher eukaryotes.",
      "Yeast histones have fewer lysine residues than those in higher eukaryotes.",
      "The divergence in yeast histone sequences and the lower number of lysine residues may affect chromatin folding and interactions with other proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without the provided document, it's not possible to confirm or deny the existence of a linker histone in the yeast genome.\n2. UNKNOWN: Again, the absence of linker histones in Schizosaccharomyces pombe cannot be assessed without the specific document reference.\n3. UNKNOWN: Determining the divergence of yeast histone sequences as compared to those in higher eukaryotes cannot be done without additional scientific evidence or references.\n4. UNKNOWN: The statement about yeast histones having fewer lysine residues than those in higher eukaryotes requires a specific reference or dataset for confirmation.\n5. UNKNOWN: The effects of divergence in histone sequences and the number of lysine residues on chromatin folding and protein interactions are based on biological research. Without the document or studies to back up this claim, we cannot assess its validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is evidence to suggest that tomato juice may lower cholesterol levels. The study found that hamsters fed 3% or 9% tomato paste containing 0.2% cholesterol had reduced rates of serum total cholesterol (TC) and low density lipoprotein (LDL) levels, compared to the cholesterol group. Additionally, the study found that the plasma malondialdehyde (MDA) levels significantly decreased after ingestion of tomato paste for 8 weeks, indicating the potent antioxidant activity of the tomato paste.\nThe study also found that the increased activities of superoxide dismutases (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) supported the antioxidant effects of the tomato paste. Two dimension-gel electrophoresis (2-DE) analysis revealed that carbonic anhydrase III (CAIII) and adenylate kinase 2 (AK2) may be two important regulators involved in the anti-lipid and antioxidant effects of tomato paste.\nOverall, the study suggests that tomato juice may have a positive impact on cholesterol levels by reducing the levels of LDL cholesterol and increasing the levels of HDL cholesterol, as well as by providing antioxidant effects. However, it is important to note that this study was conducted on hamsters, and more research is needed to confirm these findings in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study found that hamsters fed tomato paste containing 0.2% cholesterol showed reduced rates of serum total cholesterol (TC) and low density lipoprotein (LDL) levels.\n2. The study reported a significant decrease in plasma malondialdehyde (MDA) levels after 8 weeks of ingesting tomato paste.\n3. The activities of superoxide dismutases (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) were increased in the study, suggesting antioxidant effects of tomato paste.\n4. Two dimension-gel electrophoresis (2-DE) analysis in the study indicated that carbonic anhydrase III (CAIII) and adenylate kinase 2 (AK2) may be involved in the anti-lipid and antioxidant effects of tomato paste.\n5. The study suggests that tomato juice might reduce LDL cholesterol levels and increase HDL cholesterol levels.",
    "llama-2-7b-chat-hf_fact": [
      "A study found that hamsters fed tomato paste containing 0.2% cholesterol showed reduced rates of serum total cholesterol (TC) and low density lipoprotein (LDL) levels.",
      "The study reported a significant decrease in plasma malondialdehyde (MDA) levels after 8 weeks of ingesting tomato paste.",
      "The activities of superoxide dismutases (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) were increased in the study, suggesting antioxidant effects of tomato paste.",
      "Two dimension-gel electrophoresis (2-DE) analysis in the study indicated that carbonic anhydrase III (CAIII) and adenylate kinase 2 (AK2) may be involved in the anti-lipid and antioxidant effects of tomato paste.",
      "The study suggests that tomato juice might reduce LDL cholesterol levels and increase HDL cholesterol levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The study suggests that tomato paste, not tomato juice, might have an effect on cholesterol levels, specifically mentioning the reduction of LDL cholesterol levels. The effect on HDL cholesterol levels is not specified in the given statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that Hsp70 and Hsp110 can affect mRNA stability in endocervical cells exposed to semen. The study found that exposure to semen induces the expression of Hsp70 mRNA in endocervical cells, as detected by RT-PCR and ELISA. This suggests that Hsp70 may play a role in protecting mRNA from degradation in response to stress caused by semen exposure.\nAdditionally, the study found that HSP70 mRNA was detected in 52.8% of endocervical cell samples obtained from women at varying times after sexual intercourse, with the highest percentage of samples expressing HSP70 mRNA observed at 11 hours after exposure. This suggests that the induction of HSP70 mRNA may be a rapid response to semen exposure.\nIt is worth noting that the study did not directly measure the stability of mRNA in response to semen exposure, but rather detected the expression of HSP70 mRNA as an indicator of mRNA stability. However, given the known role of HSP70 in protecting mRNA from degradation, it is likely that the induction of HSP70 mRNA in response to semen exposure is related to the stability of mRNA in endocervical cells.\nIn summary, the study suggests that exposure to semen induces the expression of HSP70 mRNA in endocervical cells, which may be related to the stability of mRNA in these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 can affect mRNA stability in endocervical cells exposed to semen.\n2. The study found that exposure to semen induces the expression of Hsp70 mRNA in endocervical cells.\n3. The expression of Hsp70 mRNA in endocervical cells was detected using RT-PCR and ELISA techniques.\n4. HSP70 mRNA was detected in 52.8% of endocervical cell samples from women at varying times after sexual intercourse.\n5. The highest percentage of samples expressing HSP70 mRNA was observed at 11 hours after semen exposure.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 can affect mRNA stability in endocervical cells exposed to semen.",
      "The study found that exposure to semen induces the expression of Hsp70 mRNA in endocervical cells.",
      "The expression of Hsp70 mRNA in endocervical cells was detected using RT-PCR and ELISA techniques.",
      "HSP70 mRNA was detected in 52.8% of endocervical cell samples from women at varying times after sexual intercourse.",
      "The highest percentage of samples expressing HSP70 mRNA was observed at 11 hours after semen exposure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement involves specific scientific information that is not common knowledge and cannot be confirmed without access to the relevant study or scientific literature.\n2. UNKNOWN: Similar to the first statement, without the specific study or literature, the claim about the induction of Hsp70 mRNA expression in endocervical cells is impossible to confirm or refute.\n3. FALSE [correction]: The techniques mentioned, RT-PCR (reverse transcription-polymerase chain reaction) and ELISA (enzyme-linked immunosorbent assay), are used for different purposes; RT-PCR is used to detect mRNA expression while ELISA is typically used for protein detection. The statement incorrectly suggests that both techniques were used for Hsp70 mRNA detection.\n4. UNKNOWN: This is a specific research finding that requires access to the study data to verify its accuracy.\n5. UNKNOWN: As with the previous statements pertaining to the research findings, without access to the specific study, information about the timing of the highest percentage of samples expressing HSP70 mRNA cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, both type I and type III iodothyronine deiodinases are present in skeletal muscle in the chicken. The study found immunopositive signals in the hepatocytes in general and a zonal distribution for both enzymes in the liver, with maximum protein expression in a thin layer of hepatocytes bordering the blood veins. Additionally, both deiodinases were co-expressed in the kidney, specifically in the tubular epithelial cells and with the transitional epithelium, and the inner longitudinal and outer circular muscle layers of the ureter. No staining could be detected in the lamina propria or in the fat tissue surrounding the ureter.\nTherefore, based on the information provided in the document, it can be concluded that both type I and type III iodothyronine deiodinases are present in skeletal muscle in the chicken.",
    "llama-2-7b-chat-hf_fact_raw": "1. Both type I and type III iodothyronine deiodinases are present in chicken skeletal muscle.\n2. The study detected immunopositive signals for both type I and type III deiodinases in liver hepatocytes.\n3. Protein expression for both deiodinases showed a zonal distribution in the liver, with maximum expression near the blood veins.\n4. In the kidney, both type I and type III deiodinases were co-expressed in the tubular epithelial cells.\n5. Type I and type III iodothyronine deiodinases were also found in the inner longitudinal and outer circular muscle layers of the ureter in chickens.",
    "llama-2-7b-chat-hf_fact": [
      "Both type I and type III iodothyronine deiodinases are present in chicken skeletal muscle.",
      "The study detected immunopositive signals for both type I and type III deiodinases in liver hepatocytes.",
      "Protein expression for both deiodinases showed a zonal distribution in the liver, with maximum expression near the blood veins.",
      "In the kidney, both type I and type III deiodinases were co-expressed in the tubular epithelial cells.",
      "Type I and type III iodothyronine deiodinases were also found in the inner longitudinal and outer circular muscle layers of the ureter in chickens."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Protein expression for both deiodinases showed a zonal distribution in the liver, with maximum expression near the central veins, also known as hepatic veins, not blood veins. The term \"blood veins\" is nonspecific, whereas hepatic central veins are a specific anatomical structure in the liver lobule where zonal expression of proteins often occurs.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are inflammatory caspase proteins:\n1. Caspase-1\n2. Caspase-4\n3. Nucleotide-binding domain leucine-rich repeat containing, Pyrin domain containing-3 (NLRP3)\n4. Absent in melanoma 2 (AIM2)\nCaspase-1 is activated in different innate immune complexes called inflammasomes, and its activity regulates unconventional protein secretion of many other proteins involved in inflammation and repair. Caspase-4 is a poorly characterized member of the caspase family that is involved in endoplasmic reticulum stress-induced apoptosis, but its gene is located on the same locus as the caspase-1 gene, which raises the possibility that caspase-4 plays a role in inflammation. Expression of caspase-4 is required for UVB-induced activation of proIL-1 and for unconventional protein secretion by skin-derived keratinocytes, and caspase-4 physically interacts with its central molecule caspase-1.\nTherefore, based on the information provided in the document, caspase-1 and caspase-4 are two inflammatory caspase proteins that play important roles in inflammation and innate immunity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is an inflammatory caspase protein.\n2. Caspase-4 is an inflammatory caspase protein.\n3. NLRP3 (Nucleotide-binding domain leucine-rich repeat containing, Pyrin domain containing-3) is an inflammatory caspase protein.\n4. AIM2 (Absent in melanoma 2) is an inflammatory caspase protein.\n5. Caspase-4 is located on the same locus as the caspase-1 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is an inflammatory caspase protein.",
      "Caspase-4 is an inflammatory caspase protein.",
      "NLRP3 (Nucleotide-binding domain leucine-rich repeat containing, Pyrin domain containing-3) is an inflammatory caspase protein.",
      "AIM2 (Absent in melanoma 2) is an inflammatory caspase protein.",
      "Caspase-4 is located on the same locus as the caspase-1 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: NLRP3 is not a caspase protein; it is an inflammasome sensor that can activate inflammatory caspases.\n4. FALSE [correction]: AIM2 is not a caspase protein; it is an inflammasome sensor that recognizes double-stranded DNA.\n5. FALSE [correction]: Caspase-4 is not located on the same locus as the caspase-1 gene; they are located on different chromosomes. Caspase-1 is on chromosome 11, while caspase-4 is located on chromosome 11q22.2-22.3.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is a potential link between the Aurora B kinase and the polycomb protein Ring1B.\nAurora B kinase is a key protein that regulates many events during cell mitosis, including chromosome segregation and cytokinesis. The document reports the discovery of a novel splicing variant of Aurora C, named Aurora C-SV, which encodes a 290-amino-acid protein that is expressed at high levels in human testis. The in vitro kinase assay shows that Aurora C-SV phosphorylates MBP, and its T179A mutant loses the kinase activity. During cell mitosis, Aurora C-SV-EGFP associates with chromosomes in prophase and metaphase, and then transfers to the central spindle midzone and the cortex where the contract ring forms during the transition from anaphase to telophase. It remains in the midbody during cytokinesis.\nRing1B is a polycomb protein that is involved in the regulation of chromatin modification and gene expression during cell differentiation and development. It has been shown to play a role in the maintenance of pluripotency in embryonic stem cells and the regulation of cell fate decisions in various tissues.\nGiven the role of Aurora C-SV in chromosome segregation and cytokinesis, it is possible that Ring1B may interact with Aurora C-SV to regulate these processes. For example, Ring1B may modulate the activity of Aurora C-SV during cell division, or the two proteins may work together to ensure proper chromosome segregation and cytokinesis. However, further research is needed to confirm this hypothesis.\nIn summary, while there is no direct evidence linking Aurora B kinase and Ring1B, the discovery of Aurora C-SV and its role in cell mitosis suggests that there may be a connection between these two proteins that warrants further investigation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase regulates events during cell mitosis, including chromosome segregation and cytokinesis.\n2. A novel splicing variant of Aurora C, named Aurora C-SV, encodes a 290-amino-acid protein highly expressed in human testis.\n3. Aurora C-SV phosphorylates MBP, and a T179A mutant of Aurora C-SV loses kinase activity.\n4. During cell mitosis, Aurora C-SV associates with chromosomes in prophase and metaphase, and then relocates to the central spindle midzone and the cortex during the transition from anaphase to telophase.\n5. Ring1B is involved in the maintenance of pluripotency in embryonic stem cells and the regulation of cell fate decisions in various tissues.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase regulates events during cell mitosis, including chromosome segregation and cytokinesis.",
      "A novel splicing variant of Aurora C, named Aurora C-SV, encodes a 290-amino-acid protein highly expressed in human testis.",
      "Aurora C-SV phosphorylates MBP, and a T179A mutant of Aurora C-SV loses kinase activity.",
      "During cell mitosis, Aurora C-SV associates with chromosomes in prophase and metaphase, and then relocates to the central spindle midzone and the cortex during the transition from anaphase to telophase.",
      "Ring1B is involved in the maintenance of pluripotency in embryonic stem cells and the regulation of cell fate decisions in various tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Aurora B kinase is indeed known for its role in regulating several events during cell mitosis, including chromosome alignment, segregation, and cytokinesis.\n2. UNKNOWN: Without specific literature or passage referring to the novel splicing variant named Aurora C-SV as described, this statement remains unclear and cannot be verified as true or false.\n3. UNKNOWN: The specificity of the phosphorylation of MBP (myelin basic protein, I presume) by Aurora C-SV and the effect of the T179A mutation cannot be assessed without additional context or reference to scientific literature verifying the claim.\n4. UNKNOWN: The localization and dynamics of Aurora C-SV during cell mitosis, as described, would require verification from a scientific study or paper, which is not provided here.\n5. UNKNOWN: Ring1B, better known as RING1B (part of the Polycomb group of proteins), is involved in chromatin remodeling and gene repression, which could be related to pluripotency maintenance and cell fate decisions. However, without specific context or references, it's not possible to assert the correctness of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor Splice Sites:\n1. GU-rich sequences: The most common non-canonical sequence motif at donor splice sites is a GU-rich sequence, which is found in 40% of the EST-confirmed donor sites.\n2. AG-rich sequences: AG-rich sequences are the second most common non-canonical sequence motif at donor splice sites, found in 23% of the EST-confirmed donor sites.\n3. G/C-rich sequences: G/C-rich sequences are found in 17% of the EST-confirmed donor sites.\nAcceptor Splice Sites:\n1. GT-rich sequences: The most common non-canonical sequence motif at acceptor splice sites is a GT-rich sequence, which is found in 43% of the EST-confirmed acceptor sites.\n2. AG-rich sequences: AG-rich sequences are the second most common non-canonical sequence motif at acceptor splice sites, found in 21% of the EST-confirmed acceptor sites.\n3. G/C-rich sequences: G/C-rich sequences are found in 16% of the EST-confirmed acceptor sites.\nIt is important to note that these non-canonical sequence motifs are not exclusive to vertebrates and can be found in other organisms as well. Additionally, the frequency of these motifs may vary depending on the species and the specific tissue or cell type being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are the most common non-canonical sequence motif at donor splice sites in vertebrates, found in 40% of the EST-confirmed donor sites.\n2. AG-rich sequences are the second most common non-canonical sequence motif at donor splice sites in vertebrates, found in 23% of the EST-confirmed donor sites.\n3. G/C-rich sequences are found in 17% of the EST-confirmed donor sites for vertebrates.\n4. GT-rich sequences are the most common non-canonical sequence motif at acceptor splice sites in vertebrates, found in 43% of the EST-confirmed acceptor sites.\n5. AG-rich sequences are the second most common non-canonical sequence motif at acceptor splice sites in vertebrates, found in 21% of the EST-confirmed acceptor sites.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are the most common non-canonical sequence motif at donor splice sites in vertebrates, found in 40% of the EST-confirmed donor sites.",
      "AG-rich sequences are the second most common non-canonical sequence motif at donor splice sites in vertebrates, found in 23% of the EST-confirmed donor sites.",
      "G/C-rich sequences are found in 17% of the EST-confirmed donor sites for vertebrates.",
      "GT-rich sequences are the most common non-canonical sequence motif at acceptor splice sites in vertebrates, found in 43% of the EST-confirmed acceptor sites.",
      "AG-rich sequences are the second most common non-canonical sequence motif at acceptor splice sites in vertebrates, found in 21% of the EST-confirmed acceptor sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GT-rich sequences, not GU-rich sequences, are the most common canonical sequence motif at donor splice sites in vertebrates. The GT dinucleotide is part of the consensus sequence at the 5' end of introns (donor sites).\n2. UNKNOWN: Without specific and reliable data on non-canonical sequence motifs for donor splice sites, it's not possible to confirm the prevalence of AG-rich sequences at these sites.\n3. UNKNOWN: Similarly, without specific information or sources, it's not possible to validate the percentage of G/C-rich sequences found at EST-confirmed donor sites for vertebrates.\n4. FALSE [correction]: It is the canonical sequence AG, not GT-rich sequences, that is most common at the 3' end of introns (acceptor sites) in vertebrates. The AG dinucleotide is part of the consensus sequence at the acceptor splice site.\n5. UNKNOWN: Without specific data, it's not possible to confirm the prevalence of AG-rich sequences at acceptor splice sites, although AG is part of the consensus splice site sequence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the event that results in the acetylation of S6K1 is the treatment of wild type ubiquitin with [1-(13)C]acetyl salicylate or [1,1'-(13)C(2)]acetic anhydride. The study demonstrates that His-68 makes a positive contribution to the rate of acetylation of Lys-6 by labeled aspirin, and a pair of transient resonances is observed after treatment of wild type ubiquitin with the labeled acetic anhydride but not upon treatment of the H68N mutant. These resonances are assigned to the acetylated His-68 residue. The loss of intensity of the acetylhistidine resonances is accompanied by an increase in intensity of the acetyl-Lys-6 peak, supporting the existence of a transacetylation process between the acetylhistidine 68 and lysine 6 residues located on the protein surface. Therefore, this study provides evidence for the acetylation of S6K1 on the protein surface.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 occurs when wild type ubiquitin is treated with [1-(13)C]acetyl salicylate or [1,1'-(13)C(2)]acetic anhydride.\n2. The study suggests that His-68 contributes positively to the acetylation rate of Lys-6 by labeled aspirin.\n3. A pair of transient resonances is observed after treating wild type ubiquitin with the labeled acetic anhydride but not with the H68N mutant.\n4. The resonances mentioned are attributed to the acetylated His-68 residue.\n5. The study indicates a transacetylation process between the acetylhistidine 68 and lysine 6 residues.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 occurs when wild type ubiquitin is treated with [1-(13)C]acetyl salicylate or [1,1'-(13)C(2)]acetic anhydride.",
      "The study suggests that His-68 contributes positively to the acetylation rate of Lys-6 by labeled aspirin.",
      "A pair of transient resonances is observed after treating wild type ubiquitin with the labeled acetic anhydride but not with the H68N mutant.",
      "The resonances mentioned are attributed to the acetylated His-68 residue.",
      "The study indicates a transacetylation process between the acetylhistidine 68 and lysine 6 residues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: If the resonances disappear with the H68N mutant, then it would suggest they are attributed to the acetylation of His-68 rather than indicating acetylation occurred at that residue.\n5. UNKNOWN\n\nThe true or false nature of the technical statements about the acetylation of S6K1 and the specifics of a study cannot be determined with certainty without the relevant scientific context or data. Corrections provided are based on common scientific inference, but further context would be needed to confirm the accuracy of the statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the cause of episodic ataxia type 6 in the boy described is a previously unreported variant in the SCN2A gene. This variant is predicted to be protein-damaging and is considered to be de novo, meaning it was not inherited from the boy's parents. The variant was identified through whole exome sequencing, which found a genetic mutation in the SCN2A gene that was not present in the boy's parents. This suggests that the mutation occurred spontaneously in the boy, leading to the development of episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 in the described case is caused by a variant in the SCN2A gene.\n2. The variant in the SCN2A gene is predicted to be protein-damaging.\n3. The variant is considered to be de novo, not inherited from the boy's parents.\n4. Whole exome sequencing was used to identify the genetic mutation in the SCN2A gene.\n5. The mutation in the SCN2A gene was not present in the boy's parents, indicating it occurred spontaneously.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 in the described case is caused by a variant in the SCN2A gene.",
      "The variant in the SCN2A gene is predicted to be protein-damaging.",
      "The variant is considered to be de novo, not inherited from the boy's parents.",
      "Whole exome sequencing was used to identify the genetic mutation in the SCN2A gene.",
      "The mutation in the SCN2A gene was not present in the boy's parents, indicating it occurred spontaneously."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the passage providing the specific details about the case, inheritance pattern, the prediction about protein damage, and the method used for identifying the mutation, it's not possible to accurately determine the truthfulness of these statements. Each of these statements would require specific genetic and medical information related to the case described to be assessed accurately.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, chromomethylases are not specifically mentioned as being present in animal genomes. The document focuses on the genome evolution of chromalveolates, which are a group of organisms that include both animal and plant pathogens, as well as free-living organisms such as ciliates and algae. While the document does mention that many gene families show species-specific expansions in the plant pathogen oomycete Phytophthora, it does not provide information on the presence or absence of chromomethylases in animal genomes. Therefore, I must assume that chromomethylases are not present in animal genomes based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. PRODORIC: This package provides a comprehensive collection of TFBSs with corresponding position weight matrices, as well as a pattern matching tool (Virtual Footprint) for the prediction of genome-based regulons and analysis of individual promoter regions.\n2. GBPro: This package offers an interactive genome browser for visualizing TFBS search results in their genomic context and linking to gene and regulator-specific information in PRODORIC.\n3. TFBS: This package provides a set of tools for the analysis of TFBSs, including the prediction of TFBSs, the analysis of their binding affinity, and the identification of potential regulatory elements.\n4. RegulonDB: This package provides a comprehensive collection of TFBSs and their corresponding regulatory elements, as well as tools for the prediction of TFBSs and the analysis of their binding affinity.\n5. TRANSFAC: This package provides a comprehensive collection of TFBSs and their corresponding regulatory elements, as well as tools for the prediction of TFBSs and the analysis of their binding affinity.\n6. ChIPseek: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and their binding affinity.\n7. HISAT2: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and their binding affinity.\n8. STAR: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and their binding affinity.\nThese packages can be used for a variety of TFBS analysis tasks, including the prediction of TFBSs, the analysis of their binding affinity, and the identification of potential regulatory elements.",
    "llama-2-7b-chat-hf_fact_raw": "1. PRODORIC is a package in R/Bioconductor that includes a collection of transcription factor binding sites and provides a pattern matching tool called Virtual Footprint.\n2. GBPro is an R/Bioconductor package that features an interactive genome browser for visualizing transcription factor binding site search results.\n3. The TFBS package in R/Bioconductor offers tools for the prediction, analysis of binding affinity, and identification of regulatory elements related to transcription factor binding sites.\n4. RegulonDB is a package available in R/Bioconductor that contains a collection of transcription factor binding sites, corresponding regulatory elements, and tools for prediction and analysis.\n5. The TRANSFAC package in R/Bioconductor includes a comprehensive collection of transcription factor binding sites and regulatory elements, along with predictive and analytical tools.",
    "llama-2-7b-chat-hf_fact": [
      "PRODORIC is a package in R/Bioconductor that includes a collection of transcription factor binding sites and provides a pattern matching tool called Virtual Footprint.",
      "GBPro is an R/Bioconductor package that features an interactive genome browser for visualizing transcription factor binding site search results.",
      "The TFBS package in R/Bioconductor offers tools for the prediction, analysis of binding affinity, and identification of regulatory elements related to transcription factor binding sites.",
      "RegulonDB is a package available in R/Bioconductor that contains a collection of transcription factor binding sites, corresponding regulatory elements, and tools for prediction and analysis.",
      "The TRANSFAC package in R/Bioconductor includes a comprehensive collection of transcription factor binding sites and regulatory elements, along with predictive and analytical tools."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: PRODORIC is indeed a database in R/Bioconductor that includes a collection of transcription factor binding sites and provides a tool for pattern matching which can be referred to as Virtual Footprint.\n2. UNKNOWN: While there is no R/Bioconductor package named GBPro, it cannot be confirmed if the statement is referring to an actual package's functionalities under a different name, or it is a hypothetical package. Therefore, without specific information on a package called GBPro, the statement's veracity is unknown.\n3. TRUE: The TFBS (Transcription Factor Binding Sites) package in R/Bioconductor is designed for the manipulation and analysis of transcription factor binding sites and includes tools that could be used for prediction, binding affinity analysis, and identification of regulatory elements.\n4. FALSE [correction]: RegulonDB is not a package in R/Bioconductor; it is a database containing information about transcription factors, binding sites, and regulatory elements in Escherichia coli (E. coli). However, there could be tools to access RegulonDB data from R/Bioconductor, but RegulonDB itself is not a package in that platform.\n5. FALSE [correction]: TRANSFAC is not available as a package in R/Bioconductor. Instead, TRANSFAC is a proprietary database managed by BIOBASE Corporation that provides data on transcription factors, their binding sites, and regulated genes. Access to TRANSFAC data within R could potentially be through different tools or packages that interface with the database, but TRANSFAC itself is not an R/Bioconductor package.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some clinical trials for the prevention of sarcopenia:\n1. \"Exercise and Sarcopenia: A Systematic Review and Meta-Analysis\" by Maria J. Rodriguez-Maez et al. (2018) - This study found that exercise interventions were effective in improving muscle mass, muscle strength, and physical performance in older adults. The study included 10 studies with a total of 1,010 participants.\n2. \"Resistance Training and Sarcopenia: A Systematic Review and Meta-Analysis\" by J. A. Skelton et al. (2018) - This study found that resistance training was effective in improving muscle mass and muscle strength in older adults. The study included 14 studies with a total of 1,311 participants.\n3. \"Effects of Exercise on Sarcopenia: A Systematic Review and Meta-Analysis\" by H. Y. Lee et al. (2019) - This study found that exercise interventions were effective in improving muscle mass, muscle strength, and physical performance in older adults. The study included 17 studies with a total of 1,530 participants.\n4. \"The Effects of Physical Activity on Sarcopenia: A Systematic Review\" by A. M. C. S. Sousa et al. (2019) - This study found that physical activity was effective in improving muscle mass, muscle strength, and physical performance in older adults. The study included 12 studies with a total of 1,053 participants.\n5. \"Exercise and Sarcopenia Prevention: A Systematic Review and Meta-Analysis\" by J. M. H. M. van der Velde et al. (2020) - This study found that exercise interventions were effective in preventing sarcopenia in older adults. The study included 15 studies with a total of 1,277 participants.\nIt is important to note that these studies had varying results and limitations, and more research is needed to confirm the effectiveness of these interventions. Additionally, the measurement of sarcopen",
    "llama-2-7b-chat-hf_fact_raw": "1. The study \"Exercise and Sarcopenia: A Systematic Review and Meta-Analysis\" by Maria J. Rodriguez-Maez et al. was conducted in 2018 and included 10 studies with a total of 1,010 participants.\n2. \"Resistance Training and Sarcopenia: A Systematic Review and Meta-Analysis\" by J. A. Skelton et al., conducted in 2018, included 14 studies with a total of 1,311 participants.\n3. H. Y. Lee et al.'s study \"Effects of Exercise on Sarcopenia: A Systematic Review and Meta-Analysis\" included 17 studies with a total of 1,530 participants and was published in 2019.\n4. The study \"The Effects of Physical Activity on Sarcopenia: A Systematic Review\" by A. M. C. S. Sousa et al. was conducted in 2019 and comprised a review of 12 studies with 1,053 participants.\n5. In the study \"Exercise and Sarcopenia Prevention: A Systematic Review and Meta-Analysis\" conducted by J. M. H. M. van der Velde et al. in 2020, there were 15 studies with a total of 1,277 participants.",
    "llama-2-7b-chat-hf_fact": [
      "The study \"Exercise and Sarcopenia: A Systematic Review and Meta-Analysis\" by Maria J. Rodriguez-Maez et al. was conducted in 2018 and included 10 studies with a total of 1,010 participants.",
      "\"Resistance Training and Sarcopenia: A Systematic Review and Meta-Analysis\" by J. A. Skelton et al., conducted in 2018, included 14 studies with a total of 1,311 participants.",
      "H. Y. Lee et al.'s study \"Effects of Exercise on Sarcopenia: A Systematic Review and Meta-Analysis\" included 17 studies with a total of 1,530 participants and was published in 2019.",
      "The study \"The Effects of Physical Activity on Sarcopenia: A Systematic Review\" by A. M. C. S. Sousa et al. was conducted in 2019 and comprised a review of 12 studies with 1,053 participants.",
      "In the study \"Exercise and Sarcopenia Prevention: A Systematic Review and Meta-Analysis\" conducted by J. M. H. M. van der Velde et al. in 2020, there were 15 studies with a total of 1,277 participants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout the actual research articles or reliable sources to verify the exact titles, authors, publication years, and the number of studies and participants involved in each specified study, it's impossible to confirm the accuracy of the given details. Therefore, the truth value of these statements cannot be determined from the provided information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\". It is a publicly available database that stores information on all membrane proteins that contain MoRFs, including their secondary structure, position in the protein topology, and interactions with partners. The database is hosted on a MySQL database with a user-friendly web interface and includes a Jmol applet for visualization of the structures. The aim of the database is to provide valuable information related to disorder-based protein-protein interactions in membrane proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB.\"\n2. mpMoRFsDB is a publicly available database.\n3. This database contains information on the secondary structure, position in protein topology, and interactions with partners of membrane proteins containing MoRFs.\n4. The database is hosted on a MySQL platform.\n5. mpMoRFsDB includes a Jmol applet for the visualization of structures.",
    "llama-2-7b-chat-hf_fact": [
      "The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB.\"",
      "mpMoRFsDB is a publicly available database.",
      "This database contains information on the secondary structure, position in protein topology, and interactions with partners of membrane proteins containing MoRFs.",
      "The database is hosted on a MySQL platform.",
      "mpMoRFsDB includes a Jmol applet for the visualization of structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the content and nature of mpMoRFsDB seem correct given the name suggests a focus on molecular recognition features in membrane proteins. However, without specific information on what technology the database is using (such as MySQL) or precise details about its features (such as the inclusion of a Jmol applet), the veracity of statements 4 and 5 can't be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, rivaroxaban is metabolized in the kidneys through the uptake of the drug by organic anion transporters, primarily OAT3. The study found that rivaroxaban inhibited hOAT3 with an IC50 value of >5 M, indicating significant inhibition of this transporter. Additionally, specific uptake of rivaroxaban was observed only in human and mouse OAT3-expressing cells, suggesting that OAT3 plays a critical role in the kidney uptake of rivaroxaban.\nThe study also showed that a defect in mOat3 reduced the kidney-to-plasma concentration ratio of rivaroxaban by 38% in mice, indicating that OAT3 is involved in the renal clearance of rivaroxaban. Furthermore, probenecid treatment reduced the kidney-to-plasma concentration ratio of rivaroxaban in rats by 73%, suggesting that OAT3 is also involved in the renal uptake of rivaroxaban.\nOverall, the study suggests that OAT3 is the primary transporter responsible for the renal uptake of rivaroxaban, and that the uptake of rivaroxaban by OAT3 in the kidneys plays a critical role in the drug's pharmacokinetics and drug-drug interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys through the uptake by organic anion transporters, particularly OAT3.\n2. Rivaroxaban inhibited human OAT3 (hOAT3) with an IC50 value of greater than 5 M, indicating significant inhibition.\n3. Specific uptake of rivaroxaban was observed in human and mouse OAT3-expressing cells.\n4. A defect in mouse Oat3 reduced the kidney-to-plasma concentration ratio of rivaroxaban by 38% in mice.\n5. Treatment with probenecid reduced the kidney-to-plasma concentration ratio of rivaroxaban in rats by 73%.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys through the uptake by organic anion transporters, particularly OAT3.",
      "Rivaroxaban inhibited human OAT3 (hOAT3) with an IC50 value of greater than 5 M, indicating significant inhibition.",
      "Specific uptake of rivaroxaban was observed in human and mouse OAT3-expressing cells.",
      "A defect in mouse Oat3 reduced the kidney-to-plasma concentration ratio of rivaroxaban by 38% in mice.",
      "Treatment with probenecid reduced the kidney-to-plasma concentration ratio of rivaroxaban in rats by 73%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver by CYP3A4/5 and CYP2J2 enzymes, and also undergoes renal excretion but is not known to be specifically metabolized in the kidneys through uptake by organic anion transporters (OATs).\n2. FALSE [correction]: An IC50 value greater than 5 M typically indicates weak inhibition, not significant inhibition. Without additional context, the strength of inhibition can't be accurately determined.\n3. UNKNOWN: Without specific research findings or data, it is unclear whether specific uptake of rivaroxaban was observed in human and mouse OAT3-expressing cells.\n4. UNKNOWN: Without specific research findings or data, it is unclear whether a defect in mouse Oat3 reduced the kidney-to-plasma concentration ratio of rivaroxaban by 38% in mice.\n5. UNKNOWN: Without specific research findings or data, it is unclear whether treatment with probenecid reduced the kidney-to-plasma concentration ratio of rivaroxaban in rats by 73%.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genes that are regulated by TRalpha2 in the heart are:\n1. Cardiac troponin T gene: The LacZ expression pattern throughout development was very similar to that of the endogenous cardiac troponin T gene.\n2. Chloramphenicol acetyltransferase (CAT) gene: When the MEF2 core sequence and its flanking TCTGG site were mutated (Mut5), CAT transgene expression was significantly decreased in the heart, and ectopic expression of the transgene was also observed.\nIt is important to note that these findings are based on the analysis of transgenic mice carrying the rat cardiac troponin T proximal promoter fused to a LacZ or CAT reporter gene, and may not necessarily apply to other genes or tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is involved in the regulation of the cardiac troponin T gene in the heart.\n2. Mutations in the MEF2 core sequence and its flanking TCTGG site can lead to decreased expression of the chloramphenicol acetyltransferase (CAT) gene in the heart.\n3. The LacZ expression pattern throughout development was similar to the expression pattern of the endogenous cardiac troponin T gene.\n4. Ectopic expression of the chloramphenicol acetyltransferase (CAT) gene was observed when the MEF2 core sequence and its flanking TCTGG site were mutated.\n5. The findings mentioned are based on the analysis of transgenic mice carrying the rat cardiac troponin T proximal promoter fused to a LacZ or CAT reporter gene.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is involved in the regulation of the cardiac troponin T gene in the heart.",
      "Mutations in the MEF2 core sequence and its flanking TCTGG site can lead to decreased expression of the chloramphenicol acetyltransferase (CAT) gene in the heart.",
      "The LacZ expression pattern throughout development was similar to the expression pattern of the endogenous cardiac troponin T gene.",
      "Ectopic expression of the chloramphenicol acetyltransferase (CAT) gene was observed when the MEF2 core sequence and its flanking TCTGG site were mutated.",
      "The findings mentioned are based on the analysis of transgenic mice carrying the rat cardiac troponin T proximal promoter fused to a LacZ or CAT reporter gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TRalpha2 is a known thyroid hormone receptor that can be involved in the regulation of various genes, including possibly the cardiac troponin T gene in the heart.\n\n2. UNKNOWN: This statement likely refers to a specific experimental study. Whether mutations in the MEF2 core sequence and its adjacent TCTGG site lead to decreased expression of the chloramphenicol acetyltransferase (CAT) gene in the heart would depend on the results of that particular study, which are not provided here.\n\n3. UNKNOWN: This statement refers to experimental results comparing the LacZ expression pattern to the expression pattern of the endogenous cardiac troponin T gene. Without specific data or findings from the mentioned study, its not possible to confirm the accuracy of this statement.\n\n4. UNKNOWN: Like statement 2, this refers to particular experimental findings concerning mutations in the MEF2 core sequence and its flanking TCTGG site affecting the expression of the chloramphenicol acetyltransferase (CAT) gene. The outcome about ectopic expression would depend on those specific experimental results, which are not available within the provided context.\n\n5. UNKNOWN: This statement outlines a method used in a specific study. Assuming the research methodology is accurately reported, it could be considered true, but without access to the actual study or additional context, it is difficult to verify the correctness of this statement regarding the analysis performed on transgenic mice.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the available biomedical question answering systems:\n1. Automatic Biomedical Question Answering System: This system uses machine learning approaches to automatically classify biomedical questions into one of the four categories: yes/no, factoid, list, and summary.\n2. BioASQ Challenge: This is a standard annotated dataset of biomedical questions that can be used to evaluate the performance of biomedical question answering systems.\n3. Handcrafted lexico-syntactic patterns: These are features extracted from biomedical questions using a proposed method that can be used to train machine learning algorithms for biomedical question classification.\n4. Support Vector Machine (SVM): This is a machine learning algorithm that can be used to classify biomedical questions based on handcrafted lexico-syntactic patterns.\n5. Other machine learning algorithms: The document mentions that other machine learning algorithms such as Naive Bayes and Random Forest can also be used for biomedical question classification.\nIt's worth noting that these are just some of the available biomedical question answering systems and methods, and there may be other systems and approaches that have been proposed in the literature.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Automatic Biomedical Question Answering System classifies biomedical questions into four categories: yes/no, factoid, list, and summary.\n2. The BioASQ Challenge provides a standard annotated dataset for evaluating biomedical question answering systems.\n3. Handcrafted lexico-syntactic patterns can be utilized to train machine learning algorithms for classifying biomedical questions.\n4. Support Vector Machine (SVM) is used as a machine learning algorithm for classifying biomedical questions.\n5. Machine learning algorithms such as Naive Bayes and Random Forest are mentioned as methods for biomedical question classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Automatic Biomedical Question Answering System classifies biomedical questions into four categories: yes/no, factoid, list, and summary.",
      "The BioASQ Challenge provides a standard annotated dataset for evaluating biomedical question answering systems.",
      "Handcrafted lexico-syntactic patterns can be utilized to train machine learning algorithms for classifying biomedical questions.",
      "Support Vector Machine (SVM) is used as a machine learning algorithm for classifying biomedical questions.",
      "Machine learning algorithms such as Naive Bayes and Random Forest are mentioned as methods for biomedical question classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Automatic Biomedical Question Answering System, more commonly referred to as BioASQ, classifies biomedical questions into five types: yes/no, factoid, list, summary, and exact answer.\n2. TRUE\n3. TRUE: While the statement does not provide specific details, it is reasonable that handcrafted lexico-syntactic patterns can be used in the process of training machine learning algorithms, as feature engineering is a common practice in machine learning.\n4. TRUE: Support Vector Machine (SVM) can be and is used as a machine learning algorithm for various classification tasks, including biomedical question classification.\n5. TRUE: Machine learning algorithms like Naive Bayes and Random Forest are commonly mentioned and used for classification tasks, including biomedical question classification.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the trancription factor that activates the betalain pathway is NFAT (Nuclear Factor of Activated T Cells). The document mentions that NFATc4 and GATA4 transcription factors are involved in the activation of the CnA(beta) promoter, which is the promoter of the calcineurin-A(beta) gene. This suggests that NFATc4 and GATA4 play a role in regulating the expression of the CnA(beta) gene, and therefore, the betalain pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. NFAT (Nuclear Factor of Activated T Cells) activates the betalain pathway.\n2. NFATc4 and GATA4 transcription factors are involved in the activation of the CnA(beta) promoter.\n3. The CnA(beta) promoter is the promoter of the calcineurin-A(beta) gene.\n4. NFATc4 and GATA4 play a role in regulating the expression of the CnA(beta) gene.\n5. The expression of the CnA(beta) gene is linked to the betalain pathway.",
    "llama-2-7b-chat-hf_fact": [
      "NFAT (Nuclear Factor of Activated T Cells) activates the betalain pathway.",
      "NFATc4 and GATA4 transcription factors are involved in the activation of the CnA(beta) promoter.",
      "The CnA(beta) promoter is the promoter of the calcineurin-A(beta) gene.",
      "NFATc4 and GATA4 play a role in regulating the expression of the CnA(beta) gene.",
      "The expression of the CnA(beta) gene is linked to the betalain pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NFAT (Nuclear Factor of Activated T-Cells) is not known to activate the betalain pathway. The betalain biosynthetic pathway is primarily found in plants, while NFAT is involved in the immune response in animals.\n2. TRUE: NFATc4 and GATA4 are transcription factors known to be involved in the activation of the CnA(beta) promoter, which is a part of the regulatory mechanisms in cardiac muscle cells and other cell types.\n3. TRUE: The CnA(beta) promoter is indeed the promoter of the calcineurin-A(beta) gene, which is a regulatory element controlling the transcription of this gene.\n4. TRUE: NFATc4 and GATA4 are known to play a crucial role in the regulation of the CnA(beta) gene's expression in various tissues including cardiac muscle.\n5. FALSE [correction]: The expression of the CnA(beta) gene is not directly linked to the betalain pathway. The CnA(beta) gene is associated with the calcineurin signaling pathway in animals, whereas the betalain pathway is involved in the production of pigments in plants.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. Titanium dioxide (TiO(2)) enrichment: This technology provides high efficient enrichment with optimum peptide-to-beads ratio, resulting in high selectivity and large sample loading capacity compared to online TiO(2) chromatography.\n2. Strong anion exchange (SAX) fractionation: This technology is used to enrich phosphopeptides from the eluate of TiO(2) enrichment, providing high complementary features and recovering large amounts of multiphosphopeptides.\n3. Strong cation exchange (SCX) fractionation: This technology is used to further enrich phosphopeptides from the SAX fractionations, resulting in high-quality phosphosite identification.\nThe combination of these technologies provides a robust workflow for global phosphoproteome analysis, allowing for the identification of up to 5063 unique phosphosites from a starting material of 4-mg HeLa cell lysate.",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2) enrichment is a technology used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. Titanium dioxide enrichment offers high selectivity and large sample loading capacity.\n3. Strong anion exchange (SAX) fractionation is used after TiO2 enrichment to enrich phosphopeptides.\n4. Strong cation exchange (SCX) fractionation is utilized following SAX fractionation for further enrichment of phosphopeptides.\n5. The combination of these technologies has allowed for the identification of up to 5063 unique phosphosites from a 4-mg HeLa cell lysate.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2) enrichment is a technology used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.",
      "Titanium dioxide enrichment offers high selectivity and large sample loading capacity.",
      "Strong anion exchange (SAX) fractionation is used after TiO2 enrichment to enrich phosphopeptides.",
      "Strong cation exchange (SCX) fractionation is utilized following SAX fractionation for further enrichment of phosphopeptides.",
      "The combination of these technologies has allowed for the identification of up to 5063 unique phosphosites from a 4-mg HeLa cell lysate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Titanium dioxide (TiO2) enrichment is indeed a technique used in phosphoproteomic analyses to selectively enrich phosphorylated peptides.\n2. TRUE - TiO2 enrichment is known for its high selectivity and its ability to handle large sample loads, which is beneficial for proteomics studies.\n3. TRUE - Strong anion exchange (SAX) fractionation is often used after TiO2 enrichment as a way to further purify and enrich phosphopeptides before mass spectrometry analysis.\n4. FALSE [correction]: Strong cation exchange (SCX) fractionation is not typically used after SAX fractionation for further enrichment of phosphopeptides. SCX can be used as an alternative to SAX or before SAX fractionation, but it is not common to use both successively for further enrichment due to their similar ion exchange properties.\n5. UNKNOWN - The statement about the identification of 5063 unique phosphosites from a specific amount of HeLa cell lysate may be accurate, but without a reference to the specific study or experiment, it's difficult to determine the truthfulness of this quantitative claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorder that is rated by the Palmini classification is schizophrenia. The document mentions the finger and palm ridge characteristics of a sample of Italian schizophrenic males, which suggests that the Palmini classification is being used to assess the fingerprints of individuals with schizophrenia.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it is possible that viruses may be involved in the etiology of human subacute thyroiditis. The document mentions that subacute thyroiditis is presumed to be caused by a viral infection, and there have been only two reported cases of familial subacute thyroiditis in the literature. Additionally, the document suggests that transmission of a possible viral infection from an older sister to her younger sister may have caused the same clinical picture in the younger sister three weeks after the older sister's illness. While the information provided is limited, it suggests that viruses may play a role in the development of subacute thyroiditis in genetically predisposed individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is presumed to be caused by a viral infection.\n2. There have been only two reported cases of familial subacute thyroiditis in the literature.\n3. A possible viral infection transmission from an older sister to her younger sister is suggested to have caused the same clinical picture in the younger sister.\n4. The transmission occurred three weeks after the older sister's illness.\n5. Viruses may play a role in the development of subacute thyroiditis in genetically predisposed individuals.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is presumed to be caused by a viral infection.",
      "There have been only two reported cases of familial subacute thyroiditis in the literature.",
      "A possible viral infection transmission from an older sister to her younger sister is suggested to have caused the same clinical picture in the younger sister.",
      "The transmission occurred three weeks after the older sister's illness.",
      "Viruses may play a role in the development of subacute thyroiditis in genetically predisposed individuals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There have been more than two reported cases of familial subacute thyroiditis in the literature.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that STAT3 is not directly involved in the suppression of autophagy by EIF2AK2. The document mentions that activation of the autophagy pathway may be responsible for the apoptosis-inducing effect of statin, but does not mention STAT3 as a regulatory factor in this process.\nThe document does, however, provide evidence that autophagy is involved in the radiosensitizing effects of statin. The authors found that inhibition of the autophagic process using small interfering RNAs (siRNA) targeting Atg7 and/or Atg12 significantly reduced radiosensitivity of PC3 cells. Additionally, the data indicate that activation of the autophagy pathway may be responsible for the apoptosis-inducing effect of statin, and that combined treatment with radiation and autophagic inducer, such as statin, may be synergistic in inducing cell death of PC3 cells.\nTherefore, while STAT3 is not directly involved in the suppression of autophagy by EIF2AK2, the document suggests that autophagy plays a role in the radiosensitizing effects of statin and that the combination of statin and radiation may be synergistic in inducing cell death in PC3 cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is not directly involved in the suppression of autophagy by EIF2AK2 according to the document.\n2. Activation of the autophagy pathway may be responsible for the apoptosis-inducing effect of statin.\n3. Inhibition of the autophagic process using siRNA targeting Atg7 and/or Atg12 reduced radiosensitivity of PC3 cells.\n4. Autophagy is involved in the radiosensitizing effects of statin.\n5. Combined treatment with radiation and an autophagic inducer like statin may be synergistic in inducing cell death of PC3 cells.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is not directly involved in the suppression of autophagy by EIF2AK2 according to the document.",
      "Activation of the autophagy pathway may be responsible for the apoptosis-inducing effect of statin.",
      "Inhibition of the autophagic process using siRNA targeting Atg7 and/or Atg12 reduced radiosensitivity of PC3 cells.",
      "Autophagy is involved in the radiosensitizing effects of statin.",
      "Combined treatment with radiation and an autophagic inducer like statin may be synergistic in inducing cell death of PC3 cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific document and its contents to verify the statements, it's impossible to determine the truthfulness of these technical assertions about molecular biology and cancer treatment effects.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "The Theatre software tool is designed for the integrated analysis of high-dimensional gene expression data, array CGH data, and SNP array data with associated clinical data. It provides interactive visualization capabilities and a comprehensive data manager to organize and analyze these different types of data. The software offers various interactive tools for visualizing and exploring the data, including heatmaps, dendrograms, barcharts, histograms, eventcharts, and a chromosome browser.\nThe Theatre software tool is particularly useful for translational cancer research, where researchers need to analyze large amounts of data from different sources to gain insights into the underlying biology of cancer. The software's ability to integrate and visualize gene expression data, genomic data, and clinical data makes it an ideal tool for identifying patterns and correlations between these different types of data.\nSome of the key features of the Theatre software tool include:\n1. Interactive visualization: The software provides a range of interactive visualization tools, including heatmaps, dendrograms, barcharts, histograms, eventcharts, and a chromosome browser. These tools allow researchers to explore the data in a dynamic and fully linked manner, making it easier to identify patterns and correlations.\n2. Comprehensive data manager: The software includes a comprehensive data manager that allows researchers to organize and analyze different types of data, including gene expression data, genomic data, and clinical data.\n3. Unsupervised data analytics: The Theatre software tool provides unsupervised data analytics capabilities, including clustering, seriation algorithms, and biclustering algorithms. These algorithms can help researchers identify patterns and correlations in the data that may not be immediately apparent.\n4. Exploratory data analysis: The software provides a range of exploratory data analysis tools, including principal component analysis (PCA), hierarchical clustering, and density-based clustering. These tools can help researchers identify patterns and correlations in the data and gain insights into the underlying biology of cancer.\nOverall, the Theatre software tool is a powerful tool for integrating and analyzing high-dimensional gene expression data, array CGH data, and SNP array data with associated clinical data. Its interactive visualization capabilities, comprehensive data manager, and unsupervised data analytics capabilities make it an ideal",
    "llama-2-7b-chat-hf_fact_raw": "1. The Theatre software tool is designed for the integrated analysis of high-dimensional gene expression data, array CGH data, and SNP array data with associated clinical data.\n2. The Theatre software tool provides interactive visualization capabilities, including heatmaps, dendrograms, barcharts, histograms, eventcharts, and a chromosome browser.\n3. It includes a comprehensive data manager that allows researchers to organize and analyze different types of genomic and clinical data.\n4. The software offers unsupervised data analytics capabilities, such as clustering, seriation algorithms, and biclustering algorithms.\n5. The Theatre software tool is particularly useful for translational cancer research for analyzing large amounts of data from different sources.",
    "llama-2-7b-chat-hf_fact": [
      "The Theatre software tool is designed for the integrated analysis of high-dimensional gene expression data, array CGH data, and SNP array data with associated clinical data.",
      "The Theatre software tool provides interactive visualization capabilities, including heatmaps, dendrograms, barcharts, histograms, eventcharts, and a chromosome browser.",
      "It includes a comprehensive data manager that allows researchers to organize and analyze different types of genomic and clinical data.",
      "The software offers unsupervised data analytics capabilities, such as clustering, seriation algorithms, and biclustering algorithms.",
      "The Theatre software tool is particularly useful for translational cancer research for analyzing large amounts of data from different sources."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific details to refute these statements and given that they align with the typical functionality of integrated bioinformatics tools for genomic data analysis, they are presumed to be correct. These capabilities as mentioned are plausible for a comprehensive software platform designed for such purposes and are common features in bioinformatics software tools.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is not considered to be optimal due to its lack of consideration of local context dependencies. The paper suggests that a novel method, Markov pairwise protein sequence alignment (MPPSA), which takes these dependencies into consideration, is superior to the Smith-Waterman algorithm for pairwise protein sequence comparison. Therefore, the execution time (complexity) of the Smith-Waterman algorithm is likely to be higher than that of the MPPSA method.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, FLVCR1 is a member of the atypical MFS transporter family (AMTF1).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the interacting partners of GATA-1 that were discovered through the biotinylation tagging approach are:\n1. Streptavidin: The direct binding of biotinylated GATA-1 to streptavidin in nuclear extracts resulted in the single-step capture of the tagged factor and associated proteins, which were eluted and identified by mass spectrometry.\n2. Other transcription factors: The characterization of several distinct GATA-1 complexes with other transcription factors and chromatin remodeling cofactors, which are involved in activation and repression of gene targets.\n3. Chromatin remodeling cofactors: The characterization of several distinct GATA-1 complexes with other transcription factors and chromatin remodeling cofactors, which are involved in activation and repression of gene targets.\nThese interacting partners were identified through the use of the biotinylation tagging approach, which involves the efficient purification of protein complexes using the very high affinity of the biotin/(strept)avidin system. By fusing a short peptide tag to the N-terminus of GATA-1 and using the BirA biotin ligase to biotinylate the tag, the tagged GATA-1 can be captured and isolated using streptavidin, allowing for the identification of its interacting partners by mass spectrometry.",
    "llama-2-7b-chat-hf_fact_raw": "1. Streptavidin was found to directly bind with biotinylated GATA-1 in nuclear extracts.\n2. The biotinylation tagging approach led to the identification of several distinct GATA-1 protein complexes with other transcription factors.\n3. The biotinylation tagging approach was used to identify chromatin remodeling cofactors that form complexes with GATA-1.\n4. The biotinylation tagging approach uses the high affinity of the biotin/(strept)avidin system to purify protein complexes.\n5. A short peptide tag was fused to the N-terminus of GATA-1, and BirA biotin ligase was used to biotinylate the tag for capturing and isolating GATA-1 using streptavidin.",
    "llama-2-7b-chat-hf_fact": [
      "Streptavidin was found to directly bind with biotinylated GATA-1 in nuclear extracts.",
      "The biotinylation tagging approach led to the identification of several distinct GATA-1 protein complexes with other transcription factors.",
      "The biotinylation tagging approach was used to identify chromatin remodeling cofactors that form complexes with GATA-1.",
      "The biotinylation tagging approach uses the high affinity of the biotin/(strept)avidin system to purify protein complexes.",
      "A short peptide tag was fused to the N-terminus of GATA-1, and BirA biotin ligase was used to biotinylate the tag for capturing and isolating GATA-1 using streptavidin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout specific context and details on the exact methodology used, it is not possible to confirm the precise location of the peptide tag on GATA-1 or the specific use of BirA biotin ligase in this scenario.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, TAF10 interacting with the GATA1 transcription factor is likely to result in the activation of transcription. The document describes TAF10 as a coactivator that functions as a site of protein-protein contact between activators like Sp1 and the TFIID complex. Sp1 is a transcription factor that is known to interact with GATA1 and other transcription factors to activate transcription. Therefore, it is likely that TAF10 interacting with GATA1 would enhance the ability of GATA1 to activate transcription.\nAdditionally, the document mentions that TAF10 contains several glutamine- and serine/threonine-rich regions that are similar to the protein-protein interaction domains of the regulatory transcription factor Sp1. These regions may be involved in the interaction between TAF10 and GATA1, and could potentially facilitate the activation of transcription by GATA1.\nOverall, based on the information provided in the document, it is likely that TAF10 interacting with GATA1 would result in the activation of transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 functions as a coactivator in the transcription process.\n2. TAF10 serves as a site of protein-protein contact between activators like Sp1 and the TFIID complex.\n3. Sp1 is a transcription factor known to interact with GATA1 to activate transcription.\n4. TAF10 contains glutamine- and serine/threonine-rich regions.\n5. The interaction between TAF10 and GATA1 is likely to enhance GATA1's ability to activate transcription.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 functions as a coactivator in the transcription process.",
      "TAF10 serves as a site of protein-protein contact between activators like Sp1 and the TFIID complex.",
      "Sp1 is a transcription factor known to interact with GATA1 to activate transcription.",
      "TAF10 contains glutamine- and serine/threonine-rich regions.",
      "The interaction between TAF10 and GATA1 is likely to enhance GATA1's ability to activate transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - TAF10 (TBP-associated factor 10) is part of the TFIID complex which functions as a coactivator in the process of transcription initiation.\n2. TRUE - TAF10 is known to serve as a contact point for protein-protein interactions, including those involving transcription factors like Sp1 and components of the transcription machinery like the TFIID complex.\n3. FALSE [correction]: Sp1 is a transcription factor, but it is not known for interacting with GATA1 to activate transcription. Sp1 generally binds to GC-rich promoters and has its own distinct set of target genes.\n4. UNKNOWN - Without specific domain information about TAF10, the presence of glutamine- and serine/threonine-rich regions cannot be confirmed.\n5. FALSE [correction]: There is no well-established interaction between TAF10 and GATA1 specifically in the context of enhancing GATA1's ability to activate transcription. GATA1 is a transcription factor with its specific functions, and TAF10 interacts with the TFIID complex and various transcription activators, but a direct and enhancing interaction with GATA1 specifically is not well-documented.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems available for chronic pain management. The grounded theory study you provided highlights the importance of decision-making skills for individuals managing persistent pain. Decision support systems can help individuals with chronic pain make informed decisions about their treatment options and improve their overall self-management.\nSome examples of decision support systems for chronic pain management include:\n1. Pain management apps: These apps provide a range of tools and resources to help individuals manage their pain, including pain diaries, medication reminders, and relaxation techniques. Some popular pain management apps include Painometer, PainTracker, and MyPain.\n2. Online decision aids: These are interactive tools that provide information and guidance on chronic pain management options, such as medication, physical therapy, and alternative therapies. Online decision aids can help individuals make informed decisions about their treatment options and create personalized treatment plans.\n3. Telehealth platforms: Telehealth platforms provide remote access to healthcare professionals and can be used to consult with pain management specialists. These platforms can help individuals with chronic pain receive timely and personalized advice on their treatment options.\n4. Peer support groups: Peer support groups provide a safe and supportive environment for individuals with chronic pain to share their experiences and learn from others. These groups can help individuals develop decision-making skills and receive emotional support during the self-management process.\n5. Clinical decision support systems: These systems provide healthcare professionals with real-time, evidence-based recommendations for chronic pain management. Clinical decision support systems can help healthcare professionals make informed decisions about treatment options and improve patient outcomes.\nIn conclusion, decision support systems can play a crucial role in improving chronic pain management by providing individuals with the information and resources they need to make informed decisions about their treatment options. By leveraging these systems, individuals with chronic pain can better manage their condition and improve their overall quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems are available for chronic pain management.\n2. Pain management apps sometimes offer features such as pain diaries, medication reminders, and relaxation techniques.\n3. Online decision aids are interactive tools that help with chronic pain management and personal treatment plans.\n4. Telehealth platforms enable remote access to healthcare professionals for consultation on pain management.\n5. Clinical decision support systems offer real-time, evidence-based recommendations to healthcare professionals for managing chronic pain.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems are available for chronic pain management.",
      "Pain management apps sometimes offer features such as pain diaries, medication reminders, and relaxation techniques.",
      "Online decision aids are interactive tools that help with chronic pain management and personal treatment plans.",
      "Telehealth platforms enable remote access to healthcare professionals for consultation on pain management.",
      "Clinical decision support systems offer real-time, evidence-based recommendations to healthcare professionals for managing chronic pain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, angiogenin is localized in the cytoplasm. The text states that angiogenin is a protein belonging to the RNase A superfamily, and its RNase activity is essential for its angiogenic activity. The document also mentions that members of the RNase A family carry out RNase activity, but they differ in their strength and specificity. However, the document does not provide any information about the subcellular localization of angiogenin. Therefore, based on the information provided, it can be inferred that angiogenin is localized in the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that belongs to the RNase A superfamily.\n2. Angiogenin's RNase activity is essential for its angiogenic activity.\n3. Members of the RNase A family have RNase activity.\n4. The RNase A family members differ in their strength and specificity.\n5. Angiogenin is localized in the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that belongs to the RNase A superfamily.",
      "Angiogenin's RNase activity is essential for its angiogenic activity.",
      "Members of the RNase A family have RNase activity.",
      "The RNase A family members differ in their strength and specificity.",
      "Angiogenin is localized in the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Angiogenin's RNase activity is not essential for its angiogenic activity; it promotes angiogenesis through other pathways as well.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin is localized mainly in the nucleus as well as in the cytoplasm, and it can be secreted out of the cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ranolazine appears to affect kinase signaling activation in the heart by blocking sustained Na(+) channel activity, particularly in cells expressing LQT-3 mutant channels. The study found that ranolazine preferentially blocks sustained Na(+) channel current in LQT-3 mutant channels, with an IC(50) value of 15 microM compared to 135 microM for peak Na(+) channel current. This suggests that ranolazine has a greater affinity for the sustained Na(+) channel current in these mutant channels.\nThe study also found that the effect of ranolazine on Na(+) channel current is reduced by a mutation (F1760A) in a residue previously shown to contribute critically to the binding site for local anesthetic (LA) molecules in the Na(+) channel. This suggests that the binding of LA molecules to the Na(+) channel is important for the effects of ranolazine on Na(+) channel activity.\nFurthermore, the study found that ranolazine significantly decreases action potential duration (APD) in DeltaKPQ mouse ventricular myocytes, which express LQT-3 mutant channels. This suggests that ranolazine may have a direct effect on the electrical activity of the heart, potentially by blocking sustained Na(+) channel activity.\nOverall, the study suggests that ranolazine may be a useful blocker of sustained Na(+) channel activity induced by inherited mutations that cause human disease, and that these effects are likely due to interactions of ranolazine with the receptor site for LA molecules in the sodium channel.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine blocks sustained Na(+) channel activity, particularly in cells expressing LQT-3 mutant channels.\n2. Ranolazine preferentially blocks sustained Na(+) channel current in LQT-3 mutant channels with an IC(50) value of 15 microM, compared to 135 microM for peak Na(+) channel current.\n3. The effect of ranolazine on Na(+) channel current is reduced by the F1760A mutation, which affects the binding site for local anesthetic molecules in the Na(+) channel.\n4. Ranolazine significantly decreases action potential duration (APD) in DeltaKPQ mouse ventricular myocytes that express LQT-3 mutant channels.\n5. The study suggests that ranolazine's effects are due to interactions with the receptor site for local anesthetic molecules in the sodium channel.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine blocks sustained Na(+) channel activity, particularly in cells expressing LQT-3 mutant channels.",
      "Ranolazine preferentially blocks sustained Na(+) channel current in LQT-3 mutant channels with an IC(50) value of 15 microM, compared to 135 microM for peak Na(+) channel current.",
      "The effect of ranolazine on Na(+) channel current is reduced by the F1760A mutation, which affects the binding site for local anesthetic molecules in the Na(+) channel.",
      "Ranolazine significantly decreases action potential duration (APD) in DeltaKPQ mouse ventricular myocytes that express LQT-3 mutant channels.",
      "The study suggests that ranolazine's effects are due to interactions with the receptor site for local anesthetic molecules in the sodium channel."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWhile the first statement is consistent with scientific understanding of ranolazine's effects on Na(+) channels, specifically in relation to long QT syndrome type 3 (LQT-3), the other statements require specific data or sources to verify the IC(50) values, the particular mutation's impact on drug efficacy, and the specific effects of ranolazine on action potential duration in mouse myocytes. The last statement is a reasonable hypothesis but would require specific study data to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the regulation of Vsr endonuclease appears to be independent of the growth phase of bacteria. The study focuses on the controlled batch cultivation of E. coli CK, which is capable of producing E. coli CK specific endonuclease. The authors investigate the conditions necessary for the controlled single- and multicycle process of batch cultivation and explore the use of thermodynamic characteristics to evaluate the effectiveness of controlled batch cultivation.\nThe study specifically mentions the optimum results obtained during the isolation of E. coli CK restriction endonuclease, which was active and contained no admixture of other endonucleases, at the period from the maximum specific growth rate to the end of the exponential growth phase, i.e. to the beginning of the stationary phase. This suggests that the regulation of Vsr endonuclease is not dependent on the growth phase of the bacteria, as the enzyme is active and can be isolated during the exponential growth phase, which is the period of rapid cell growth and division.\nTherefore, based on the information provided, it can be concluded that the regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease regulation is independent of the bacteria's growth phase.\n2. The study involves controlled batch cultivation of E. coli CK, which produces its specific endonuclease.\n3. Controlled batch cultivation is used to study single- and multicycle processes.\n4. E. coli CK restriction endonuclease was isolated during the exponential growth phase.\n5. The exponential growth phase is a period of rapid cell growth and division in bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease regulation is independent of the bacteria's growth phase.",
      "The study involves controlled batch cultivation of E. coli CK, which produces its specific endonuclease.",
      "Controlled batch cultivation is used to study single- and multicycle processes.",
      "E. coli CK restriction endonuclease was isolated during the exponential growth phase.",
      "The exponential growth phase is a period of rapid cell growth and division in bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE: Controlled batch cultivation is a technique that can be used to study various types of biological processes, including both single- and multicycle processes.\n4. UNKNOWN\n5. TRUE: The exponential growth phase, or log phase, is a period in the bacterial growth curve where cells are dividing at a constant and rapid rate, assuming ideal conditions with ample nutrients and a favorable environment.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several computational tools available for predicting the topology of beta-barrel transmembrane proteins:\n1. Hidden Markov Model (HMM) based methods: HMM-B2TMR, ProfTMB, and PRED-TMBB are considered to be the best predictors for beta-barrel transmembrane protein topology prediction. These methods use HMMs to model the probability of different transmembrane helices and loops in the protein structure.\n2. Neural Network (NN) based methods: There are several NN-based predictors available, such as TMHMM and TMpred, which use NNs to predict the transmembrane helices and loops in a protein structure.\n3. Support Vector Machine (SVM) based methods: SVM-based predictors, such as BepiPred and TM-align, use SVMs to predict the transmembrane topology of a protein.\nThe document also mentions a consensus prediction method that combines the predictions of multiple individual predictors to improve the accuracy of the prediction. This method is available in a web-based application at <http://bioinformatics.biol.uoa.gr/ConBBPRED>.\nIn summary, the computational tools available for predicting the topology of beta-barrel transmembrane proteins include HMM-based methods, NN-based methods, and SVM-based methods, as well as a consensus prediction method that combines the predictions of multiple individual predictors.",
    "llama-2-7b-chat-hf_fact_raw": "1. HMM-B2TMR, ProfTMB, and PRED-TMBB are computational tools that use Hidden Markov Models to predict beta-barrel transmembrane protein topology.\n2. TMHMM and TMpred are neural network-based methods for predicting transmembrane helices and loops in a protein structure.\n3. BepiPred and TM-align are Support Vector Machine-based methods used to predict the transmembrane topology of proteins.\n4. A consensus prediction method that combines the predictions of individual tools to improve accuracy is mentioned in the document.\n5. The consensus prediction method is available in a web-based application at http://bioinformatics.biol.uoa.gr/ConBBPRED.",
    "llama-2-7b-chat-hf_fact": [
      "HMM-B2TMR, ProfTMB, and PRED-TMBB are computational tools that use Hidden Markov Models to predict beta-barrel transmembrane protein topology.",
      "TMHMM and TMpred are neural network-based methods for predicting transmembrane helices and loops in a protein structure.",
      "BepiPred and TM-align are Support Vector Machine-based methods used to predict the transmembrane topology of proteins.",
      "A consensus prediction method that combines the predictions of individual tools to improve accuracy is mentioned in the document.",
      "The consensus prediction method is available in a web-based application at http://bioinformatics.biol.uoa.gr/ConBBPRED."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: BepiPred is a tool for predicting linear B-cell epitopes, while TM-align is an algorithm for sequence-independent protein structure comparisons, not for predicting the transmembrane topology of proteins.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Galassi classification is used for the diagnosis and management of inherited metabolic disorders, specifically homocystinuria, galactosaemia, maple syrup urine disease, and biotinidase deficiency.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the common features of Shapiro syndrome are:\n1. Mental retardation: Shapiro syndrome is characterized by mild to moderate mental retardation, which is a common feature of this condition.\n2. Characteristic faecies: The syndrome is associated with distinctive facial features, including a flat nasal bridge, widely spaced eyes, and a small jaw.\n3. Broad thumbs and large toes: Individuals with Shapiro syndrome typically have broad thumbs and large toes, which are a distinctive feature of the condition.\n4. Short stature: Short stature is a common feature of Shapiro syndrome, and individuals with the condition tend to be shorter than average.\n5. Cryptorchidism: Cryptorchidism, or undescended testes, is a common associated feature of Shapiro syndrome.\nIt is important to note that Shapiro syndrome is a rare genetic disorder, and the features listed above may not be present in every individual with the condition. Additionally, the severity and distribution of these features can vary widely between individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by mild to moderate mental retardation.\n2. The syndrome is associated with distinctive facial features, including a flat nasal bridge, widely spaced eyes, and a small jaw.\n3. Broad thumbs and large toes are a distinctive feature of individuals with Shapiro syndrome.\n4. Short stature is a common feature of Shapiro syndrome.\n5. Cryptorchidism is a common associated feature of Shapiro syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by mild to moderate mental retardation.",
      "The syndrome is associated with distinctive facial features, including a flat nasal bridge, widely spaced eyes, and a small jaw.",
      "Broad thumbs and large toes are a distinctive feature of individuals with Shapiro syndrome.",
      "Short stature is a common feature of Shapiro syndrome.",
      "Cryptorchidism is a common associated feature of Shapiro syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent hypothermia, hyperhidrosis, and agenesis of the corpus callosum; it does not typically include mild to moderate mental retardation as a defining feature.\n2. FALSE [correction]: The syndrome described with distinctive facial features, including a flat nasal bridge, widely spaced eyes, and a small jaw, is more characteristic of certain chromosomal disorders, such as Down syndrome, rather than Shapiro syndrome.\n3. FALSE [correction]: Broad thumbs and large toes are distinctive features of Rubinstein-Taybi syndrome, not Shapiro syndrome.\n4. UNKNOWN: Short stature can occur in Shapiro syndrome, but it is not listed as a defining characteristic, and there is variable expressivity in individuals with the condition.\n5. UNKNOWN: Cryptorchidism may occur in individuals with various syndromes and developmental disorders, but it is not specifically associated with Shapiro syndrome as a common feature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disease that is linked to mutations within BRAG1 is glial versus neuronal differentiation. The T202M mutation in ERK1, a kinase downstream of BRAF, is implicated in this process. Additionally, the presence of a truncating mutation in MAP2 in the ganglioglioma (GG) sample suggests that other genes may also play a role in tumor morphology.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the main inhibitor of protein phosphatase 1 (PP1) is inhibitor-1. Specifically, the phosphorylated form of inhibitor-1, which is converted into a potent inhibitor of native PP1 when Thr35 is phosphorylated by cAMP-dependent protein kinase (PKA), is the main inhibitor of PP1. However, the PKA-phosphorylated form of inhibitor-1 displays a weak activity in inhibition of recombinant PP1, suggesting that there may be a slight structural discrepancy between native and recombinant PP1, resulting in a different affinity for the inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-1 is the main inhibitor of protein phosphatase 1 (PP1).\n2. The phosphorylated form of inhibitor-1 becomes a potent inhibitor of PP1 when Thr35 is phosphorylated.\n3. cAMP-dependent protein kinase (PKA) is responsible for the phosphorylation of Thr35 on inhibitor-1.\n4. The PKA-phosphorylated form of inhibitor-1 has weak activity in inhibiting recombinant PP1.\n5. There is a suggested structural discrepancy between native and recombinant PP1 that affects their affinity for inhibitor-1.",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-1 is the main inhibitor of protein phosphatase 1 (PP1).",
      "The phosphorylated form of inhibitor-1 becomes a potent inhibitor of PP1 when Thr35 is phosphorylated.",
      "cAMP-dependent protein kinase (PKA) is responsible for the phosphorylation of Thr35 on inhibitor-1.",
      "The PKA-phosphorylated form of inhibitor-1 has weak activity in inhibiting recombinant PP1.",
      "There is a suggested structural discrepancy between native and recombinant PP1 that affects their affinity for inhibitor-1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Inhibitor-1 is indeed known as a main inhibitor of protein phosphatase 1 (PP1).\n2. TRUE: The phosphorylation of Thr35 on inhibitor-1 enhances its inhibitory effect on PP1, making it a potent inhibitor.\n3. TRUE: cAMP-dependent protein kinase (PKA) is known to phosphorylate Thr35 on inhibitor-1, which results in the inhibition of PP1 activity.\n4. FALSE [correction]: The PKA-phosphorylated form of inhibitor-1 has strong activity in inhibiting PP1, not weak activity.\n5. UNKNOWN: Without specific context or information provided about the research or studies referring to such a structural discrepancy, it is difficult to determine the veracity of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. Mismatch repair (MMR) system: Overexpression of the MMR system significantly diminished the accumulation of mutations in cells deficient in the error prevention GO (8-oxo-G) system during stationary phase, suggesting that the MMR system plays a general role in correcting base mispairing induced by oxidative stress during stationary phase.\n2. Error prevention GO (8-oxo-G) system: The results showed that starved B. subtilis cells lacking a functional error prevention GO system had a dramatic propensity to increase the number of stationary-phase-induced revertants, suggesting that the GO system plays a role in preventing mutations during stationary phase.\n3. Oxidative stress: The results suggest that oxidative stress is a mechanism that generates genetic diversity in starved cells of B. subtilis, promoting stationary-phase-induced mutagenesis in this soil microorganism.\nIn conclusion, the mechanisms that underlie adaptive mutagenesis in B. subtilis are related to the repair of DNA damage caused by oxidative stress, specifically the MMR system and the error prevention GO system. The absence or depression of both systems contributes to the production of stationary-phase mutants in B. subtilis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of the Mismatch Repair (MMR) system reduces the accumulation of mutations in Bacillus subtilis cells that lack the error prevention GO system during the stationary phase.\n2. Bacillus subtilis cells lacking a functional error prevention GO system exhibit an increase in stationary-phase-induced revertants.\n3. Oxidative stress is associated with generating genetic diversity in starved Bacillus subtilis cells, leading to stationary-phase-induced mutagenesis.\n4. The MMR system plays a role in correcting base mispairing induced by oxidative stress in Bacillus subtilis during the stationary phase.\n5. The absence or deficiency of the MMR and the error prevention GO systems contributes to the production of stationary-phase mutants in Bacillus subtilis.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of the Mismatch Repair (MMR) system reduces the accumulation of mutations in Bacillus subtilis cells that lack the error prevention GO system during the stationary phase.",
      "Bacillus subtilis cells lacking a functional error prevention GO system exhibit an increase in stationary-phase-induced revertants.",
      "Oxidative stress is associated with generating genetic diversity in starved Bacillus subtilis cells, leading to stationary-phase-induced mutagenesis.",
      "The MMR system plays a role in correcting base mispairing induced by oxidative stress in Bacillus subtilis during the stationary phase.",
      "The absence or deficiency of the MMR and the error prevention GO systems contributes to the production of stationary-phase mutants in Bacillus subtilis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Overexpression of the Mismatch Repair (MMR) system could indeed reduce the accumulation of mutations in bacterial cells that lack other repair systems, as the MMR system's primary role is to correct DNA replication errors, which could include those that arise from lack of the GO system during the stationary phase.\n\n2. TRUE: Bacillus subtilis cells that lack a functional error prevention GO system would likely show an increase in revertants during the stationary phase because the GO system helps prevent oxidative DNA damage, and its absence would permit the accumulation of mutations.\n\n3. TRUE: Oxidative stress is known to cause DNA damage, and in the case of starved Bacillus subtilis cells, it can lead to genetic diversity through a process known as stationary-phase-induced mutagenesis. This process can promote survival under nutrient-limited conditions.\n\n4. TRUE: The MMR system is responsible for correcting base mispairing that can occur due to a variety of reasons, including oxidative stress. It's reasonable to assume it plays this role in Bacillus subtilis during the stationary phase as well.\n\n5. TRUE: Both the MMR and the error prevention GO systems are involved in DNA repair and the prevention of mutations. In their absence or when they are deficient, bacterial cells like Bacillus subtilis would accumulate mutations, including those that arise during the stationary phase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the patient's application of heated popcorn kernels to their wrist and knee for extended periods of time caused the erythema ab igne. The chronic heat exposure from the microwaved popcorn kernels likely led to the development of reticulated pigmentation, which is a characteristic of erythema ab igne. The fact that the patient's symptoms occurred in the setting of chronic arthritic pains suggests that the heat application may have exacerbated the patient's condition. It is important to note that while the advent of central heating may have contributed to a decline in the incidence of erythema ab igne in some areas, the use of local heat sources, such as heated water bottles or microwaved popcorn kernels, can still lead to the development of this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. The application of heated popcorn kernels to the wrist and knee caused erythema ab igne.\n2. Chronic heat exposure from the microwaved popcorn kernels likely led to reticulated pigmentation characteristic of erythema ab igne.\n3. The patient was using heat application due to chronic arthritic pains.\n4. The advent of central heating may have contributed to a decline in the incidence of erythema ab igne in some areas.\n5. The use of local heat sources like heated water bottles or microwaved popcorn kernels can lead to the development of erythema ab igne.",
    "llama-2-7b-chat-hf_fact": [
      "The application of heated popcorn kernels to the wrist and knee caused erythema ab igne.",
      "Chronic heat exposure from the microwaved popcorn kernels likely led to reticulated pigmentation characteristic of erythema ab igne.",
      "The patient was using heat application due to chronic arthritic pains.",
      "The advent of central heating may have contributed to a decline in the incidence of erythema ab igne in some areas.",
      "The use of local heat sources like heated water bottles or microwaved popcorn kernels can lead to the development of erythema ab igne."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is insufficient information provided about the specific case to determine whether the application of heated popcorn kernels to the wrist and knee caused erythema ab igne. Without details from a medical report or case study, the accuracy of the statement cannot be verified.\n2. TRUE: The statement is consistent with the condition of erythema ab igne, which is known to cause reticulated pigmentation due to chronic heat exposure, such as that from microwaved popcorn kernels.\n3. UNKNOWN: While the statement is plausible since patients with chronic arthritic pain often use heat application for relief, there is not enough information given to confirm this was the reason for the patient's use of heat in this case.\n4. TRUE: The advent of central heating is often associated with a reduction in the use of localized heat sources for warmth, which could contribute to a decline in the incidence of erythema ab igne, as it is typically caused by prolonged and repeated exposure to a source of heat.\n5. TRUE: It is recognized that the use of local heat sources like heated water bottles or microwaved popcorn kernels can result in prolonged heat exposure that can lead to the development of erythema ab igne.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide (HCTZ) are:\n1. Hypertension: HCTZ is a diuretic that is used to treat hypertension, or high blood pressure.\n2. Class IV of the Biopharmaceutics Classification System: HCTZ belongs to class IV of the Biopharmaceutics Classification System, which means it is a drug that is primarily metabolized by the liver.\n3. No requirement for dissolution and dissolution profile testing: There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs, such as Lab 5 and Lab 6, which contain HCTZ.\n4. Incompatibility with lactose and mannitol: HCTZ is incompatible with lactose and mannitol, which may explain the lack of equivalence of the generic pharmaceutical product.\nIt is important to note that the information provided is based on the document provided and may not be comprehensive or up-to-date. If you have any further questions or concerns, please let me know.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat hypertension, or high blood pressure.\n2. Hydrochlorothiazide belongs to class IV of the Biopharmaceutics Classification System.\n3. There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs containing HCTZ.\n4. Hydrochlorothiazide is incompatible with lactose and mannitol.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat hypertension, or high blood pressure.",
      "Hydrochlorothiazide belongs to class IV of the Biopharmaceutics Classification System.",
      "There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs containing HCTZ.",
      "Hydrochlorothiazide is incompatible with lactose and mannitol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hydrochlorothiazide belongs to class I of the Biopharmaceutics Classification System, which includes drugs with high solubility and high permeability.\n3. FALSE [correction]: There is a requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs containing HCTZ to ensure the quality and efficacy of the medication.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence after radical prostatectomy (RP). In a study published in the Journal of Urology, six patients with severe post-operative incontinence after RP were treated with transurethral submucosal injection therapy using polydimethylsiloxane (PDS) particles. The results showed that after a mean follow-up of 15.5 months, five patients were dry, with no incontinence during the day or night, while one patient improved significantly but still required two pads during the day. The side-effects of therapy were minimal, with dysuria and urinary retention being the most common complications. The study concluded that transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after RP.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence after radical prostatectomy.\n2. A study published in the Journal of Urology covered six patients with severe post-operative incontinence after radical prostatectomy.\n3. The treatment used for these patients involved transurethral submucosal injection therapy with polydimethylsiloxane (PDS) particles.\n4. After a mean follow-up of 15.5 months, five of the treated patients experienced no incontinence during the day or night.\n5. The side-effects of the therapy included dysuria and urinary retention.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence after radical prostatectomy.",
      "A study published in the Journal of Urology covered six patients with severe post-operative incontinence after radical prostatectomy.",
      "The treatment used for these patients involved transurethral submucosal injection therapy with polydimethylsiloxane (PDS) particles.",
      "After a mean follow-up of 15.5 months, five of the treated patients experienced no incontinence during the day or night.",
      "The side-effects of the therapy included dysuria and urinary retention."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: After a mean follow-up of 15.5 months, four of the treated patients experienced no incontinence during the day or night.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no association between the moon cycle and the rupture risk of intracranial aneurysms. The study found that there was no correlation between the lunar phase and the incidence of aneurysmal subarachnoid hemorrhage (SAH), the location of the aneurysm, the initial clinical presentation, or the amount of subarachnoid blood. The study concluded that the moon does not influence the incidence of aneurysmal SAH or the grade of initial neurological deterioration or amount of subarachnoid blood. Therefore, the association between the moon cycle and rupture risk of intracranial aneurysms is negligible or non-existent.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no association between the moon cycle and the rupture risk of intracranial aneurysms according to the referenced study.\n2. The study found no correlation between the lunar phase and the incidence of aneurysmal subarachnoid hemorrhage.\n3. According to the study, the lunar phase does not correlate with the location of the aneurysm.\n4. The study indicates that there is no correlation between the lunar phase and the initial clinical presentation of aneurysmal subarachnoid hemorrhage.\n5. The study found no correlation between the lunar phase and the amount of subarachnoid blood in the context of aneurysmal subarachnoid hemorrhage.",
    "llama-2-7b-chat-hf_fact": [
      "There is no association between the moon cycle and the rupture risk of intracranial aneurysms according to the referenced study.",
      "The study found no correlation between the lunar phase and the incidence of aneurysmal subarachnoid hemorrhage.",
      "According to the study, the lunar phase does not correlate with the location of the aneurysm.",
      "The study indicates that there is no correlation between the lunar phase and the initial clinical presentation of aneurysmal subarachnoid hemorrhage.",
      "The study found no correlation between the lunar phase and the amount of subarachnoid blood in the context of aneurysmal subarachnoid hemorrhage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the referenced study provided for review, it's not possible to determine the veracity of these statements. Scientific conclusions must be drawn directly from the data and methodology presented in the study, and in this case, the study itself is not provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein does regulate the splicing process. According to the provided information, the HuR protein modulates mRNA splicing, trafficking, translation, and stability. The report mentions that HuR interacts with thousands of cellular transcripts, including non-coding RNAs such as natural antisense transcripts from stress responsive loci. The study also found that secondary structures of 66-75 nucleotides enhance HuR's recognition of its specific RNA targets composed of short primary sequence patterns. These findings suggest that HuR plays a role in regulating the splicing process by interacting with RNAs and modulating their stability and translation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein regulates the splicing process.\n2. The HuR protein modulates mRNA splicing, trafficking, translation, and stability.\n3. HuR interacts with thousands of cellular transcripts, including non-coding RNAs.\n4. Natural antisense transcripts from stress responsive loci are among the cellular transcripts HuR interacts with.\n5. Secondary structures of 66-75 nucleotides enhance HuR's recognition of specific RNA targets.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein regulates the splicing process.",
      "The HuR protein modulates mRNA splicing, trafficking, translation, and stability.",
      "HuR interacts with thousands of cellular transcripts, including non-coding RNAs.",
      "Natural antisense transcripts from stress responsive loci are among the cellular transcripts HuR interacts with.",
      "Secondary structures of 66-75 nucleotides enhance HuR's recognition of specific RNA targets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein does not directly regulate the splicing process but rather modulates mRNA stability and translation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Nuclear localization: Prothymosin alpha has been shown to localize to the nucleus in COS cells transfected with the human prothymosin alpha gene, as well as in constructs where the prothymosin alpha nucleic acid sequences were fused in-frame with either the amino or carboxyl terminus of the beta-galactosidase gene in COS cells.\n2. Nuclear targeting signal: The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, has been identified as part of the nuclear targeting signal, which enables the protein to localize to the nucleus.\n3. Lack of amino-terminal signal peptide: Prothymosin alpha lacks an amino-terminal signal peptide, which was once thought to be a precursor for thymosin alpha 1, a putative peptide hormone secreted by the thymus.\nIn summary, the prothymosin alpha c-terminal peptide is primarily involved in nuclear localization and targeting, and does not appear to have any direct role in the production of thymosin alpha 1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha localizes to the nucleus in COS cells when transfected with the human prothymosin alpha gene.\n2. Prothymosin alpha can also localize to the nucleus when its nucleic acid sequences are fused in-frame with either the amino or carboxyl terminus of the beta-galactosidase gene in COS cells.\n3. The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, is part of the nuclear targeting signal.\n4. Prothymosin alpha lacks an amino-terminal signal peptide.\n5. It was once thought that prothymosin alpha was a precursor for thymosin alpha 1, but it is now known that it does not have a direct role in the production of thymosin alpha 1.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha localizes to the nucleus in COS cells when transfected with the human prothymosin alpha gene.",
      "Prothymosin alpha can also localize to the nucleus when its nucleic acid sequences are fused in-frame with either the amino or carboxyl terminus of the beta-galactosidase gene in COS cells.",
      "The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, is part of the nuclear targeting signal.",
      "Prothymosin alpha lacks an amino-terminal signal peptide.",
      "It was once thought that prothymosin alpha was a precursor for thymosin alpha 1, but it is now known that it does not have a direct role in the production of thymosin alpha 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - However, this statement's accuracy depends on specific experimental evidence indicating that the TKKQKT sequence is involved in nuclear localization. If such evidence is missing or contradictory, then the statement could be considered false or unknown.\n4. TRUE - Prothymosin alpha, being a nuclear protein, typically does not have a signal peptide; signal peptides are usually found on proteins that are secreted or targeted to certain organelles outside the nucleus.\n5. TRUE - Prothymosin alpha was once thought to be a precursor to thymosin alpha 1, but further research has shown that they are distinct molecules with different functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the peptide that plays a pivotal role in human cystatin C fibrillization is megalin/cubilin. The document states that chicken cystatin, a homologue of human cystatin C, binds to renal brush-border membranes in a saturable and reversible manner with low affinity and high capacity, and that bovine albumin is the most potent competitor among other megalin/cubilin ligands tested. The presence of Ca(+2) ions is also necessary for effective cystatin binding by brush-border membranes. These findings strongly support the hypothesis that chicken cystatin is a novel ligand for megalin/cubilin receptors tandem on proximal tubular cells, which suggests that megalin/cubilin plays a pivotal role in cystatin C fibrillization.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide that plays a pivotal role in human cystatin C fibrillization is megalin/cubilin.\n2. Chicken cystatin binds to renal brush-border membranes in a saturable and reversible manner.\n3. Chicken cystatin binds to renal brush-border membranes with low affinity and high capacity.\n4. Bovine albumin is the most potent competitor among other megalin/cubilin ligands tested.\n5. The presence of Ca(+2) ions is necessary for effective cystatin binding by brush-border membranes.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide that plays a pivotal role in human cystatin C fibrillization is megalin/cubilin.",
      "Chicken cystatin binds to renal brush-border membranes in a saturable and reversible manner.",
      "Chicken cystatin binds to renal brush-border membranes with low affinity and high capacity.",
      "Bovine albumin is the most potent competitor among other megalin/cubilin ligands tested.",
      "The presence of Ca(+2) ions is necessary for effective cystatin binding by brush-border membranes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The peptide that plays a pivotal role in human cystatin C fibrillization is L68Q mutant cystatin C, not megalin/cubilin.\n2. TRUE\n3. FALSE [correction]: Chicken cystatin binds to renal brush-border membranes with high affinity, not low affinity, and low capacity.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no direct answer to the question of whether the concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). However, there are some hints in the document that could be relevant to this question.\nFirstly, the document mentions the presence of androgen-binding proteins in the cytosol of human benign prostatic hypertrophic tissue, which suggests that there are proteins in the tissue that are involved in binding to androgens. HIF-1 is a transcription factor that is involved in response to hypoxia and is known to be regulated by androgens, so it is possible that these androgen-binding proteins may also play a role in regulating HIF-1 expression.\nSecondly, the document mentions that the binding of prostatic cytosol and 3H-DHT (a non-steroidal androgen) increased with increasing concentrations of Ca2+ or Mg2+. This suggests that the binding of androgens to their receptors in the prostate tissue may be influenced by the concentration of these ions, which could in turn affect the expression of HIF-1.\nHowever, it is important to note that the document does not provide direct evidence of a change in HIF-1 concentration after the administration of ethyol, and further research would be needed to confirm whether this occurs. Therefore, the answer to the user's question is uncertain based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1 is a transcription factor involved in response to hypoxia.\n2. HIF-1 expression is known to be regulated by androgens.\n3. The document mentions the presence of androgen-binding proteins in the cytosol of human benign prostatic hypertrophic tissue.\n4. The binding of prostatic cytosol and 3H-DHT increases with increasing concentrations of Ca2+ or Mg2+.\n5. There is a suggestion that androgen receptors' binding in the prostate may be influenced by the concentration of Ca2+ or Mg2+, which could affect HIF-1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1 is a transcription factor involved in response to hypoxia.",
      "HIF-1 expression is known to be regulated by androgens.",
      "The document mentions the presence of androgen-binding proteins in the cytosol of human benign prostatic hypertrophic tissue.",
      "The binding of prostatic cytosol and 3H-DHT increases with increasing concentrations of Ca2+ or Mg2+.",
      "There is a suggestion that androgen receptors' binding in the prostate may be influenced by the concentration of Ca2+ or Mg2+, which could affect HIF-1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: HIF-1 expression is known to be regulated by oxygen levels, not directly by androgens.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific document containing these statements, especially for statements 3 to 5, we cannot verify their accuracy. They are specific enough that without the context provided by the document mentioned, we can't determine their truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Set7 deposits histone marks on the following proteins:\n1. p53: SET7/9 methylates non-histone proteins, including p53, and participates in their posttranslational modifications.\n2. H3K4: SET7/9 transcriptionally activates the genes via H3K4 mono-methylation, but the target genes are poorly understood.\nIn the study, SET7/9 was found to be related to carcinogenesis, as loss or weak expression of SET7/9 protein was observed in 34.3% of gastric cancers (GCs) compared to matched non-cancerous tissues. Knockdown of SET7/9 in GC cells increased cell proliferation, migration, and invasion, and activated matrix metalloproteinase genes (MMP1, MMP7, and MMP9). SET7/9 was also found to bind and mono-methylate H3K4 at the region of the approximately 4-6 kb upstream from the SREK1IP1 transcriptional start site and the promoters of PGC and CDC28B. These findings suggest that SET7/9 has tumor suppressor functions and loss of SET7/9 may contribute to gastric cancer progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. SET7/9 methylates non-histone proteins, including p53.\n2. SET7/9 transcriptionally activates genes via H3K4 mono-methylation.\n3. In a study, weak expression or loss of SET7/9 protein was observed in 34.3% of gastric cancers.\n4. Knockdown of SET7/9 in gastric cancer cells increased cell proliferation, migration, and invasion.\n5. SET7/9 binds and mono-methylates H3K4 at regions upstream from the transcriptional start site of SREK1IP1 and the promoters of PGC and CDC28B.",
    "llama-2-7b-chat-hf_fact": [
      "SET7/9 methylates non-histone proteins, including p53.",
      "SET7/9 transcriptionally activates genes via H3K4 mono-methylation.",
      "In a study, weak expression or loss of SET7/9 protein was observed in 34.3% of gastric cancers.",
      "Knockdown of SET7/9 in gastric cancer cells increased cell proliferation, migration, and invasion.",
      "SET7/9 binds and mono-methylates H3K4 at regions upstream from the transcriptional start site of SREK1IP1 and the promoters of PGC and CDC28B."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: SET7/9 (also known as SETD7) is known for its enzymatic activity of methylating lysines on both histone and non-histone proteins, including p53 which is a key tumor suppressor protein.\n2. TRUE: SET7/9 is known to transcriptionally activate genes by catalyzing the mono-methylation of histone H3 on lysine 4 (H3K4me1), which is often associated with gene activation.\n3. UNKNOWN: Without access to the specific study mentioned in the statement, it is not possible to confirm the occurrence and frequency of weak expression or loss of SET7/9 protein in gastric cancers.\n4. UNKNOWN: Similarly, without the details of the study or experiment that investigated the effects of SET7/9 knockdown in gastric cancer cells, the effects on cell proliferation, migration, and invasion cannot be verified.\n5. UNKNOWN: The specificity of SET7/9 binding and mono-methylation of H3K4 at regions upstream from the transcriptional start site of specific genes (like SREK1IP1, PGC, and CDC28B mentioned in the statement) would need to be confirmed by reviewing the relevant research articles or scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the localization of the protein encoded by the gene DNAJC11 is in the mammalian brain. The document mentions the interaction of HSJ1a and HSJ1b proteins with the mammalian brain constitutive 70-kDa heat-shock protein (hsc70) in vitro. The enhancement of the weak intrinsic ATPase activity of hsc70 by stoichiometric amounts of HSJ1a and HSJ1b is mediated by an increase in the rate of bound ATP hydrolysis, suggesting that these proteins regulate the affinity of hsc70 for the permanently unfolded substrate, carboxymethylated alpha-lactalbumin. Additionally, the document suggests that HSJ1 proteins induce a conformational change in hsc70 that can mimic the effect mediated by K+ and therefore modulate hsc70 substrate release by another mechanism rather than merely stimulating the hsc70 ATPase activity. As HSJ1 proteins have limited similarity to DnaJ, it is suggested that this action is being mediated by the J domain alone, and that this modulation of hsc70 substrate binding will be common to all proteins that contain a J domain. Therefore, based on the information provided in the document, the localization of the protein encoded by the gene DNAJC11 is in the mammalian brain, specifically in the constitutive 70-kDa heat-shock protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized in the mammalian brain.\n2. HSJ1a and HSJ1b proteins interact with the mammalian brain 70-kDa heat-shock protein (hsc70) in vitro.\n3. HSJ1a and HSJ1b proteins enhance the ATPase activity of hsc70",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized in the mammalian brain.",
      "HSJ1a and HSJ1b proteins interact with the mammalian brain 70-kDa heat-shock protein (hsc70) in vitro.",
      "HSJ1a and HSJ1b proteins enhance the ATPase activity of hsc70"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n\nRationale:\n1. The statement is too specific without additional context, making it difficult to verify without detailed knowledge of the protein in question or a specific citation from a research study. DNAJC11 is indeed a gene that encodes a member of the family of DnaJ (Hsp40) homologs, but its localization in the mammalian brain requires specific literature to confirm.\n\n2. The statement could be true as HSJ1a and HSJ1b are indeed members of the family of DnaJ (Hsp40) homologs. This family is known to interact with Hsp70 family proteins, such as hsc70, which is a cognate heat-shock protein. These interactions usually occur in vitro as part of their protein chaperoning activity, which suggests that the statement is plausible.\n\n3. The statement is true, as it is a well-documented function of DnaJ (Hsp40) proteins like HSJ1a and HSJ1b to enhance the ATPase activity of Hsp70 family members like hsc70. This is part of the mechanism through which these chaperone systems promote the folding and proper assembly of other proteins.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is: Yes, ultraconserved elements are depleted among copy number variants (CNVs).\nThe document states that ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell. Additionally, the document finds that even newly formed de novo CNVs are significantly depleted for UCEs, indicating that the depletion of UCEs is not limited to CNVs that have passed through meiosis.\nHowever, the document also notes that CNVs arising specifically in cancer cells are not depleted for UCEs and can even become significantly enriched, which raises the possibility that CNVs that arise somatically and are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, the lack of depletion for UCEs from cancer CNVs may reflect the diseased state.\nOverall, the document provides evidence that ultraconserved elements are depleted among copy number variants in the human genome, although the mechanisms underlying this depletion may vary depending on the context in which the CNVs arise.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome.\n2. Deletion or duplication of an ultraconserved element can be deleterious to the mammalian cell.\n3. Newly formed de novo copy number variants are significantly depleted for ultraconserved elements.\n4. Copy number variants that arise specifically in cancer cells are not depleted for ultraconserved elements and can become significantly enriched.\n5. The depletion of ultraconserved elements among copy number variants may vary depending on the context in which the CNVs arise.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome.",
      "Deletion or duplication of an ultraconserved element can be deleterious to the mammalian cell.",
      "Newly formed de novo copy number variants are significantly depleted for ultraconserved elements.",
      "Copy number variants that arise specifically in cancer cells are not depleted for ultraconserved elements and can become significantly enriched.",
      "The depletion of ultraconserved elements among copy number variants may vary depending on the context in which the CNVs arise."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nFor the fourth statement, the context does not provide enough information to assess whether copy number variants specifically in cancer cells are indeed not depleted for ultraconserved elements and can become significantly enriched. More specific scientific evidence is required to verify this claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the substrate of the Haspin kinase during mitosis is histone H3. The document states that Haspin catalyzes the phosphorylation of Thr3 in histone H3, which is a key step in the normal function of the chromosomal passenger complex during mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3.\n2. Haspin kinase catalyzes the phosphorylation of Thr3 in histone H3.\n3. The phosphorylation of Thr3 in histone H3 is a key step in the function of the chromosomal passenger complex during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3.",
      "Haspin kinase catalyzes the phosphorylation of Thr3 in histone H3.",
      "The phosphorylation of Thr3 in histone H3 is a key step in the function of the chromosomal passenger complex during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mechanism of viroid replication is as follows:\nViroids, such as the peach latent mosaic viroid (PLMVd), replicate via a symmetric mode involving the accumulation of both circular and linear monomeric strands of both polarities. This process occurs in the chloroplasts of infected cells, where the viroid RNA species concentrate. The replication mechanism involves the self-cleavage of the viroid strands via their hammerhead sequences, resulting in the accumulation of both strands of equal concentration.\nThe results of the study establish two hallmarks for the classification of viroids:\n1. Group A viroids, such as PLMVd, replicate in the chloroplasts via a symmetric mode.\n2. Group B viroids, which share a conserved central region, replicate in the nucleus via an asymmetric mechanism.\nThese findings have important implications for the evolutionary origin and replication of viroids, and highlight the differences between self-cleaving and non-self-cleaving viroids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids replicate via a symmetric mode that includes both circular and linear monomeric strands.\n2. The replication process of viroids occurs in the chloroplasts of infected cells.\n3. Peach latent mosaic viroid (PLMVd) replicates in the chloroplasts via a symmetric mode.\n4. Viroid RNA species self-cleave through hammerhead sequences.\n5. Group B viroids replicate in the nucleus via an asymmetric mechanism.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids replicate via a symmetric mode that includes both circular and linear monomeric strands.",
      "The replication process of viroids occurs in the chloroplasts of infected cells.",
      "Peach latent mosaic viroid (PLMVd) replicates in the chloroplasts via a symmetric mode.",
      "Viroid RNA species self-cleave through hammerhead sequences.",
      "Group B viroids replicate in the nucleus via an asymmetric mechanism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Viroids do indeed replicate via a symmetric mode that includes both circular and linear monomeric strands.\n\n2. FALSE [correction]: Viroids typically replicate in the nucleus or chloroplasts of the host cell, depending on the viroid species. The replication site can vary, and not all viroids replicate in the chloroplasts.\n\n3. TRUE: Peach latent mosaic viroid (PLMVd) is among the viroids that replicate in the chloroplasts and it does so via a symmetric rolling circle model.\n\n4. TRUE: Certain viroid RNA species can self-cleave through ribozyme sequences known as hammerhead ribozymes, which are a type of catalytic RNA.\n\n5. TRUE: Group B viroids, such as the Avocado sunblotch viroid (ASBVd), replicate in the nucleus of host cells, and they utilize an asymmetric rolling-circle mechanism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy. The study found that periostin, a matricellular protein, is significantly increased in the dystrophin-deficient diaphragm from both mdx and mdx-4cv mice, suggesting an involvement of this protein in dystrophinopathy-related fibrosis. However, there is no mention of fibronectin in the study. Therefore, based on the information provided, fibronectin is not a biomarker for Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is not considered a serum biomarker for Duchenne muscular dystrophy according to the information provided.\n2. The study referenced suggests that periostin is significantly increased in the dystrophin-deficient diaphragm from both mdx and mdx-4cv mice.\n3. Periostin is involved in dystrophinopathy-related fibrosis, as indicated by the study findings.\n4. The study mentioned does not include fibronectin in its findings.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is not considered a serum biomarker for Duchenne muscular dystrophy according to the information provided.",
      "The study referenced suggests that periostin is significantly increased in the dystrophin-deficient diaphragm from both mdx and mdx-4cv mice.",
      "Periostin is involved in dystrophinopathy-related fibrosis, as indicated by the study findings.",
      "The study mentioned does not include fibronectin in its findings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nGiven the nature of the statements, without the specific study or information referenced, it is not possible to accurately determine the veracity of these claims about fibronectin, periostin, and the study's findings regarding Duchenne muscular dystrophy or dystrophinopathy-related fibrosis. More context is needed to assess these statements properly.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the major epigenome projects whose data are contained in the DeepBlue epigenomic data server are:\n1. The Genome-Wide Association Study (GWAS) data from the Wellcome Trust Case Control Consortium (WTCCC)\n2. The Epigenome-Wide Association Study (EWAS) data from the Psychiatric Genomics Consortium (PGC)\n3. The Human Epigenome Atlas (HEA) project\n4. The Roadmap Epigenomics Project\n5. The Epigenomics of Human Disease (EHD) project\nThese projects are some of the largest and most well-known epigenome projects, and their data are widely used in the field of epigenomics. The QCEWAS R package is designed to facilitate the quality control of results files from these and other epigenome-wide association studies, and it can be used to interpret the quality of the results files, compare the results of multiple cohorts, and prepare input files for meta-analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains Genome-Wide Association Study (GWAS) data from the Wellcome Trust Case Control Consortium (WTCCC).\n2. The DeepBlue epigenomic data server includes Epigenome-Wide Association Study (EWAS) data from the Psychiatric Genomics Consortium (PGC).\n3. The Human Epigenome Atlas (HEA) project data are contained in the DeepBlue epigenomic data server.\n4. The Roadmap Epigenomics Project data are held within the DeepBlue epigenomic data server.\n5. The Epigenomics of Human Disease (EHD) project data are part of the DeepBlue epigenomic data server's collections.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains Genome-Wide Association Study (GWAS) data from the Wellcome Trust Case Control Consortium (WTCCC).",
      "The DeepBlue epigenomic data server includes Epigenome-Wide Association Study (EWAS) data from the Psychiatric Genomics Consortium (PGC).",
      "The Human Epigenome Atlas (HEA) project data are contained in the DeepBlue epigenomic data server.",
      "The Roadmap Epigenomics Project data are held within the DeepBlue epigenomic data server.",
      "The Epigenomics of Human Disease (EHD) project data are part of the DeepBlue epigenomic data server's collections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe DeepBlue epigenomic data server does contain data from the Roadmap Epigenomics Project. However, without specific and current knowledge of the DeepBlue server's database, it's not possible to confirm or correct the statements about the inclusion of GWAS data from WTCCC, EWAS data from PGC, HEA project data, or EHD project data. These statements require verification from an up-to-date source or direct access to the data server in question.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the tool that employs self-organizing maps for analyzing synonymous codon usage is the GCB (Gene Codon Bias) tool. The GCB tool uses an iterative approach for determining codon scores and allows for the computation of an index of codon bias suitable for interspecies comparison. The tool is available at <www.g21.bio.uni-goettingen.de> and can be used to calculate GCB values for individual genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GCB (Gene Codon Bias) tool uses self-organizing maps for analyzing synonymous codon usage.\n2. The GCB tool employs an iterative approach for determining codon scores.\n3. The GCB tool allows for the computation of an index of codon bias that is suitable for interspecies comparison.\n4. The GCB tool can calculate values for individual genes.",
    "llama-2-7b-chat-hf_fact": [
      "The GCB (Gene Codon Bias) tool uses self-organizing maps for analyzing synonymous codon usage.",
      "The GCB tool employs an iterative approach for determining codon scores.",
      "The GCB tool allows for the computation of an index of codon bias that is suitable for interspecies comparison.",
      "The GCB tool can calculate values for individual genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge or a verifiable source about the \"GCB (Gene Codon Bias) tool,\" it is not possible to determine whether it uses self-organizing maps for analyzing synonymous codon usage.\n2. UNKNOWN: Similarly, the statement about the GCB tool employing an iterative approach for determining codon scores cannot be verified without more information.\n3. UNKNOWN: The capabilities of the GCB tool to compute an index of codon bias suitable for interspecies comparison would require specific details about how the tool functions and what features it offers.\n4. UNKNOWN: Whether the GCB tool can calculate values for individual genes is also not verifiable without additional context or a reliable source describing the tool's functions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MINDY-1 appears to be a gene that plays a role in the regulation of lipid and glucose metabolism, particularly in the liver. The document suggests that reducing the expression of MINDY-1 in lower organisms can extend lifespan and improve insulin resistance, and that deleting the mammalian homolog of MINDY-1 can protect against aging- and diet-induced adiposity and insulin resistance in mice. The document also shows that selective inducible hepatic knockdown of MINDY-1 in rats leads to a reduction in fasting plasma insulin concentrations, plasma triglycerides, and hepatic triglyceride content, and an increase in the suppression of hepatic glucose production during a hyperinsulinemic-euglycemic clamp. These findings suggest that MINDY-1 may be a key regulator of lipid and glucose metabolism in the liver, and that reducing its expression may have beneficial effects on metabolic health.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a gene that is involved in the regulation of lipid and glucose metabolism, particularly in the liver.\n2. Reducing the expression of MINDY-1 in lower organisms has been linked to increased lifespan and improved insulin resistance.\n3. Deleting the mammalian homolog of MINDY-1 has been shown to protect against aging- and diet-induced adiposity and insulin resistance in mice.\n4. Inducible hepatic knockdown of MINDY-1 in rats leads to reduced fasting plasma insulin concentrations and plasma triglycerides.\n5. The hepatic knockdown of MINDY-1 also increases the suppression of hepatic glucose production during a hyperinsulinemic-euglycemic clamp in rats.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a gene that is involved in the regulation of lipid and glucose metabolism, particularly in the liver.",
      "Reducing the expression of MINDY-1 in lower organisms has been linked to increased lifespan and improved insulin resistance.",
      "Deleting the mammalian homolog of MINDY-1 has been shown to protect against aging- and diet-induced adiposity and insulin resistance in mice.",
      "Inducible hepatic knockdown of MINDY-1 in rats leads to reduced fasting plasma insulin concentrations and plasma triglycerides.",
      "The hepatic knockdown of MINDY-1 also increases the suppression of hepatic glucose production during a hyperinsulinemic-euglycemic clamp in rats."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAssuming the statements provided are based on research findings available up to my knowledge cutoff date, these statements about the gene MINDY-1 and the effects of its manipulation in various organisms are congruent with the kind of results that have been reported in scientific literature on the metabolism and genetics of aging. However, without the actual passage or specific studies to reference, I am assuming these statements are accurate representations of existing research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the software package available for the analysis of conserved genomic loci is GenomeInspector (GI).",
    "llama-2-7b-chat-hf_fact_raw": "1. GenomeInspector (GI) is a software package used for the analysis of conserved genomic loci.",
    "llama-2-7b-chat-hf_fact": [
      "GenomeInspector (GI) is a software package used for the analysis of conserved genomic loci."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the three diseases associated with the PIEZO2 gene are:\n1. Hypotonia: The girl in the document has generalized muscular hypotonia, which is a common symptom of PIEZO2-related disorders. Hypotonia is a condition where there is a decrease in muscle tone, leading to floppiness or weakness in the muscles.\n2. Scoliosis: The girl in the document has severe scoliosis, which is a curvature of the spine that can occur as a result of PIEZO2 mutations. Scoliosis can lead to back pain, breathing difficulties, and other complications if left untreated.\n3. Proprioceptive function deficiency: The girl in the document has deficient proprioceptive function, which is the ability to sense the position and movement of the body. This can lead to difficulties with balance, coordination, and movement.\nIt is important to note that these are the diseases associated with the PIEZO2 gene based on the information provided in Document-0, and there may be other diseases associated with this gene that are not mentioned in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. Generalized muscular hypotonia is a common symptom of PIEZO2-related disorders.\n2. Severe scoliosis can occur as a result of PIEZO2 mutations.\n3. Deficient proprioceptive function, the ability to sense the position and movement of the body, is associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Generalized muscular hypotonia is a common symptom of PIEZO2-related disorders.",
      "Severe scoliosis can occur as a result of PIEZO2 mutations.",
      "Deficient proprioceptive function, the ability to sense the position and movement of the body, is associated with the PIEZO2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules. The study found that stabilized ERAP1-ERAP2 heterodimers produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. This suggests that the physical interaction between ERAP1 and ERAP2 changes basic enzymatic parameters of ERAP1, improving its substrate-binding affinity, and creating complexes with superior peptide-trimming efficacy. These complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules.\n2. Stabilized ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.\n3. The physical interaction between ERAP1 and ERAP2 improves ERAP1's substrate-binding affinity.\n4. ERAP1-ERAP2 heterodimers have superior peptide-trimming efficacy compared to the individual enzymes.\n5. Enhanced antigen presentation by cells is associated with the coordinated expression of ERAP1 and ERAP2.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules.",
      "Stabilized ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.",
      "The physical interaction between ERAP1 and ERAP2 improves ERAP1's substrate-binding affinity.",
      "ERAP1-ERAP2 heterodimers have superior peptide-trimming efficacy compared to the individual enzymes.",
      "Enhanced antigen presentation by cells is associated with the coordinated expression of ERAP1 and ERAP2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about ERAP1-ERAP2 dimerization appears to involve specific biochemical processes but without a specific source or context, it's unclear whether this statement is true or false.\n2. UNKNOWN: Similarly, the statement regarding the efficiency of stabilized ERAP1-ERAP2 heterodimers compared to non-dimerizing enzymes is highly specific and cannot be confirmed as true or false without additional context.\n3. UNKNOWN: The claim about the physical interaction between ERAP1 and ERAP2 affecting substrate-binding affinity is another technical detail that requires specific biochemical knowledge or a relevant study reference to be verified.\n4. UNKNOWN: Without proper context or a source, the statement regarding the comparative peptide-trimming efficacy of ERAP1-ERAP2 heterodimers versus individual enzymes is not verifiable.\n5. UNKNOWN: The association between enhanced antigen presentation and the expression of ERAP1 and ERAP2 is also a specific scientific statement that would need reference to relevant research to determine its validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, R-spondin 1 and noggin have functions in non-damaged gallbladders, including:\n1. Sensitizing cells to Wnt signaling: R-spondin proteins, including R-spondin 1, sensitize cells to Wnt signaling, which is important for the regulation of cell fate decisions and tissue development.\n2. Acting as potent stem cell growth factors: R-spondin proteins have been shown to act as potent stem cell growth factors, promoting the proliferation and self-renewal of stem cells.\n3. Interacting with specific receptors: R-spondin 1 interacts with specific receptors, including LGR4/5 and ZNRF3/RNF43, which are involved in the regulation of Wnt signaling.\n4. Regulating Wnt signaling: R-spondin 1 can activate or inhibit Wnt signaling through its interaction with ZNRF3/RNF43, depending on the context. In non-damaged gallbladders, R-spondin 1 may play a role in regulating Wnt signaling in a tissue-specific manner.\nIn summary, R-spondin 1 and noggin have functions in non-damaged gallbladders related to Wnt signaling, stem cell growth, and receptor interaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 sensitizes cells to Wnt signaling, which influences cell fate decisions and tissue development.\n2. R-spondin proteins act as stem cell growth factors, promoting the proliferation and self-renewal of stem cells.\n3. R-spondin 1 interacts with specific receptors, including LGR4/5 and ZNRF3/RNF43.\n4. R-spondin 1 can activate or inhibit Wnt signaling through its interaction with ZNRF3/RNF43.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 sensitizes cells to Wnt signaling, which influences cell fate decisions and tissue development.",
      "R-spondin proteins act as stem cell growth factors, promoting the proliferation and self-renewal of stem cells.",
      "R-spondin 1 interacts with specific receptors, including LGR4/5 and ZNRF3/RNF43.",
      "R-spondin 1 can activate or inhibit Wnt signaling through its interaction with ZNRF3/RNF43."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: R-spondin 1 activates Wnt signaling through its interaction with ZNRF3/RNF43 by preventing their ability to ubiquitinate Frizzled receptors, which are necessary for Wnt signaling, thus R-spondin 1 does not inhibit the Wnt signaling pathway through this interaction.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that NADPH oxidase 5 does require a subunit for function. The document mentions that the other redox component, a flavoprotein, is now thought to be the heavy subunit of NADPH oxidase 5, based on amino acid sequence comparisons and reconstitution experiments with purified components. Additionally, the document states that pyridoxal-5'-diphospho-5'-adenosine is an inactivating affinity label for the NADPH-binding site of particulate oxidase from activated neutrophils, and that the NADPH-inhibitable incorporation is found at the same position as the immunodetectable cytochrome heavy subunit. These findings suggest that NADPH oxidase 5 has an NADPH-binding site that can only be affinity-labeled by PLP-AMP when the oxidase is active, which implies the occurrence of a conformational change in the cofactor binding site upon enzyme activation. Therefore, it can be concluded that NADPH oxidase 5 requires a subunit for function, specifically the heavy subunit, which is likely to be the flavoprotein component.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 requires a subunit to function.\n2. A flavoprotein is thought to be the heavy subunit of NADPH oxidase 5.\n3. The role of the heavy subunit in NADPH oxidase 5 has been suggested based on amino acid sequence comparisons and reconstitution experiments.\n4. Pyridoxal-5'-diphospho-5'-adenosine (PLP-AMP) is an inactivating affinity label for the NADPH-binding site of oxidase from activated neutrophils.\n5. Immunodetectable cytochrome heavy subunit is found at the same position as the NADPH-inhibitable incorporation.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 requires a subunit to function.",
      "A flavoprotein is thought to be the heavy subunit of NADPH oxidase 5.",
      "The role of the heavy subunit in NADPH oxidase 5 has been suggested based on amino acid sequence comparisons and reconstitution experiments.",
      "Pyridoxal-5'-diphospho-5'-adenosine (PLP-AMP) is an inactivating affinity label for the NADPH-binding site of oxidase from activated neutrophils.",
      "Immunodetectable cytochrome heavy subunit is found at the same position as the NADPH-inhibitable incorporation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: NADPH oxidase enzymes generally consist of multiple subunits, including membrane-bound and cytosolic components, which are necessary for their function.\n2. UNKNOWN: Without additional context or a specific source, it is unclear whether a flavoprotein is considered the heavy subunit of NADPH oxidase 5. Various NADPH oxidase isoforms have different subunit compositions, and the term \"heavy subunit\" is not standard.\n3. UNKNOWN: The role of any subunit in NADPH oxidase 5 being suggested based on amino acid sequence comparisons and reconstitution experiments would require specific scientific references to confirm its validity; thus, this statement is unknown without those references.\n4. TRUE: Pyridoxal-5'-diphospho-5'-adenosine (PLP-AMP) has been used as an affinity label for NADPH oxidase, targeting the NADPH-binding site.\n5. UNKNOWN: This statement is highly specific and seems to be derived from a particular experimental context related to immunodetection and NADPH-inhibitable incorporation. Without access to the specific scientific literature, it is impossible to confirm the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there appears to be a connection between furin and hepcidin. Furin is not directly mentioned in the passage, but it is related to hepcidin through the process of hepcidin-mediated ferroportin (FPN) degradation.\nHepcidin is a peptide hormone that regulates iron homeostasis in mammals by inducing the internalization and degradation of the FPN transporter. Increased levels of hepcidin due to inflammatory conditions can lead to impaired iron absorption and anemia of inflammation (AI). Inhibiting hepcidin-mediated FPN degradation is proposed as a strategy to combat AI.\nThe passage mentions a systematic approach involving in silico, in vitro, ex vivo, and in vivo studies to identify hepcidin-binding agents. Virtual screening of 68,752 natural compounds resulted in the identification of guanosine 5'-diphosphate (GDP) as a promising hepcidin-binding agent. The molecular dynamics simulations revealed that GDP binds to hepcidin residues involved in stabilization of the hepcidin-FPN complex. In vitro studies showed that GDP stabilized FPN and increased FPN-mediated cellular iron efflux in HepG2 and Caco-2 cells. Interestingly, the co-administration of GDP and ferrous sulphate (FeSO4) ameliorated turpentine-induced AI in mice, as indicated by increased hemoglobin levels, serum iron, FPN expression, and decreased ferritin levels.\nBased on these findings, it appears that GDP may inhibit the hepcidin-FPN interactions, which could potentially ameliorate AI. Furin may play a role in this process by facilitating the degradation of hepcidin, which could lead to increased FPN expression and iron efflux. However, further research is needed to confirm this connection and to fully understand the mechanisms involved.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin regulates iron homeostasis in mammals by inducing the internalization and degradation of the ferroportin (FPN) transporter.\n2. Increased levels of hepcidin can lead to impaired iron absorption and anemia of inflammation.\n3. Inhibiting hepcidin-mediated ferroportin degradation is proposed as a strategy to combat anemia of inflammation.\n4. Guanosine 5'-diphosphate (GDP) was identified as a promising hepcidin-binding agent through virtual screening of 68,752 natural compounds.\n5. Co-administration of GDP and ferrous sulphate (FeSO4) in mice ameliorated turpentine-induced anemia of inflammation, resulting in increased hemoglobin levels, serum iron, and FPN expression, and decreased ferritin levels.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin regulates iron homeostasis in mammals by inducing the internalization and degradation of the ferroportin (FPN) transporter.",
      "Increased levels of hepcidin can lead to impaired iron absorption and anemia of inflammation.",
      "Inhibiting hepcidin-mediated ferroportin degradation is proposed as a strategy to combat anemia of inflammation.",
      "Guanosine 5'-diphosphate (GDP) was identified as a promising hepcidin-binding agent through virtual screening of 68,752 natural compounds.",
      "Co-administration of GDP and ferrous sulphate (FeSO4) in mice ameliorated turpentine-induced anemia of inflammation, resulting in increased hemoglobin levels, serum iron, and FPN expression, and decreased ferritin levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements about hepcidin and its role in iron homeostasis, the effects of increased hepcidin levels, and the therapeutic strategy targeting hepcidin-mediated ferroportin degradation are consistent with current scientific understanding. \n\nStatements 4 and 5 might be true or false, but without specific evidence or references from recent scientific literature or clinical studies, I cannot confirm their accuracy. Thus, those are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the largest metabolic gene cluster in yeast is the galactose utilization (GAL) pathway. The document specifically mentions that the GAL cluster found in Saccharomyces and Candida yeasts originated through the relocation of native unclustered genes, and that the GAL cluster of Schizosaccharomyces yeasts was acquired through horizontal gene transfer from a Candida yeast. Additionally, the document states that the GAL cluster of Cryptococcus yeasts was assembled independently from the Saccharomyces/Candida and Schizosaccharomyces GAL clusters and coexists in the Cryptococcus genome with unclustered GAL paralogs. These findings suggest that the GAL pathway is the largest metabolic gene cluster in yeast, and that it has evolved through a complex history of gene relocation and horizontal gene transfer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the galactose utilization (GAL) pathway.\n2. The GAL cluster in Saccharomyces and Candida yeasts originated through the relocation of native unclustered genes.\n3. The GAL cluster of Schizosaccharomyces yeasts was acquired through horizontal gene transfer from a Candida yeast.\n4. The GAL cluster of Cryptococcus yeasts was assembled independently from those of Saccharomyces/Candida and Schizosaccharomyces yeasts.\n5. The Cryptococcus genome contains unclustered GAL paralogs alongside its independently assembled GAL cluster.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the galactose utilization (GAL) pathway.",
      "The GAL cluster in Saccharomyces and Candida yeasts originated through the relocation of native unclustered genes.",
      "The GAL cluster of Schizosaccharomyces yeasts was acquired through horizontal gene transfer from a Candida yeast.",
      "The GAL cluster of Cryptococcus yeasts was assembled independently from those of Saccharomyces/Candida and Schizosaccharomyces yeasts.",
      "The Cryptococcus genome contains unclustered GAL paralogs alongside its independently assembled GAL cluster."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the size of the metabolic gene cluster for galactose utilization (GAL) pathway in yeast does not provide enough context to determine its truthfulness. It would require specific scientific knowledge or research data to confirm.\n\n2. TRUE: This statement is consistent with scientific knowledge that the GAL cluster in Saccharomyces and Candida yeasts has been shown to have originated by the relocation of native unclustered genes to form a functional cluster.\n\n3. FALSE [correction]: The GAL cluster of Schizosaccharomyces yeasts is generally thought to have evolved independently, not acquired through horizontal gene transfer from a Candida yeast. Horizontal gene transfer is much rarer in complex eukaryotes like yeasts compared to prokaryotes.\n\n4. TRUE: The statement that the GAL cluster of Cryptococcus yeasts was assembled independently from those of Saccharomyces/Candida and Schizosaccharomyces yeasts is consistent with current scientific understanding. Cryptococcus species appear to have a different evolutionary history for their GAL cluster.\n\n5. UNKNOWN: This statement about the Cryptococcus genome containing unclustered GAL paralogs alongside its independently assembled GAL cluster would require specific genomic information or scientific research data to verify its truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of LIMT lncRNA is not specifically mentioned or discussed. However, the document does provide information on the functions of lncRNAs in general and the potential importance of prioritizing lncRNAs associated with diseases.\nLncRNAs are non-coding RNAs that play pivotal roles in many important biological processes, including gene regulation, chromatin modification, and RNA processing. However, research on the functions of lncRNAs in human disease is still in its infancy, and there is a need to prioritize lncRNAs that are potentially associated with diseases.\nThe document describes the development of a novel algorithm called LncPriCNet, which uses a multi-level composite network to prioritize candidate lncRNAs associated with diseases. LncPriCNet integrates genes, lncRNAs, phenotypes, and their associations to achieve an overall performance superior to that of previous methods, with high AUC values of up to 0.93. Notably, LncPriCNet still performs well when information on known disease lncRNAs is lacking.\nWhen applied to breast cancer, LncPriCNet identified known breast cancer-related lncRNAs, revealed novel lncRNA candidates, and inferred their functions via pathway analysis. The document also constructs the human disease-lncRNA landscape, reveals the modularity of the disease-lncRNA network, and identifies several lncRNA hotspots.\nIn summary, while the document does not specifically mention the role of LIMT lncRNA, it highlights the importance of prioritizing lncRNAs associated with diseases and provides a novel algorithm for doing so. The document also provides insights into the functions of lncRNAs in breast cancer and the human disease-lncRNA landscape.",
    "llama-2-7b-chat-hf_fact_raw": "1. LncRNAs are non-coding RNAs that are involved in gene regulation, chromatin modification, and RNA processing.\n2. Research on the functions of lncRNAs in human disease is at an early stage.\n3. LncPriCNet is a novel algorithm that prioritizes candidate lncRNAs associated with diseases.\n4. LncPriCNet integrates genes, lncRNAs, phenotypes, and their associations and achieves AUC values of up to 0.93.\n5. When applied to breast cancer, LncPriCNet identified known and novel breast cancer-related lncRNAs and inferred their functions through pathway analysis.",
    "llama-2-7b-chat-hf_fact": [
      "LncRNAs are non-coding RNAs that are involved in gene regulation, chromatin modification, and RNA processing.",
      "Research on the functions of lncRNAs in human disease is at an early stage.",
      "LncPriCNet is a novel algorithm that prioritizes candidate lncRNAs associated with diseases.",
      "LncPriCNet integrates genes, lncRNAs, phenotypes, and their associations and achieves AUC values of up to 0.93.",
      "When applied to breast cancer, LncPriCNet identified known and novel breast cancer-related lncRNAs and inferred their functions through pathway analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding regarding lncRNAs and represent plausible claims about a novel algorithm named LncPriCNet, which could potentially be a tool used in bioinformatics for disease-associated lncRNA research. However, detailed evaluation of the specific performance metrics like the AUC value provided in statement 4 would require access to the corresponding study or publication.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is \"girafe\".",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"girafe\" is used for performing SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"girafe\" is used for performing SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout context or additional information provided about the package \"girafe\" in R/Bioconductor, it's impossible to verify whether the statement is true or false. Generally, Bioconductor packages are used for bioinformatics analyses related to genomic data, but without specific knowledge of \"girafe,\" the claim cannot be substantiated.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the key players in radial glial specification to ependymal cells are:\n1. Radial glia: These are the first cells derived from neuroepithelial cells and possess properties of neural stem cells. They are found in the white matter of the spinal cord and play a crucial role in neural repair and regeneration after injury.\n2. Subpial astrocytes: These are the precursors of radial glia, which most likely play an important role in neural repair and regeneration after spinal cord injury (SCI).\n3. 3CB2 (a specific marker for radial glia): This antibody was used to identify and track the spread of radial glia after SCI.\n4. Nestin: This protein is expressed in radial glia and is involved in the maintenance of their stem cell properties.\n5. GFAP (glial fibrillary acidic protein): This protein is expressed in radial glia and other glial cells in the spinal cord, and is involved in the maintenance of their differentiated state.\nIn summary, the key players in radial glial specification to ependymal cells are the radial glia themselves, as well as the subpial astrocytes from which they derive. The expression of specific markers such as 3CB2, nestin, and GFAP can help identify and track these cells in the spinal cord after injury.",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glia are derived from neuroepithelial cells and possess neural stem cell properties.\n2. Subpial astrocytes are precursors to radial glia and are likely to play an important role in neural repair after spinal cord injury.\n3. The 3CB2 antibody is a specific marker for radial glia used to track their spread after spinal cord injury.\n4. Nestin protein is expressed in radial glia and is involved in maintaining their stem cell properties.\n5. GFAP is expressed in radial glia and other glial cells in the spinal cord, playing a role in maintaining a differentiated state.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glia are derived from neuroepithelial cells and possess neural stem cell properties.",
      "Subpial astrocytes are precursors to radial glia and are likely to play an important role in neural repair after spinal cord injury.",
      "The 3CB2 antibody is a specific marker for radial glia used to track their spread after spinal cord injury.",
      "Nestin protein is expressed in radial glia and is involved in maintaining their stem cell properties.",
      "GFAP is expressed in radial glia and other glial cells in the spinal cord, playing a role in maintaining a differentiated state."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Subpial astrocytes are not precursors to radial glia. Radial glia are derived from neuroepithelial cells and function as radial glial cells before differentiating into other glial cells such as astrocytes.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, triple negative gliomas are characterized by the following features on DCE MR images:\n1. Higher ADC (apparent diffusion coefficient) values: Triple negative gliomas have higher ADC values compared to other types of breast cancer, indicating a more rapid diffusion of contrast agent.\n2. Lower T1 and T2 values: Triple negative gliomas have lower T1 and T2 values, indicating a higher signal intensity on T1- and T2-weighted images.\n3. Higher lesion contrast: Triple negative gliomas have higher lesion contrast on DCE MR images, indicating a more prominent enhancement pattern.\n4. Irregular shape: Triple negative gliomas often have irregular shapes, which can make them difficult to distinguish from benign fibroadenomas.\nThese features can be used to differentiate triple negative gliomas from other types of breast cancer and benign lesions using a computer-aided diagnosis (CAD) system. The article reports an area under the receiver operating characteristic curve (Az) of 0.73 for the classification of triple-negative cancer versus all non-triple-negative lesions, indicating moderate accuracy in the classification.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by higher ADC values compared to other types of breast cancer.\n2. Triple negative gliomas are characterized by lower T1 and T2 values on DCE MR images.\n3. Triple negative gliomas are characterized by higher lesion contrast on DCE MR images.\n4. Triple negative gliomas often present with irregular shapes.\n5. A reported area under the receiver operating characteristic curve (Az) of 0.73 indicates moderate accuracy in classifying triple-negative cancer versus all non-triple-negative lesions.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by higher ADC values compared to other types of breast cancer.",
      "Triple negative gliomas are characterized by lower T1 and T2 values on DCE MR images.",
      "Triple negative gliomas are characterized by higher lesion contrast on DCE MR images.",
      "Triple negative gliomas often present with irregular shapes.",
      "A reported area under the receiver operating characteristic curve (Az) of 0.73 indicates moderate accuracy in classifying triple-negative cancer versus all non-triple-negative lesions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gliomas are a type of brain cancer, not breast cancer. Furthermore, the statement about ADC (Apparent Diffusion Coefficient) values is difficult to verify without specific research context, as ADC values can vary across studies, but it is generally understood that higher ADC values are associated with less aggressive tumors, so this characteristic would not typically be associated with triple negative gliomas which are usually more aggressive.\n2. FALSE [correction]: This statement is difficult to evaluate without specific research context, as T1 and T2 values can vary. However, generally speaking, T1 and T2 refer to relaxation times in magnetic resonance imaging (MRI), and it is not standard to discuss these in terms of 'lower' or 'higher' without context as to what they are being compared to. Moreover, the statement is also incorrect in the context that it again refers to breast cancer when mentioning triple negative gliomas, which should be related to brain cancer.\n3. UNKNOWN: The contrast characteristics of triple negative gliomas on DCE (Dynamic Contrast Enhanced) MR images would need to be determined by specific research data. Generally, DCE MRI can show differences between cancerous and non-cancerous tissue, but without context, it is not possible to verify the exact behavior of triple negative gliomas.\n4. UNKNOWN: The shape of triple-negative gliomas can vary, and while irregular shapes can be a common characteristic of malignant tumors, this generalization might not apply to all cases. A specific study or reference is needed to confirm this statement.\n5. TRUE: An Az (Area under the Curve) value of 0.73 on the receiver operating characteristic (ROC) curve does indicate moderate accuracy. The ROC curve is a graphical representation of the diagnostic ability of a binary classifier system, and an Az value between 0.7 and 0.8 is generally considered to indicate moderate accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, TOPAZ1 appears to be a gene that plays a crucial role in the development and function of male gametes, particularly in the process of spermatogenesis. The gene is highly conserved across vertebrates and is specifically expressed in germ cells, including testes and ovaries. The protein product of TOPAZ1, Topaz1, contains a PAZ domain, which is found in PIWI, Argonaute, and Zwille proteins, and is involved in the piRNA pathway.\nIn the study reported in the document, the researchers inactivated the TOPAZ1 gene in mice and observed the effects on male fertility. They found that while female fertility was not affected, male mutants were sterile, with extensive apoptosis and a complete lack of spermatids and spermatozoa in the testes. The study also showed that TOPAZ1 influences the expression of over 100 transcripts, including long non-coding RNAs, during spermatogenesis.\nBased on these findings, it can be concluded that TOPAZ1 is an essential gene for male gametogenesis and that its inactivation leads to significant disruptions in the process of spermatogenesis, resulting in male sterility. The study suggests that a highly regulated balance of long non-coding RNAs may be essential for the proper induction of male gamete production during spermatogenesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a gene that plays a role in the development and function of male gametes.\n2. The protein product of TOPAZ1, Topaz1, contains a PAZ domain.\n3. Inactivating the TOPAZ1 gene in mice resulted in male sterility due to extensive apoptosis and lack of spermatids and spermatozoa in the testes.\n4. Female fertility was not affected by the inactivation of the TOPAZ1 gene in mice.\n5. The TOPAZ1 gene influences the expression of over 100 transcripts during spermatogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a gene that plays a role in the development and function of male gametes.",
      "The protein product of TOPAZ1, Topaz1, contains a PAZ domain.",
      "Inactivating the TOPAZ1 gene in mice resulted in male sterility due to extensive apoptosis and lack of spermatids and spermatozoa in the testes.",
      "Female fertility was not affected by the inactivation of the TOPAZ1 gene in mice.",
      "The TOPAZ1 gene influences the expression of over 100 transcripts during spermatogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The protein product of TOPAZ1 is called Testis Proliferation-Associated Zinc Finger Protein (TOPAZ1), and it does not contain a PAZ domain. PAZ domains are generally found in proteins involved in RNA interference, not typically in those associated with spermatogenesis.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the gene that controls the expression of GATA-1 isoforms is the upstream hypersensitive site (HS I). The study found that inclusion of HS I markedly enhances the frequency of expressing transgenic lines and activates expression in primitive erythroid cells, recapitulating the proper pattern of GATA-1 expression during development. Therefore, it can be concluded that HS I is the gene that controls the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The upstream hypersensitive site (HS I) controls the expression of GATA-1 isoforms.\n2. Inclusion of HS I enhances the frequency of expressing transgenic lines according to the study.\n3. HS I activates expression in primitive erythroid cells.\n4. The proper pattern of GATA-1 expression during development is recapitulated by HS I.",
    "llama-2-7b-chat-hf_fact": [
      "The upstream hypersensitive site (HS I) controls the expression of GATA-1 isoforms.",
      "Inclusion of HS I enhances the frequency of expressing transgenic lines according to the study.",
      "HS I activates expression in primitive erythroid cells.",
      "The proper pattern of GATA-1 expression during development is recapitulated by HS I."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout additional context or a reference to the specific study being discussed, it is not possible to ascertain the accuracy of these claims about the upstream hypersensitive site (HS I) and its effects on the expression of GATA-1 isoforms or its role in the expression in transgenic lines or primitive erythroid cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MIRA-seq appears to be a computer program designed for the analysis and manipulation of nucleotide sequences, particularly in the context of recombinant DNA experiments. It is an interactive and self-documenting program, meaning that it provides information and instructions to the user as they work with it.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the indication of ARCALYST is to investigate the effect of atypical antipsychotics on the immediate-early gene, arc (activity-regulated cytoskeleton-associated gene), expression in the prefrontal cortex, nucleus accumbens, and posterior cingulate cortex of rats treated with phencyclidine (PCP). The study suggests that certain atypical antipsychotics, such as clozapine, olanzapine, and risperidone, can prevent PCP-induced arc expression in the prefrontal cortex and nucleus accumbens, while haloperidol can increase arc expression in the striatum. These findings may be useful in distinguishing the atypical antipsychotic properties of these drugs.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human acrocentric chromosomes involved in Robertsonian translocations are:\n* Chromosome 21 (21q)\nRobertsonian translocations between acrocentric chromosomes are the most common structural chromosomal rearrangements in humans and other organisms, and they typically involve the exchange of genetic material between two acrocentric chromosomes. In the case of the translocation 21q;21q, the two 21q arms of the rearranged chromosome have a biparental origin, meaning that one 21q arm is paternal and the other is maternal. This suggests that the formation of the Robertsonian translocation occurs in the zygote or in the first few postzygotic mitotic divisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Human acrocentric chromosomes are those involved in Robertsonian translocations.\n2. Chromosome 21, denoted as 21q, is an acrocentric chromosome that can be involved in Robertsonian translocations.\n3. Robertsonian translocations are the most common structural chromosomal rearrangements in humans.\n4. Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.\n5. In a 21q;21q Robertsonian translocation, one 21q arm is of paternal origin and the other is of maternal origin, suggesting formation during zygote stage or early postzygotic mitotic divisions.",
    "llama-2-7b-chat-hf_fact": [
      "Human acrocentric chromosomes are those involved in Robertsonian translocations.",
      "Chromosome 21, denoted as 21q, is an acrocentric chromosome that can be involved in Robertsonian translocations.",
      "Robertsonian translocations are the most common structural chromosomal rearrangements in humans.",
      "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.",
      "In a 21q;21q Robertsonian translocation, one 21q arm is of paternal origin and the other is of maternal origin, suggesting formation during zygote stage or early postzygotic mitotic divisions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Acrocentric chromosomes, which are human chromosomes with a centromere near one end, can indeed be involved in Robertsonian translocations.\n2. TRUE: Chromosome 21 is an acrocentric chromosome, and it can be involved in Robertsonian translocations.\n3. TRUE: Robertsonian translocations are considered the most common form of structural chromosomal rearrangements in humans.\n4. TRUE: Robertsonian translocations typically involve the fusion of the long arms (q arms) of two acrocentric chromosomes at their centromeres.\n5. FALSE [correction]: A 21q;21q Robertsonian translocation would be homologous, involving two chromosome 21 q arms, but the parental origin of the arms cannot be determined without additional information, and it does not exclusively suggest a formation during the zygote stage or early postzygotic mitotic divisions, as the translocation could also occur during gametogenesis (meiosis).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package that could be used for the identification of pediatric brain tumors is likely to be \"radiomicsR\". This package provides a set of functions for extracting quantitative imaging features from medical images, including MRI and CT scans. These features can be used to identify and classify different types of brain tumors, including medulloblastoma.\nThe document mentions that SSTR scintigraphy is a sensitive imaging technique for detecting vital tumor tissue in children with medulloblastoma, and that the high density of SSTR in autoradiography correlates with a sensitive imaging of these tumors by SSTR scintigraphy. This suggests that the package \"radiomicsR\" could be used to analyze the imaging features of these tumors and identify potential biomarkers for diagnosis and treatment monitoring.\nAdditionally, the document mentions that the integrity of the blood-brain barrier can be tested by Tc-99m-DTPA scintigraphy, which is also a function that can be performed using the \"radiomicsR\" package. This suggests that the package could be used to analyze the imaging features of the blood-brain barrier and identify potential biomarkers for diagnosis and treatment monitoring.\nIn summary, based on the information provided in the document, the R package \"radiomicsR\" appears to be the most suitable for the identification of pediatric brain tumors, particularly medulloblastoma, using imaging features such as SSTR scintigraphy and Tc-99m-DTPA scintigraphy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"radiomicsR\" can be used for extracting quantitative imaging features from medical images like MRI and CT scans.\n2. \"RadiomicsR\" could potentially be used to identify and classify different types of brain tumors, including medulloblastoma.\n3. SSTR scintigraphy is a sensitive imaging technique for detecting vital tumor tissue in children with medulloblastoma.\n4. A high density of SSTR in autoradiography correlates with sensitive imaging of medulloblastoma tumors by SSTR scintigraphy.\n5. The integrity of the blood-brain barrier can be tested by Tc-99m-DTPA scintigraphy, a function that can be performed using the \"radiomicsR\" package.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"radiomicsR\" can be used for extracting quantitative imaging features from medical images like MRI and CT scans.",
      "\"RadiomicsR\" could potentially be used to identify and classify different types of brain tumors, including medulloblastoma.",
      "SSTR scintigraphy is a sensitive imaging technique for detecting vital tumor tissue in children with medulloblastoma.",
      "A high density of SSTR in autoradiography correlates with sensitive imaging of medulloblastoma tumors by SSTR scintigraphy.",
      "The integrity of the blood-brain barrier can be tested by Tc-99m-DTPA scintigraphy, a function that can be performed using the \"radiomicsR\" package."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The R package \"radiomicsR\" is designed to extract quantitative imaging features from medical images, which can include MRI and CT scans.\n2. TRUE: \"RadiomicsR\" can indeed be used to identify and classify different types of tumors, provided the appropriate imaging data and analysis protocols are used, and this includes types of brain tumors such as medulloblastoma.\n3. UNKNOWN: The sensitivity of SSTR scintigraphy for detecting vital tumor tissue in children with medulloblastoma is specific to medical literature and research findings, which are not provided. Therefore, without this context, the statement's accuracy is unknown.\n4. UNKNOWN: The correlation between the density of SSTR in autoradiography and the sensitivity of SSTR scintigraphy for imaging medulloblastoma tumors is a specific claim that would require research data to verify, so without that information, its accuracy is unknown.\n5. FALSE [correction]: The integrity of the blood-brain barrier can be tested by Tc-99m-DTPA scintigraphy; however, the \"radiomicsR\" package is a tool for extracting features from imagery and likely does not directly perform scintigraphy functions such as testing the blood-brain barrier. Testing the integrity of the blood-brain barrier with Tc-99m-DTPA scintigraphy is a procedure conducted in a clinical setting.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, NEMO is not a zinc finger protein. The document specifically mentions that the nucleocapsid protein (NC) from the mouse mammary tumor virus (MMTV) contains two copies of a conserved zinc-coordinating \"CCHC array\" or \"zinc knuckle\" motif, which is common to the nucleocapsid proteins of nearly all known retroviruses. However, the document does not mention NEMO as a zinc finger protein. In fact, the document specifically states that the two zinc knuckles of the MMTV NC do not interact with each other, but instead behave as independently folded domains connected by a flexible 13-residue linker segment. Therefore, based on the information provided in the document, NEMO is not a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is not a zinc finger protein according to the information provided in the document.\n2. The nucleocapsid protein (NC) of the mouse mammary tumor virus (MMTV) contains two copies of a zinc-coordinating motif known as a \"CCHC array\" or \"zinc knuckle.\"\n3. The mentioned \"CCHC array\" or \"zinc knuckle\" motif is common to the nucleocapsid proteins of nearly all known retroviruses.\n4. The document states that the two zinc knuckles of the MMTV NC behave as independently folded domains.\n5. The two zinc knuckles of the MMTV NC are connected by a flexible 13-residue linker segment.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is not a zinc finger protein according to the information provided in the document.",
      "The nucleocapsid protein (NC) of the mouse mammary tumor virus (MMTV) contains two copies of a zinc-coordinating motif known as a \"CCHC array\" or \"zinc knuckle.\"",
      "The mentioned \"CCHC array\" or \"zinc knuckle\" motif is common to the nucleocapsid proteins of nearly all known retroviruses.",
      "The document states that the two zinc knuckles of the MMTV NC behave as independently folded domains.",
      "The two zinc knuckles of the MMTV NC are connected by a flexible 13-residue linker segment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the provided document, it's impossible to verify the accuracy of the statements regarding NEMO, MMTV NC's structure, the commonality of the CCHC array in retroviruses, the behavior of MMTV NC's zinc knuckles, and the specific details about the linker segment.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that TFIIS does affect nucleosome positioning. The study found that the lack of TFIIS leads to general increases in nucleosomal fuzziness and more restricted changes in nucleosome occupancy, which concentrates in some gene categories. Specifically, the study found that TATA-containing genes were preferentially associated with decreased occupancy in gene bodies, while TATA-like genes showed increased fuzziness. These changes in nucleosome positioning were found to correlate with functional defects in nascent transcription, as revealed by genomic run-on experiments.\nTherefore, based on the information provided in the document, the answer to the user's question is yes, TFIIS does affect nucleosome positioning.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS influences nucleosome positioning.\n2. The absence of TFIIS leads to an increase in nucleosomal fuzziness.\n3. A lack of TFIIS results in changes to nucleosome occupancy that are largely concentrated in certain gene categories.\n4. TATA-containing genes are associated with decreased nucleosome occupancy in gene bodies in the absence of TFIIS.\n5. TATA-like genes exhibit increased nucleosomal fuzziness when TFIIS is lacking.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS influences nucleosome positioning.",
      "The absence of TFIIS leads to an increase in nucleosomal fuzziness.",
      "A lack of TFIIS results in changes to nucleosome occupancy that are largely concentrated in certain gene categories.",
      "TATA-containing genes are associated with decreased nucleosome occupancy in gene bodies in the absence of TFIIS.",
      "TATA-like genes exhibit increased nucleosomal fuzziness when TFIIS is lacking."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to the specific functions and effects of the transcription factor TFIIS on nucleosome dynamics; however, without access to the current and specific research findings or a clear scientific consensus, it is difficult to determine the truth of these statements. They are highly technical and would require specific biochemical and genetic studies to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that origins of replication close to yeast centromeres fire late in the S-phase of the cell cycle. The document states that at S-phase onset, origins fire randomly and sparsely throughout the chromosomes, and it is not until later in S-phase that clusters of fired origins appear embedded in the sparser regions. These clusters are formed through the proper histone methylation and acetylation, and their locations are not inherited between cell cycles. Additionally, the document states that the rate of origin firing increases gradually, peaking just before mid S-phase, and that nearly all the available origins within the unreplicated regions are fired by the end of S-phase. These findings suggest that while some origins may fire early, the majority of origins close to centromeres fire later in the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication close to yeast centromeres fire late in the S-phase of the cell cycle.\n2. At the onset of S-phase, origins fire randomly and sparsely throughout the chromosomes.\n3. Clusters of fired origins appear later in S-phase.\n4. The rate of origin firing increases, peaking just before mid S-phase.\n5. Nearly all available origins within unreplicated regions are fired by the end of S-phase.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication close to yeast centromeres fire late in the S-phase of the cell cycle.",
      "At the onset of S-phase, origins fire randomly and sparsely throughout the chromosomes.",
      "Clusters of fired origins appear later in S-phase.",
      "The rate of origin firing increases, peaking just before mid S-phase.",
      "Nearly all available origins within unreplicated regions are fired by the end of S-phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication close to yeast centromeres tend to fire early in the S-phase of the cell cycle.\n2. UNKNOWN: Without specific research on the timing of all origins' firing, it is difficult to say whether they fire randomly, though it is known that firing is regulated and some origins fire at specific times.\n3. TRUE: Clusters of fired origins can appear later in S-phase, suggesting spatial coordination among replication origins.\n4. UNKNOWN: The detailed kinetics of replication origin firing can vary, and without specific evidence, we cannot confirm that the rate peaks just before mid S-phase.\n5. TRUE: By the end of S-phase, nearly all available origins within unreplicated regions are typically fired to ensure complete replication of the genome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the properties of mammalian GA-sequences are:\n1. Contain the cDNA for Glutamic acid decarboxylase (GAD) from feline brain.\n2. Catalyze the production of GABA, the major inhibitory neurotransmitter in the mammalian brain.\n3. Are enzymatically active, catalyzing the conversion of glutamate to CO2 and GABA.\n4. Consist of 2265 bases with a continuous open reading frame of 625 codons.\n5. Have a sequence identical to the pyridoxal phosphate-binding site of porcine DOPA decarboxylase.\n6. Have an N-terminal residue, amino acid composition, and molecular size consistent with published characterizations of GAD.\nThe nucleotide sequence of feline GAD cDNA is reported in the passage, and the properties of mammalian GA-sequences are inferred based on the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences contain the cDNA for Glutamic acid decarboxylase (GAD) from feline brain.\n2. Mammalian GA-sequences catalyze the production of GABA, which is the major inhibitory neurotransmitter in the mammalian brain.\n3. The GA-sequences are enzymatically active and catalyze the conversion of glutamate to CO2 and GABA.\n4. Mammalian GA-sequences consist of 2265 bases with a continuous open reading frame of 625 codons.\n5. The sequence of mammalian GA-sequences is identical to the pyridoxal phosphate-binding site of porcine DOPA decarboxylase.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences contain the cDNA for Glutamic acid decarboxylase (GAD) from feline brain.",
      "Mammalian GA-sequences catalyze the production of GABA, which is the major inhibitory neurotransmitter in the mammalian brain.",
      "The GA-sequences are enzymatically active and catalyze the conversion of glutamate to CO2 and GABA.",
      "Mammalian GA-sequences consist of 2265 bases with a continuous open reading frame of 625 codons.",
      "The sequence of mammalian GA-sequences is identical to the pyridoxal phosphate-binding site of porcine DOPA decarboxylase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The term \"GA-sequences\" is not commonly used to refer to genes or cDNA sequences. If by \"GA-sequences\" it is meant that they contain the cDNA for Glutamic acid decarboxylase (GAD), then this part could be true as GAD cDNA can indeed be derived from feline brain among other mammalian sources.\n2. TRUE: Mammalian Glutamic acid decarboxylase (GAD) does catalyze the production of gamma-aminobutyric acid (GABA), which is the major inhibitory neurotransmitter in the mammalian brain.\n3. FALSE [correction]: The GA-sequences, or more specifically GAD enzymes, catalyze the conversion of glutamate to GABA, not to CO2 and GABA. CO2 is a byproduct of the reaction.\n4. UNKNOWN: This statement provides specific information about the length and coding capacity of mammalian GA-sequences, but without access to specific genetic data or references, the accuracy of \"2265 bases with a continuous open reading frame of 625 codons\" cannot be verified.\n5. FALSE [correction]: While mammalian GAD and porcine DOPA decarboxylase may both bind pyridoxal phosphate and thus share some sequence similarity at their active sites, it is unlikely the sequences are identical due to species-specific differences and differences in the enzymes themselves.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 5 Groucho-related genes (GRG) contained in the mouse genome: Grg1, Grg2, Grg3, Grg4, and Grg5/AES.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 5 Groucho-related genes (GRG) contained in the mouse genome.\n2. The Groucho-related genes present in the mouse genome are named Grg1, Grg2, Grg3, Grg4, and Grg5/AES.",
    "llama-2-7b-chat-hf_fact": [
      "There are 5 Groucho-related genes (GRG) contained in the mouse genome.",
      "The Groucho-related genes present in the mouse genome are named Grg1, Grg2, Grg3, Grg4, and Grg5/AES."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Groucho-related genes present in the mouse genome are named Grg1, Grg2, Grg3, Grg4, and Grg5/TLE6.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the RNA polymerase II subunit that carries RNA cleavage activity is the C11 subunit. The document states that a mutant form of RNA polymerase III (Pol III) that was heterocomplemented with a subunit from Schizosaccharomyces pombe (C11) was affected in transcription termination in vivo, and that a purified form of the enzyme (Pol III Delta) lacked the intrinsic RNA cleavage activity of complete Pol III. In vitro reconstitution experiments also demonstrated that Pol III RNA cleavage activity is mediated by C11. Additionally, mutagenesis of two conserved residues in C11, which are critical for the TFIIS-dependent cleavage activity of Pol II, is lethal. These findings suggest that C11 is the subunit that carries the RNA cleavage activity in RNA polymerase II.",
    "llama-2-7b-chat-hf_fact_raw": "1. The RNA polymerase II subunit with RNA cleavage activity is identified as the C11 subunit.\n2. A mutant form of RNA polymerase III that included a subunit from Schizosaccharomyces pombe (C11) showed altered transcription termination in vivo.\n3. Pol III Delta, a purified form of the enzyme, lacked the intrinsic RNA cleavage activity of complete Pol III.\n4. In vitro reconstitution experiments indicated that Pol III RNA cleavage activity is mediated by the C11 subunit.\n5. Mutation of two conserved residues in C11 that are important for TFIIS-dependent cleavage activity of Pol II resulted in lethality.",
    "llama-2-7b-chat-hf_fact": [
      "The RNA polymerase II subunit with RNA cleavage activity is identified as the C11 subunit.",
      "A mutant form of RNA polymerase III that included a subunit from Schizosaccharomyces pombe (C11) showed altered transcription termination in vivo.",
      "Pol III Delta, a purified form of the enzyme, lacked the intrinsic RNA cleavage activity of complete Pol III.",
      "In vitro reconstitution experiments indicated that Pol III RNA cleavage activity is mediated by the C11 subunit.",
      "Mutation of two conserved residues in C11 that are important for TFIIS-dependent cleavage activity of Pol II resulted in lethality."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The RNA polymerase II subunit with RNA cleavage activity in the context of transcription is known as TFIIS, not C11.\n2. UNKNOWN: There is not enough context provided to confirm whether this statement about a mutated form of RNA polymerase III is true or false.\n3. UNKNOWN: The context does not specify what \"Pol III Delta\" refers to or if this statement accurately describes its properties.\n4. FALSE [correction]: Typically, the TFIIS protein, not the C11 subunit, is associated with RNA cleavage activity in Pol II, and there's insufficient context to confirm whether this statement applies accurately to Pol III in vitro studies.\n5. UNKNOWN: While mutation of conserved residues in certain proteins can lead to lethality, there's not enough information to confirm the specifics about the C11 subunit and any comparison to TFIIS-dependent cleavage without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genetic basis of Ohdo syndrome is likely to be related to a mutation or variation in a gene or genes involved in the development and maintenance of the skeleton. The syndrome is characterized by joint laxity and skeletal deformities, which are thought to be caused by a genetic defect that affects the structure and function of the bones and joints.\nOhdo syndrome is a rare genetic disorder that is caused by mutations in the PTPN11 gene, which encodes a protein called SHP-2. SHP-2 is a key regulator of signaling pathways involved in the development and maintenance of the skeleton, and mutations in this gene have been shown to lead to the characteristic skeletal abnormalities of Ohdo syndrome.\nIn addition to the PTPN11 gene, other genes that have been implicated in the development of Ohdo syndrome include the PTEN gene, which encodes a protein that regulates the PI3K/AKT signaling pathway, and the SLC24A5 gene, which encodes a protein involved in the transport of calcium ions in the bone.\nWhile the genetic basis of Ohdo syndrome is still not fully understood, research has shown that mutations in these genes can lead to the characteristic skeletal abnormalities and joint laxity seen in the syndrome. Further research is needed to determine the full range of genetic factors that contribute to the development of Ohdo syndrome and to identify potential therapeutic targets for the treatment of the syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is thought to be caused by a genetic defect that affects the structure and function of bones and joints.\n2. Mutations in the PTPN11 gene, which encodes SHP-2 protein, have been shown to lead to the skeletal abnormalities of Ohdo syndrome.\n3. The SHP-2 protein is a regulator of signaling pathways involved in the development and maintenance of the skeleton.\n4. The PTEN gene associated with Ohdo syndrome encodes a protein that regulates the PI3K/AKT signaling pathway.\n5. The SLC24A5 gene, also implicated in Ohdo syndrome, encodes a protein involved in the transport of calcium ions in the bone.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is thought to be caused by a genetic defect that affects the structure and function of bones and joints.",
      "Mutations in the PTPN11 gene, which encodes SHP-2 protein, have been shown to lead to the skeletal abnormalities of Ohdo syndrome.",
      "The SHP-2 protein is a regulator of signaling pathways involved in the development and maintenance of the skeleton.",
      "The PTEN gene associated with Ohdo syndrome encodes a protein that regulates the PI3K/AKT signaling pathway.",
      "The SLC24A5 gene, also implicated in Ohdo syndrome, encodes a protein involved in the transport of calcium ions in the bone."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the MED12 gene, not the PTPN11 gene, have been shown to lead to the developmental abnormalities of Ohdo syndrome.\n3. TRUE\n4. FALSE [correction]: The PTEN gene is not associated with Ohdo syndrome; it is implicated in a number of conditions, including Cowden syndrome, and it regulates the PI3K/AKT signaling pathway, but not specifically in the context of Ohdo syndrome.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is GOstats. GOstats is a Bioconductor package written in R that allows users to test GO terms for over or under-representation using either a classical hypergeometric test or a conditional hypergeometric test that uses the relationships among GO terms to decorrelate the results. The package is available as an R package from the Bioconductor project.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called GOstats.\n2. GOstats allows users to test Gene Ontology (GO) terms for over or under-representation.\n3. GOstats employs a classical hypergeometric test or a conditional hypergeometric test in its analysis.\n4. The conditional hypergeometric test in GOstats uses the relationships among GO terms to decorrelate the results.\n5. GOstats is available for download from the Bioconductor project.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called GOstats.",
      "GOstats allows users to test Gene Ontology (GO) terms for over or under-representation.",
      "GOstats employs a classical hypergeometric test or a conditional hypergeometric test in its analysis.",
      "The conditional hypergeometric test in GOstats uses the relationships among GO terms to decorrelate the results.",
      "GOstats is available for download from the Bioconductor project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: While GOstats is an R/Bioconductor package for statistical analysis, it is not specifically developed for the analysis of psychiatric disease genes; it is developed for general analysis of GO terms in various contexts including different diseases.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign in intracerebral hemorrhage refers to a specific pattern of brain swelling observed on MRI scans. It is characterized by a whirlpool or swirling motion of the brain tissue around the site of the hemorrhage, which can indicate increased intracranial pressure and potential for further brain damage.\nIn the case of the term newborn hospitalized for meconium aspiration syndrome, the presence of a swirl sign on MRI suggests that the cerebellar hematoma caused hydrocephalus, which can lead to further complications such as increased intracranial pressure, brain edema, and brain damage. The successful evacuation of the hematoma through neuroendoscopy may have helped to resolve these complications and improve the patient's neurological function.\nIt is important to note that the swirl sign is not a diagnostic criterion for intracerebral hemorrhage, and its presence does not necessarily indicate the need for neurosurgical intervention. However, in severe cases of intracerebral hemorrhage, the swirl sign can be a useful indicator of increased intracranial pressure and potential for further brain damage, and may warrant prompt medical attention.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign in intracerebral hemorrhage is observed on MRI scans.\n2. It is characterized by a swirling motion of brain tissue around the site of a hemorrhage.\n3. Presence of swirl sign can indicate increased intracranial pressure and the potential for further brain damage.\n4. In the context of a term newborn with meconium aspiration syndrome, a cerebellar hematoma indicated by a swirl sign on MRI could cause hydrocephalus.\n5. The swirl sign itself is not a diagnostic criterion for intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign in intracerebral hemorrhage is observed on MRI scans.",
      "It is characterized by a swirling motion of brain tissue around the site of a hemorrhage.",
      "Presence of swirl sign can indicate increased intracranial pressure and the potential for further brain damage.",
      "In the context of a term newborn with meconium aspiration syndrome, a cerebellar hematoma indicated by a swirl sign on MRI could cause hydrocephalus.",
      "The swirl sign itself is not a diagnostic criterion for intracerebral hemorrhage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by the presence of a heterogeneous internal appearance within a hematoma on a CT scan, not a swirling motion of brain tissue.\n3. TRUE: The presence of swirl sign in intracerebral hemorrhage is suggestive of an active or ongoing bleeding, which can potentially lead to increased intracranial pressure and the potential for more severe secondary brain injury.\n4. TRUE: In the context of a term newborn with meconium aspiration syndrome, if imaging such as an MRI reveals a cerebellar hematoma with a swirl sign, it may indicate bleeding that could lead to complications such as hydrocephalus.\n5. FALSE [correction]: The swirl sign is a radiologic finding that can be seen on CT scans of the head and is a diagnostic criterion for active or ongoing bleeding within an intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that Arabidopsis ROF1 expression is induced by the production of reactive oxygen species (ROS) via the action of two NADPH oxidases (AtrbohD and AtrbohF) in the jasmonic acid (JA) signaling pathway. The study found that treatment with methyl JA (MeJA) significantly suppressed the accumulation of ROS and the expression of genes regulated by MYC2, a transcription factor involved in the JA-evoked response, in both Atrboh single knockout mutants. Additionally, the study found that the production of ROS via Atrbohs depends on the function of COI1, a master regulator of the JA-evoked response, but not MYC2. Therefore, it can be inferred that Arabidopsis ROF1 expression is induced by the production of ROS via Atrbohs in the JA signaling pathway, and this process is mediated by COI1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by the production of reactive oxygen species (ROS).\n2. The NADPH oxidases AtrbohD and AtrbohF are involved in the production of ROS in the jasmonic acid signaling pathway.\n3. Methyl jasmonate (MeJA) treatment significantly suppressed the accumulation of ROS and the expression of genes regulated by MYC2.\n4. The production of ROS via AtrbohD and AtrbohF depends on the function of COI1, a master regulator in the JA signaling pathway.\n5. MYC2 is not necessary for ROS production by Atrbohs in the context of ROF1 expression in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by the production of reactive oxygen species (ROS).",
      "The NADPH oxidases AtrbohD and AtrbohF are involved in the production of ROS in the jasmonic acid signaling pathway.",
      "Methyl jasmonate (MeJA) treatment significantly suppressed the accumulation of ROS and the expression of genes regulated by MYC2.",
      "The production of ROS via AtrbohD and AtrbohF depends on the function of COI1, a master regulator in the JA signaling pathway.",
      "MYC2 is not necessary for ROS production by Atrbohs in the context of ROF1 expression in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is well-established that in plants, the expression of certain genes such as ROF1 can be induced by the production of reactive oxygen species (ROS), which can result from various environmental stressors.\n2. TRUE: NADPH oxidases, such as AtrbohD and AtrbohF, have been implicated in the production of ROS within the jasmonic acid (JA) signaling pathway in Arabidopsis thaliana.\n3. FALSE [correction]: Methyl jasmonate (MeJA) treatment usually leads to the increased production of ROS and promotes the expression of genes that are regulated by MYC2 within the JA signaling pathway. MYC2 is a transcription factor that plays a crucial role in this pathway.\n4. TRUE: COI1 (CORONATINE INSENSITIVE 1) is indeed a master regulator of the jasmonic acid signaling pathway. The function of NADPH oxidases like AtrbohD and AtrbohF in the production of ROS is often dependent on JA signaling components, including COI1.\n5. UNKNOWN: Without specific context or experimental evidence provided, we cannot definitively determine whether MYC2 is necessary for ROS production by Atrbohs in the context of ROF1 expression in Arabidopsis. MYC2 is an important regulator in the JA signaling pathway, and its involvement with ROS production can be complex.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the most common cause of hereditary renal amyloidosis is mutant transthyretin (ATTRm).",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutant transthyretin (ATTRm) is the most common cause of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Mutant transthyretin (ATTRm) is the most common cause of hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutant transthyretin (ATTRm) amyloidosis is commonly associated with hereditary ATTR amyloidosis affecting the nerves and heart, not primarily the kidneys. The most common cause of hereditary renal amyloidosis is related to mutations in the genes encoding for fibrillary proteins, such as the genes for apolipoprotein A-I, apolipoprotein A-II, lysozyme, or fibrinogen A alpha-chain, depending on the population.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed using methods such as isolation of membrane proteins from small amounts of tissue and the HysTag-quantification method. A study published in 2005 by Nielsen et al. used these methods to perform a quantitative proteomic analysis of three functionally distinct compartments of mouse brain, including the hippocampus, and found 976 unique peptides corresponding to 555 unique proteins. The study showed that there were significant differences in the levels of some proteins between brain areas, with some proteins having an excellent correlation between proteomic data and previously published mRNA expression levels or intensity of immunostaining. This study demonstrates the potential of using proteomic analysis to study brain membrane proteins in mouse models of neurological diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed through various methods.\n2. One of the methods used for analyzing the mouse hippocampus proteome includes the isolation of membrane proteins from small amounts of tissue.\n3. The HysTag-quantification method has been employed for proteomic analysis of the mouse hippocampus.\n4. A study by Nielsen et al. published in 2005 performed a quantitative proteomic analysis on three distinct compartments of the mouse brain, including the hippocampus.\n5. The 2005 study by Nielsen et al. identified 976 unique peptides corresponding to 555 unique proteins in the mouse brain compartments analyzed.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed through various methods.",
      "One of the methods used for analyzing the mouse hippocampus proteome includes the isolation of membrane proteins from small amounts of tissue.",
      "The HysTag-quantification method has been employed for proteomic analysis of the mouse hippocampus.",
      "A study by Nielsen et al. published in 2005 performed a quantitative proteomic analysis on three distinct compartments of the mouse brain, including the hippocampus.",
      "The 2005 study by Nielsen et al. identified 976 unique peptides corresponding to 555 unique proteins in the mouse brain compartments analyzed."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage or additional details, it is impossible to verify statements 3, 4, and 5. Proteomic analysis of the mouse hippocampus could employ various quantitative methods, but without reference to a specific study, the use of HysTag-quantification or the results of the Nielsen et al. study cannot be ascertained.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, mouse chromosomes are not acrocentric. Instead, they are metacentric, meaning they have a intermediate size between acrocentric and metacentric chromosomes. The document mentions that most murine chromosomes are quite similar in size, which makes it difficult to isolate a pure mouse chromosome. However, by analyzing cell lines with Robertsonian translocations or isochromosomes, the authors were able to obtain metacentric chromosomes that are different in size and morphology from normal acrocentric chromosomes. These metacentric chromosomes can be easily recognized by fluorescence microscopy when collected onto serum-albumin-coated microscope slides.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are metacentric.\n2. Metacentric chromosome size falls between acrocentric and metacentric chromosomes in terms of size.\n3. Most murine chromosomes are quite similar in size, complicating the isolation of a pure mouse chromosome.\n4. Cell lines with Robertsonian translocations or isochromosomes were used to obtain metacentric chromosomes.\n5. Metacentric chromosomes collected onto serum-albumin-coated microscope slides can be easily recognized by fluorescence microscopy.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are metacentric.",
      "Metacentric chromosome size falls between acrocentric and metacentric chromosomes in terms of size.",
      "Most murine chromosomes are quite similar in size, complicating the isolation of a pure mouse chromosome.",
      "Cell lines with Robertsonian translocations or isochromosomes were used to obtain metacentric chromosomes.",
      "Metacentric chromosomes collected onto serum-albumin-coated microscope slides can be easily recognized by fluorescence microscopy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Most mouse chromosomes are telocentric, not metacentric; they have the centromere at one end of the chromosome.\n2. FALSE [correction]: The statement doesn't make sense as it compares metacentric chromosomes to themselves. Generally, chromosome size can range from large metacentric to medium-sized submetacentric to small acrocentric or telocentric chromosomes based on the position of the centromere.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is likely to be a drug that targets the \"undruggable\" gene II-tubulin. The document highlights the potential of siRNA-based drugs to play an important role in precision medicine for pancreatic cancer by silencing the expression of genes, including those that are difficult to inhibit using chemical agents. The use of star polymer nanoparticles to deliver siRNA to pancreatic tumors in an orthotopic pancreatic cancer mouse model is also discussed in the document, suggesting that this delivery method may be effective in delivering siRNA to pancreatic cancer cells. Therefore, it is likely that the siRNA-based drug in clinical trials for pancreatic cancer is designed to target II-tubulin using star polymer nanoparticles for delivery.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.\n2. The siRNA-based drug targets the \"undruggable\" gene II-tubulin.\n3. The document indicates that siRNA-based drugs can silence gene expression.\n4. Star polymer nanoparticles are being used as a delivery method for siRNA to pancreatic tumors in an orthotopic pancreatic cancer mouse model.\n5. The mentioned delivery method using star polymer nanoparticles has been suggested to be effective for pancreatic cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "There is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.",
      "The siRNA-based drug targets the \"undruggable\" gene II-tubulin.",
      "The document indicates that siRNA-based drugs can silence gene expression.",
      "Star polymer nanoparticles are being used as a delivery method for siRNA to pancreatic tumors in an orthotopic pancreatic cancer mouse model.",
      "The mentioned delivery method using star polymer nanoparticles has been suggested to be effective for pancreatic cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without the specific name or details of the drug and its clinical trial status, the veracity of this statement cannot be ascertained.\n2. FALSE [correction]: It is unlikely that the gene targeted would be referred to as \"II-tubulin\" since genes are typically not named with such characters. It's possible the statement meant to refer to \"beta-II-tubulin\" or another similarly named gene involved in microtubule formation.\n3. TRUE: siRNA (small interfering RNA) is a well-known tool for silencing gene expression by triggering the destruction of specific mRNA molecules in the process known as RNA interference (RNAi).\n4. UNKNOWN: While star polymer nanoparticles are a type of delivery system investigated for the delivery of siRNA, without specific context or research details, we cannot confirm if this particular method is being used for orthotopic pancreatic cancer mouse models.\n5. UNKNOWN: Without specific results or references to studies regarding the efficacy of star polymer nanoparticles in delivering siRNA to pancreatic cancer cells, the effectiveness of this method cannot be accurately assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore refers to the pores that are formed in the phase-separated freestanding EC/HPC films as a result of the molecular weight of HPC. The pore size and connectivity are affected by the choice of HPC Mw grade used in the film, which in turn impacts the film's permeability.\nThe study found that as the molecular weight of HPC increases, the phase-separated structure changes from HPC-discontinuous to bicontinuous, resulting in connected complex-shaped pores in the higher Mw films. This leads to higher permeabilities in these films. On the other hand, films with lower Mw HPC have unconnected oval-shaped HPC-rich domains and lower water permeability.\nIn summary, the HPG pore is a critical factor in determining the permeability of EC/HPC films, and the choice of HPC Mw grade used in the film can significantly impact this property.",
    "llama-2-7b-chat-hf_fact_raw": "1. HPG pore refers to pores in phase-separated freestanding EC/HPC films affected by the molecular weight of Hydroxypropyl Cellulose (HPC).\n2. The pore size and connectivity of the HPG pore are influenced by the Hydroxypropyl Cellulose (HPC) molecular weight (Mw) grade used in the film.\n3. Higher molecular weight HPC leads to connected complex-shaped pores in the films, resulting in increased permeability.\n4. Films with lower molecular weight HPC contain unconnected oval-shaped HPC-rich domains and display lower water permeability.\n5. The HPG pore plays a crucial role in determining the permeability of EC/HPC films.",
    "llama-2-7b-chat-hf_fact": [
      "HPG pore refers to pores in phase-separated freestanding EC/HPC films affected by the molecular weight of Hydroxypropyl Cellulose (HPC).",
      "The pore size and connectivity of the HPG pore are influenced by the Hydroxypropyl Cellulose (HPC) molecular weight (Mw) grade used in the film.",
      "Higher molecular weight HPC leads to connected complex-shaped pores in the films, resulting in increased permeability.",
      "Films with lower molecular weight HPC contain unconnected oval-shaped HPC-rich domains and display lower water permeability.",
      "The HPG pore plays a crucial role in determining the permeability of EC/HPC films."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN \n2. TRUE \n3. TRUE \n4. TRUE \n5. TRUE\n\nFor the first statement, without additional context regarding the acronym HPG, it's difficult to confirm its accuracy. If HPG stands for \"Hydroxypropyl Guar,\" which is a different polymer than Hydroxypropyl Cellulose (HPC), then the statement could be false. However, if HPG is a typographic or contextual error and is meant to refer to a characteristic or specific type of pore within EC/HPC films, then it could be true. More context is needed to accurately assess this statement. The other statements are consistent with the known effects of polymer molecular weight on the structure and properties of polymer films.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing the complete mitochondrial genomes of 959 species of nematodes, which are a group of microscopic worms that are found in a wide range of environments, including soil, water, and plants. The initiative is using next-generation sequencing technologies, such as HiSeq sequencing, to produce complete mitochondrial genomes of nematodes without the need for a reference sequence.\nThe project is focused on understanding the variations of nematode mitogenomes (mtDNA), which are the genetic material found in the mitochondria of nematodes. Mitochondria are found in the cells of all living organisms and play a crucial role in energy production. The mtDNA of nematodes is particularly interesting because it is highly variable and can be used to identify different species and races of nematodes.\nThe initiative is using a genome skimming approach, which involves sequencing the mitochondrial genome in a non-targeted manner, to assemble the complete mtDNA sequence of a root-knot nematode (Meloidogyne graminicola) for the first time. The study has resulted in the assembly of an AT-rich genome of 20,030 bp with a mean sequencing depth superior to 300. Thirty-six genes were identified using a semi-automated approach, and a comparison with a gene map of the M. javanica mitochondrial genome revealed that the gene order is conserved within this nematode lineage. However, deep genome rearrangements were observed when comparing with other species of the superfamily Hoplolaimoidea.\nThe findings of this study have the potential to open new avenues for species/race identification, phylogenetics, and population genetics of nematodes. The complete mitochondrial genomes of nematodes can be used to study the evolutionary relationships between different species and races of nematodes, as well as to identify genetic markers that can be used to track the movement and distribution of nematode populations.\nIn summary, the 959 Nematode Genomes initiative is a groundbreaking research project",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the complete mitochondrial genomes of 959 species of nematodes.\n2. Next-generation sequencing technologies, such as HiSeq sequencing, are employed in the 959 Nematode Genomes initiative.\n3. The project uses a genome skimming approach to sequence the mitochondrial genome of nematodes.\n4. The project assembled a complete mtDNA sequence of Meloidogyne graminicola, which has an AT-rich genome of 20,030 base pairs.\n5. The study identified thirty-six genes in the Meloidogyne graminicola mitochondrial genome using a semi-automated approach.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the complete mitochondrial genomes of 959 species of nematodes.",
      "Next-generation sequencing technologies, such as HiSeq sequencing, are employed in the 959 Nematode Genomes initiative.",
      "The project uses a genome skimming approach to sequence the mitochondrial genome of nematodes.",
      "The project assembled a complete mtDNA sequence of Meloidogyne graminicola, which has an AT-rich genome of 20,030 base pairs.",
      "The study identified thirty-six genes in the Meloidogyne graminicola mitochondrial genome using a semi-automated approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative, generally referred to as the \"959 Project,\" aims to sequence the genomic DNA of 959 nematode species, not just the complete mitochondrial genomes.\n2. TRUE: Next-generation sequencing technologies, such as HiSeq, are commonly used in large-scale genomics initiatives like the 959 Nematode Genomes project.\n3. UNKNOWN: Without specific details from the passage, it's unclear whether the project uses a genome skimming approach for sequencing the mitochondrial genomes specifically; genome skimming is a technique that can be employed, but the statement's accuracy regarding its use in the initiative is unknown.\n4. UNKNOWN: Without confirmation from the passage, the specific details about the mitochondrial DNA (mtDNA) sequence of Meloidogyne graminicola, including its size and AT-richness, cannot be verified.\n5. UNKNOWN: Without additional information, it cannot be determined whether thirty-six genes were identified in the mitochondrial genome of Meloidogyne graminicola using a semi-automated approach.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is likely to be \"niphtest\". This package is specifically designed for analyzing NIPT data and provides functions for calculating the various risk estimates and p-values associated with NIPT testing.\nThe \"niphtest\" package is a part of the \"prenatal\" project, which is a collection of R packages for analyzing prenatal testing data. The package is designed to be easy to use and provides a variety of functions for analyzing NIPT data, including functions for calculating the risk of trisomy 21, 18, and 13, as well as functions for calculating the probability of a normal result given the maternal age and other risk factors.\nIn addition to the \"niphtest\" package, there are several other R packages that can be used for analyzing NIPT data, including \"nipd\", \"nipdtest\", and \"nipdrisk\". However, based on the information provided in the document, it seems that \"niphtest\" is the most relevant and widely used package for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"niphtest\" R package is developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. The \"niphtest\" R package is part of the \"prenatal\" project.\n3. The \"niphtest\" package includes functions for calculating the risk of trisomy 21, 18, and 13.\n4. The \"niphtest\" package provides functions for calculating the probability of a normal result based on maternal age and other risk factors.\n5. Other R packages for analyzing NIPT data include \"nipd\", \"nipdtest\", and \"nipdrisk\".",
    "llama-2-7b-chat-hf_fact": [
      "The \"niphtest\" R package is developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The \"niphtest\" R package is part of the \"prenatal\" project.",
      "The \"niphtest\" package includes functions for calculating the risk of trisomy 21, 18, and 13.",
      "The \"niphtest\" package provides functions for calculating the probability of a normal result based on maternal age and other risk factors.",
      "Other R packages for analyzing NIPT data include \"nipd\", \"nipdtest\", and \"nipdrisk\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without further context, it's impossible to verify the existence or purpose of an R package named \"niphtest.\" It would require more information or a search in a repository like CRAN or Bioconductor.\n2. UNKNOWN: The association of the \"niphtest\" R package to a \"prenatal\" project cannot be confirmed without additional context or data about the project's packages and their purposes.\n3. UNKNOWN: Whether the \"niphtest\" package includes functions for calculating the risk of trisomy 21, 18, and 13 is not known without specific information on the package's functionality or without examining its documentation.\n4. UNKNOWN: Claims regarding the functionality of the \"niphtest\" package, such as calculating probabilities of normal results, require examination of the package's documentation or a description of its features.\n5. UNKNOWN: The existence and functionality of other R packages named \"nipd,\" \"nipdtest,\" and \"nipdrisk\" need to be confirmed by checking in R package repositories or software documentation. Without such verification, the truthfulness of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as acute idiopathic blue finger or recurrent painful bruising of the fingers, is a rare and benign medical condition that is characterized by recurrent episodes of painful bruising of the fingers, typically caused by minimal or everyday traumata. The condition was first described by Achenbach in 1933 and has been reported in a limited number of cases since then.\nThe symptoms of Achenbach's syndrome typically begin in adulthood and may include:\n* Painful bruising of the fingers, which may be triggered by minor trauma such as bumping or pinching the fingers\n* Swelling and discoloration of the affected fingers\n* Limited range of motion in the affected fingers\n* In some cases, the bruising may be accompanied by a feeling of numbness or tingling in the fingers\nThe exact cause of Achenbach's syndrome is not known, but it is believed to be related to a problem with the blood vessels in the fingers. The condition is not thought to be related to any underlying medical condition, such as a bleeding disorder or a connective tissue disease.\nThe diagnosis of Achenbach's syndrome is typically made based on a combination of clinical findings and a thorough medical history. Imaging studies, such as X-rays or ultrasound, may be ordered to rule out other potential causes of the symptoms.\nTreatment for Achenbach's syndrome is generally focused on managing the symptoms and preventing further injury. This may include:\n* Avoiding activities that trigger the bruising\n* Wearing protective gear, such as gloves, when engaging in activities that may cause injury\n* Applying ice or heat to the affected area to reduce swelling and pain\n* Taking over-the-counter pain medications, such as ibuprofen or acetaminophen, as needed\nIn most cases, Achenbach's syndrome is a self-limiting condition that resolves on its own within a few weeks or months. However, in some cases, the condition may persist or recur over time.\nIt is important to note that while Achenbach's syndrome is generally considered to be a benign condition, it",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by recurrent episodes of painful bruising of the fingers.\n2. The condition was first described by Achenbach in 1933. \n3. Symptoms of Achenbach's syndrome typically include painful bruising, swelling and discoloration of the fingers, and a limited range of motion in the affected fingers.\n4. The diagnosis of Achenbach's syndrome is typically made based on clinical findings and medical history, often ruling out other causes with imaging studies.\n5. Achenbach's syndrome is generally a self-limiting condition that resolves within a few weeks or months, though it can persist or recur over time.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by recurrent episodes of painful bruising of the fingers.",
      "The condition was first described by Achenbach in 1933.",
      "Symptoms of Achenbach's syndrome typically include painful bruising, swelling and discoloration of the fingers, and a limited range of motion in the affected fingers.",
      "The diagnosis of Achenbach's syndrome is typically made based on clinical findings and medical history, often ruling out other causes with imaging studies.",
      "Achenbach's syndrome is generally a self-limiting condition that resolves within a few weeks or months, though it can persist or recur over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Achenbach's syndrome was first described by Achenbach in 1958.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the paper, the algorithm used for detection of long repeat expansions is SAGRI (Spectrum Assisted Genomic Repeat Identifier). SAGRI is a novel approach that uses the spectrum of the genomic sequence (i.e., a set of sequence k-mers for some k) to detect genomic repeats. The technique involves scanning the genome twice: the first scan detects candidate pairs of repeat segments by reconstructing portions of the Euler path of the (k-1)-mer graph of the genome only in correspondence with likely repeat sites, and the second scan validates the candidate pairs by labeling the genome for hits in the (much smaller) spectrum of the repeat candidates. The design parameters of the technique are selected based on a careful probabilistic analysis. SAGRI is compared to three leading repeat-finding tools on both synthetic and natural DNA sequences and is found to be uniformly superior in versatility and accuracy, while being quite competitive in speed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The algorithm used for detection of long repeat expansions is called SAGRI (Spectrum Assisted Genomic Repeat Identifier).\n2. SAGRI uses the spectrum of the genomic sequence to detect genomic repeats.\n3. The detection involves a two-scan process: the first scan detects candidate pairs of repeat segments and the second scan validates these candidates.\n4. The design parameters of SAGRI are chosen based on a probabilistic analysis.\n5. SAGRI has been found to be superior in versatility and accuracy compared to three leading repeat-finding tools.",
    "llama-2-7b-chat-hf_fact": [
      "The algorithm used for detection of long repeat expansions is called SAGRI (Spectrum Assisted Genomic Repeat Identifier).",
      "SAGRI uses the spectrum of the genomic sequence to detect genomic repeats.",
      "The detection involves a two-scan process: the first scan detects candidate pairs of repeat segments and the second scan validates these candidates.",
      "The design parameters of SAGRI are chosen based on a probabilistic analysis.",
      "SAGRI has been found to be superior in versatility and accuracy compared to three leading repeat-finding tools."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to a specific algorithm called SAGRI, its functionalities, processes, and a comparison with other tools. However, without access to specific scientific literature or information regarding the SAGRI algorithm, it is impossible to accurately verify these claims. Therefore, all statements are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, neuroligin-3 promotes the growth of several types of high-grade gliomas (HGG), including:\n1. Adult and pediatric glioblastoma (GBM)\n2. Anaplastic oligodendroglioma\n3. Diffuse intrinsic pontine glioma (DIPG)\nThe document suggests that neuroligin-3 promotes glioma proliferation through the PI3K-mTOR pathway, and that its secretion from neurons and oligodendrocyte precursor cells is mediated by the ADAM10 sheddase. The study also shows that patient-derived orthotopic xenografts of paediatric GBM, DIPG, and adult GBM fail to grow in Nlgn3 knockout mice, and that inhibitors of ADAM10 can robustly block HGG xenograft growth.\nTherefore, based on the information provided in the document, neuroligin-3 appears to promote the growth of several types of HGG, including adult and pediatric GBM, anaplastic oligodendroglioma, and DIPG.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth of high-grade gliomas (HGG).\n2. Types of HGG promoted by neuroligin-3 include adult and pediatric glioblastoma (GBM), anaplastic oligodendroglioma, and diffuse intrinsic pontine glioma (DIPG).\n3. Neuroligin-3 promotes glioma proliferation through the PI3K-mTOR pathway.\n4. Neuroligin-3 secretion is mediated by the ADAM10 sheddase.\n5. Patient-derived orthotopic xenografts of pediatric GBM, DIPG, and adult GBM fail to grow in Nlgn3 knockout mice.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth of high-grade gliomas (HGG).",
      "Types of HGG promoted by neuroligin-3 include adult and pediatric glioblastoma (GBM), anaplastic oligodendroglioma, and diffuse intrinsic pontine glioma (DIPG).",
      "Neuroligin-3 promotes glioma proliferation through the PI3K-mTOR pathway.",
      "Neuroligin-3 secretion is mediated by the ADAM10 sheddase.",
      "Patient-derived orthotopic xenografts of pediatric GBM, DIPG, and adult GBM fail to grow in Nlgn3 knockout mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements are consistent with findings from scientific studies on the role of neuroligin-3 in the promotion of high-grade gliomas, including its effects on different tumor types, pathways, and the use of neuroligin-3 knockout models to assess tumor growth. However, it should be noted that these are findings from specific studies and are subject to further verification and replication in the scientific community.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the approximate size of gas vesicles in different procaryotic groups is:\n* 80-100 nm in width\n* Variable length, ranging from 0.2 to over 1.0 mum (0.2-1.0 micrometers)\nSo, gas vesicles are typically around 80-100 nm in width and can range in length from 0.2 to 1.0 micrometers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are approximately 80-100 nm in width.\n2. The length of gas vesicles can range from 0.2 to over 1.0 micrometers.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are approximately 80-100 nm in width.",
      "The length of gas vesicles can range from 0.2 to over 1.0 micrometers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the BET proteins:\n1. BRD4 (Bromodomain and Extra Terminal) - This protein is a member of the BET family and is essential for the recognition of acetylated lysine (KAc) residues in histones.\n2. BRD2 (Bromodomain and Extra Terminal) - Like BRD4, BRD2 is also a member of the BET family and plays a crucial role in the recognition of acetylated histones.\n3. BRDT (Bromodomain and Extra Terminal Domain) - This protein is another member of the BET family and has been shown to play a role in the regulation of gene expression.\n4. BET1 (Bromodomain and Extra Terminal 1) - This protein is a member of the BET family and has been implicated in the regulation of cellular processes such as cell proliferation and differentiation.\n5. BET2 (Bromodomain and Extra Terminal 2) - Similar to BET1, BET2 is also a member of the BET family and has been shown to play a role in the regulation of gene expression.\nIt is important to note that this list is not exhaustive and there may be other BET proteins that have not been identified or characterized in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD4 is a member of the BET protein family.\n2. BRD4 is involved in recognizing acetylated lysine residues in histones.\n3. BRD2, another member of the BET family, plays a role in the recognition of acetylated histones.\n4. BRDT is a member of the BET family that helps regulate gene expression.\n5. BET1 and BET2 are members of the BET family implicated in cellular processes like proliferation and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "BRD4 is a member of the BET protein family.",
      "BRD4 is involved in recognizing acetylated lysine residues in histones.",
      "BRD2, another member of the BET family, plays a role in the recognition of acetylated histones.",
      "BRDT is a member of the BET family that helps regulate gene expression.",
      "BET1 and BET2 are members of the BET family implicated in cellular processes like proliferation and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BET1 and BET2 are not typically referred to as members of the BET (bromodomain and extra-terminal domain) family of proteins, which includes BRD2, BRD3, BRD4, and BRDT. BET1 and BET2 are not implicated in recognizing acetylated lysine residues in histones or involved in gene expression regulation in the way that the BET family proteins are known for.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm developed for prediction of protein subcellular localization using deep learning is the comprehensive system integrating protein sequence-derived data and text-based information. The system is tested on three large data sets and demonstrates better performance than previously reported results for a wide range of eukaryotic subcellular localizations.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be a misspelling or abbreviation for Pasteurella multocida, which is a type of bacteria that can cause infection in the eyes, including corneal ulcers.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is related to Pasteurella multocida.\n2. Pasteurella multocida is a type of bacteria.\n3. Pasteurella multocida can cause infection in the eyes.\n4. Pasteurella multocida can lead to corneal ulcers.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is related to Pasteurella multocida.",
      "Pasteurella multocida is a type of bacteria.",
      "Pasteurella multocida can cause infection in the eyes.",
      "Pasteurella multocida can lead to corneal ulcers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MULTOVL refers to a generic pesticide product, whereas Pasteurella multocida is a bacterium and not related to pesticides.\n2. TRUE\n3. TRUE: Pasteurella multocida can cause ocular infections, particularly if transferred from an animal bite or scratch to the eye area.\n4. TRUE: The infection caused by Pasteurella multocida can lead to corneal ulcers if the bacteria infect the cornea of the eye.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, GDF15 can potentially be used as a biomarker for metformin treatment. The document describes the development of an immunoassay for measuring circulating GDF15 concentrations in human serum and plasma, and the results of this assay in a group of apparently healthy elderly individuals and patients with chronic heart failure (CHF).\nThe study found that GDF15 concentrations were associated with age and with other markers of cardiovascular disease, such as cystatin C and C-reactive protein. In CHF patients, GDF15 concentrations were found to be increased and closely related to disease severity. These findings suggest that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with cardiovascular disease.\nHowever, it is important to note that the study did not specifically investigate the relationship between GDF15 and metformin treatment, and further research is needed to confirm whether GDF15 can be used as a biomarker for metformin treatment. Additionally, the study only measured GDF15 concentrations in a small group of patients, and larger, more diverse studies will be needed to validate the use of GDF15 as a biomarker for metformin treatment.\nIn summary, while the study provides some evidence to suggest that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment, further research is needed to confirm this finding and to determine the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 concentrations were associated with age and with other markers of cardiovascular disease.\n2. Patients with chronic heart failure had increased GDF15 concentrations.\n3. The severity of chronic heart failure is closely related to GDF15 concentrations.\n4. The study developed an immunoassay for measuring circulating GDF15 concentrations in human serum and plasma.\n5. The study suggesting GDF15 as a potential biomarker for metformin treatment did not specifically investigate the relationship between GDF15 and metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 concentrations were associated with age and with other markers of cardiovascular disease.",
      "Patients with chronic heart failure had increased GDF15 concentrations.",
      "The severity of chronic heart failure is closely related to GDF15 concentrations.",
      "The study developed an immunoassay for measuring circulating GDF15 concentrations in human serum and plasma.",
      "The study suggesting GDF15 as a potential biomarker for metformin treatment did not specifically investigate the relationship between GDF15 and metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The study suggesting GDF15 as a potential biomarker for metformin treatment likely investigated the relationship between GDF15 and metformin treatment, as this is implied by the statement that GDF15 was suggested as a biomarker for metformin treatment. Without a specific study reference, it's not possible to provide a definitive true or false answer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that recursive splicing is more common in short introns. The study found that a higher frequency of intron retention (IR) in human cDNAs is associated with individual introns that have weaker splice sites, genes with shorter intron lengths, higher expression levels, and lower density of both exon splicing silencers (ESSs) and the intronic splicing enhancer GGG. Both groups of retained introns presented events conserved in mouse, in which the retained introns were also short and presented weaker splice sites. These findings suggest that cis-regulatory elements, such as ESSs and the intronic splicing enhancer GGG, play a crucial role in regulating IR, and that the interplay among these features is important in the regulation of the relative frequency of IR.\nIn particular, the study found that short introns are more likely to undergo recursive splicing, as they have weaker splice sites and are more likely to be retained in the mature transcript. This is consistent with the idea that recursive splicing is a mechanism by which cells can regulate the expression of genes with short introns, by retaining the intron in the mature transcript and avoiding the production of a truncated transcript.\nOverall, the study provides evidence that recursive splicing is more common in short introns, and suggests that cis-regulatory elements play a crucial role in regulating this type of alternative splicing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is found to be more common in short introns according to a study.\n2. A higher frequency of intron retention in human cDNAs is linked with genes having shorter intron lengths.\n3. Genes with higher expression levels and lower density of ESSs as well as the intronic splicing enhancer GGG are associated with a higher frequency of intron retention.\n4. Retained introns in the study were also conserved in mice, where they were short and had weaker splice sites.\n5. The study suggests that cis-regulatory elements are important in the regulation of intron retention frequencies.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is found to be more common in short introns according to a study.",
      "A higher frequency of intron retention in human cDNAs is linked with genes having shorter intron lengths.",
      "Genes with higher expression levels and lower density of ESSs as well as the intronic splicing enhancer GGG are associated with a higher frequency of intron retention.",
      "Retained introns in the study were also conserved in mice, where they were short and had weaker splice sites.",
      "The study suggests that cis-regulatory elements are important in the regulation of intron retention frequencies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe provided statements pertain to specific findings from a scientific study on gene splicing. Without the actual study details or results, it's impossible to verify the accuracy of statements 1 through 4. These findings would need to be referenced directly from the study for accurate validation. However, statement 5 is generally true as cis-regulatory elements are known to be important in the regulation of gene expression, including intron retention frequencies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the TALE-iD method is used for genome targeting using programmable DNA binding proteins called TALEs. TALEs consist of multiple concatenated repeats that recognize specific nucleobases in DNA, and their binding ability to epigenetic and modified nucleobases is studied in this document. The research finds that the natural RVD (repeat variable diresidue) NI is insensitive to the epigenetic nucleobase N6-methyladenine (6mA), but accommodation of 6mA by RVDs with altered hydrophobic surfaces and abilities of hydrogen bonding to the N6-amino group or N7 atom of A is observed. This tolerance of N6 substitution is transferrable to bulky N6-alkynyl substituents usable for click chemistry and even to a large rhodamine dye, establishing the N6 position of A as the first site of DNA that offers label introduction within TALE target sites without interference. These findings will guide future in vivo studies with TALEs and expand their applicability as DNA capture probes for analytical applications in vitro. Therefore, the TALE-iD method can be used for targeting specific DNA sequences for various applications such as genome editing, gene expression, and DNA analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method involves genome targeting using programmable DNA binding proteins called TALEs.\n2. TALEs are made up of concatenated repeats that are designed to recognize specific nucleobases in DNA.\n3. The research mentioned studies TALE binding to epigenetic and modified nucleobases, specifically the insensitivity of the RVD NI to N6-methyladenine (6mA).\n4. The ability to accommodate N6-methyladenine (6mA) has been observed in RVDs with altered hydrophobic surfaces and hydrogen bonding capabilities.\n5. The TALE-iD method enables the introduction of labels at the N6 position of A in DNA sequences without interfering with TALE target sites.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method involves genome targeting using programmable DNA binding proteins called TALEs.",
      "TALEs are made up of concatenated repeats that are designed to recognize specific nucleobases in DNA.",
      "The research mentioned studies TALE binding to epigenetic and modified nucleobases, specifically the insensitivity of the RVD NI to N6-methyladenine (6mA).",
      "The ability to accommodate N6-methyladenine (6mA) has been observed in RVDs with altered hydrophobic surfaces and hydrogen bonding capabilities.",
      "The TALE-iD method enables the introduction of labels at the N6 position of A in DNA sequences without interfering with TALE target sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is Document-0.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it is estimated that approximately 84% of the genes in Saccharomyces cerevisiae (yeast) are the result of an ancient whole genome duplication. This estimate is based on a computer simulation and analytical method that were used to estimate the number of duplicated chromosomal regions in the yeast genome after a whole genome duplication event approximately 10(8) years ago. The simulation produced an estimate of 8% of the original genes being retained in duplicate after the duplication, and 70-100 reciprocal translocations occurred between chromosomes. Additionally, an analytical method produced an independent estimate of 84 map disruptions. These results suggest that many smaller duplicated chromosomal regions exist in the yeast genome in addition to the 55 originally reported. However, it is not possible to determine the original order of chromosomal blocks in the ancestral unduplicated genome without information from one or more additional species. If the genome sequence of one other species, such as Kluyveromyces lactis, were known, it should be possible to identify 150-200 paired regions covering the whole yeast genome and to reconstruct approximately two-thirds of the original order of blocks of genes in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 84% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. A computer simulation estimated that 8% of original genes were retained in duplicate after the whole genome duplication event in yeast.\n3. Between 70-100 reciprocal translocations occurred between chromosomes after the whole genome duplication event in yeast.\n4. An analytical method produced an independent estimate of 84 map disruptions in the yeast genome.\n5. The whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred approximately 10^8 years ago.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 84% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "A computer simulation estimated that 8% of original genes were retained in duplicate after the whole genome duplication event in yeast.",
      "Between 70-100 reciprocal translocations occurred between chromosomes after the whole genome duplication event in yeast.",
      "An analytical method produced an independent estimate of 84 map disruptions in the yeast genome.",
      "The whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred approximately 10^8 years ago."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A computer simulation estimated that about 92% of original genes were lost and approximately 8% were retained in duplicate after the whole genome duplication event in yeast.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred approximately 100 million years ago, but 10^8 is a representation of this number, so the statement can be considered TRUE if interpreted as an estimation in numbers.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the complex that is bound by estrogen-related receptor  (Esrrb) is the complex consisting of Estrogen receptor beta (ER/ESR2) and specificity protein-1 (SP1). The study demonstrates that MMP-19 levels are downregulated in ovaries of female BERKO mice, which are subfertile due to an increase in fibrosis around the maturing follicle and a decrease in blood supply. The study also shows that MMP-19 is a transcriptional target of ligand-bound activated ER acting on the SP1 binding site. Therefore, the complex consisting of ER and SP1 is the one that is bound by MMP-19.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor  (Esrrb) is bound by the complex of Estrogen receptor beta (ER/ESR2) and specificity protein-1 (SP1).\n2. MMP-19 levels are found to be downregulated in ovaries of BERKO (Beta Estrogen Receptor KnockOut) mice.\n3. BERKO mice are subfertile due to increased fibrosis around the maturing follicle and decreased blood supply.\n4. MMP-19 is identified as a transcriptional target of ligand-bound activated Estrogen receptor beta (ER) acting on the SP1 binding site.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor  (Esrrb) is bound by the complex of Estrogen receptor beta (ER/ESR2) and specificity protein-1 (SP1).",
      "MMP-19 levels are found to be downregulated in ovaries of BERKO (Beta Estrogen Receptor KnockOut) mice.",
      "BERKO mice are subfertile due to increased fibrosis around the maturing follicle and decreased blood supply.",
      "MMP-19 is identified as a transcriptional target of ligand-bound activated Estrogen receptor beta (ER) acting on the SP1 binding site."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen-related receptor  (Esrrb) and Estrogen receptor beta (ER/ESR2) are two different receptors. Esrrb is not known to be bound by the ER/ESR2 and SP1 complex, whereas ER may bind to SP1 to regulate gene expression.\n2. UNKNOWN (Without specific research data or findings presented, determining the regulation of MMP-19 levels in BERKO mice is not possible.)\n3. UNKNOWN (The subfertility of BERKO mice could be due to numerous factors, and without context from specific research, attributing it to increased fibrosis and decreased blood supply is not verifiable.)\n4. UNKNOWN (Without additional context, confirming MMP-19 as a transcriptional target of ligand-bound activated ER at the SP1 binding site cannot be done. This statement would require supporting evidence from scientific research.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ZCCHC17 appears to play a crucial role in regulating the expression of the ZRG17 gene in response to zinc status. The study suggests that the Zap1 transcription factor regulates the expression of ZRG17 by binding to a specific DNA element called the ZRE (zinc-responsive element) in the ZRG17 promoter. When zinc levels are low, Zap1 binds to the ZRE and induces the expression of ZRG17, which in turn helps maintain ER function by transporting zinc into the ER. The study also shows that ZRG17 protein levels correlate closely with mRNA levels, further supporting the idea that ZRG17 is a direct target of Zap1. Overall, the role of ZCCHC17 is to regulate the expression of ZRG17 in response to zinc status, which is important for maintaining ER function.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 regulates the expression of ZRG17 in response to zinc status.\n2. The Zap1 transcription factor controls the expression of ZRG17 by binding to the ZRE (zinc-responsive element) in the ZRG17 promoter.\n3. When zinc levels are low, Zap1 binds to the ZRE and induces the expression of ZRG17.\n4. ZRG17 helps maintain endoplasmic reticulum (ER) function by transporting zinc into the ER.\n5. ZRG17 protein levels correlate closely with mRNA levels, indicating that ZRG17 is a direct target of Zap1.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 regulates the expression of ZRG17 in response to zinc status.",
      "The Zap1 transcription factor controls the expression of ZRG17 by binding to the ZRE (zinc-responsive element) in the ZRG17 promoter.",
      "When zinc levels are low, Zap1 binds to the ZRE and induces the expression of ZRG17.",
      "ZRG17 helps maintain endoplasmic reticulum (ER) function by transporting zinc into the ER.",
      "ZRG17 protein levels correlate closely with mRNA levels, indicating that ZRG17 is a direct target of Zap1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge about ZCCHC17 and ZRG17, it is impossible to determine the accuracy of this statement.\n2. UNKNOWN: While the statement conveys a specific mechanism involving the Zap1 transcription factor and ZRG17 expression, the correctness of this statement requires specialized knowledge of the gene regulatory mechanisms for these specific genes.\n3. UNKNOWN: Similar to the previous statements, detailed knowledge about the regulation of ZRG17 by Zap1 is needed to verify this statement.\n4. UNKNOWN: The function of ZRG17 mentioned here is specific, and its factual accuracy would require a reference to a reliable source or specific scientific knowledge regarding the role of this protein.\n5. UNKNOWN: Correlation between protein levels and mRNA levels as evidence of direct target regulation is a statement that requires empirical data to confirm or deny; hence, without additional information, this statement's truth cannot be established.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the proteins that form the nuclear pore basket in human cells are:\n1. Nup43 (hNUP43) - The crystal structure of hNup43 was solved and it adopts a seven-bladed -propeller fold.\n2. Nup85 - The binary complex of Nup85-Seh1L recruits hNup43 to form a ternary complex.\nTherefore, the answer to the user's question is: Nup43 and Nup85.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nup43 (hNUP43) is a protein that forms the nuclear pore basket in human cells.\n2. The crystal structure of hNup43 has been solved.\n3. hNup43 adopts a seven-bladed beta-propeller fold.\n4. Nup85 is a protein that forms the nuclear pore basket in human cells.\n5. The binary complex of Nup85-Seh1L recruits hNup43 to form a ternary complex.",
    "llama-2-7b-chat-hf_fact": [
      "Nup43 (hNUP43) is a protein that forms the nuclear pore basket in human cells.",
      "The crystal structure of hNup43 has been solved.",
      "hNup43 adopts a seven-bladed beta-propeller fold.",
      "Nup85 is a protein that forms the nuclear pore basket in human cells.",
      "The binary complex of Nup85-Seh1L recruits hNup43 to form a ternary complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Nup43 (hNUP43) is a protein that is part of the nuclear pore complex, but it does not form the basket structure. That is primarily formed by proteins like Nup153 in human cells.\n2. TRUE\n3. FALSE [correction]: There might be a misunderstanding here. hNup43 is not highlighted in literature for adopting a seven-bladed beta-propeller fold. However, proteins such as Nup133, which is also a part of the nuclear pore complex, do adopt this fold.\n4. TRUE: Nup85 is indeed a protein that contributes to the structure of the nuclear pore complex, though not specifically to the basket structure.\n5. TRUE: The binary complex of Nup85-Seh1 does interact with other nucleoporins like Nup43, contributing to the formation of the nuclear pore complex in eukaryotic cells.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, gepotidacin is a topoisomerase II inhibitor. Specifically, it is a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Gepotidacin is described as a first-in-class medication.\n3. Gepotidacin's chemical structure is referred to as triazaacenaphthylene.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Gepotidacin is described as a first-in-class medication.",
      "Gepotidacin's chemical structure is referred to as triazaacenaphthylene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase inhibitor, but it specifically targets bacterial type II topoisomerase (DNA gyrase) and type IV topoisomerase, not simply type II.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a new algorithm for the fast and accurate propagation of non-paraxial vectorial optical fields in free space. The algorithm is based on decomposing highly divergent fields into subfields with small divergence, which can then be propagated using a semi-analytical spectrum of plane waves (SPW) operator with fast Fourier transformations. The key advantage of Canvas SPW is the reduction of numerical effort compared to the standard SPW operator, due to the analytical handling of linear phase terms arising after the decomposition of the fields. The algorithm has been demonstrated to be efficient and accurate in numerical results presented for two examples.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is an algorithm for propagating non-paraxial vectorial optical fields in free space.\n2. The Canvas SPW algorithm works by decomposing highly divergent fields into subfields with small divergence.\n3. The propagation in Canvas SPW is done using a semi-analytical spectrum of plane waves operator with fast Fourier transformations.\n4. Canvas SPW reduces numerical effort compared to the standard spectrum of plane waves operator by analytically handling linear phase terms after field decomposition.\n5. Numerical results demonstrating the efficiency and accuracy of Canvas SPW have been presented for two examples.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is an algorithm for propagating non-paraxial vectorial optical fields in free space.",
      "The Canvas SPW algorithm works by decomposing highly divergent fields into subfields with small divergence.",
      "The propagation in Canvas SPW is done using a semi-analytical spectrum of plane waves operator with fast Fourier transformations.",
      "Canvas SPW reduces numerical effort compared to the standard spectrum of plane waves operator by analytically handling linear phase terms after field decomposition.",
      "Numerical results demonstrating the efficiency and accuracy of Canvas SPW have been presented for two examples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are STING agonists:\n1. Idazoxan: An alpha2 adrenergic receptor antagonist that reversed apipuncture-induced antinociception in the rat formalin pain model.\n2. Methysergide: A serotonin receptor antagonist that reversed apipuncture-induced antinociception in the rat formalin pain model.\nIt is important to note that the document does not mention STING agonists directly, but rather discusses the mechanisms of apipuncture-induced antinociception and the role of different receptors in these mechanisms. The mention of idazoxan and methysergide as reversers of apipuncture-induced antinociception suggests that these compounds may act as STING agonists.",
    "llama-2-7b-chat-hf_fact_raw": "1. Idazoxan is an alpha2 adrenergic receptor antagonist.\n2. Methysergide is a serotonin receptor antagonist.\n3. Idazoxan reversed apipuncture-induced antinociception in the rat formalin pain model.\n4. Methysergide reversed apipuncture-induced antinociception in the rat formalin pain model.\n5. The document suggests that Idazoxan and Methysergide may act as STING agonists due to their role in reversing apipuncture-induced antinociception.",
    "llama-2-7b-chat-hf_fact": [
      "Idazoxan is an alpha2 adrenergic receptor antagonist.",
      "Methysergide is a serotonin receptor antagonist.",
      "Idazoxan reversed apipuncture-induced antinociception in the rat formalin pain model.",
      "Methysergide reversed apipuncture-induced antinociception in the rat formalin pain model.",
      "The document suggests that Idazoxan and Methysergide may act as STING agonists due to their role in reversing apipuncture-induced antinociception."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The document does not provide sufficient information to suggest that Idazoxan and Methysergide act as STING agonists due to their role in reversing apipuncture-induced antinociception. STING agonists pertain to the activation of the stimulator of interferon genes pathway, which is not addressed in the context given.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in Document-0, SLIC-CAGE (Sequence- and Ligation-independent Cloning-Cumulative Assembly) is a cloning method that allows for the efficient and directional cloning of DNA sequences using a simple, cost-effective, and time-saving approach. Here are the key features of SLIC-CAGE:\n1. One-step cloning: SLIC-CAGE involves a single step of cloning, which involves mixing the linearized vector, insert(s) prepared by PCR, and T4 DNA polymerase in a tube at room temperature. This simplifies the cloning process and reduces the risk of errors.\n2. High efficiency: SLIC-CAGE is highly efficient, with the ability to achieve directional cloning in just 2.5 minutes after mixing the components. This means that researchers can quickly and easily clone their DNA sequences without having to wait for a long time.\n3. Versatility: SLIC-CAGE is a versatile cloning method that can be used for a wide range of applications, including gene expression, gene editing, and genome engineering. It can also be used for cloning large DNA fragments, such as chromosomes or genomes.\n4. Room temperature cloning: SLIC-CAGE uses room temperature cloning conditions, which makes it a convenient and cost-effective method. It eliminates the need for expensive cloning equipment and allows researchers to perform the cloning reaction in a simple and straightforward manner.\nOverall, SLIC-CAGE is a powerful cloning method that offers a simple, efficient, and cost-effective way to clone DNA sequences. Its versatility and high efficiency make it a valuable tool for researchers in many fields, including molecular biology, genetic engineering, and biotechnology.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a cloning method that involves a single step of cloning.\n2. This method can achieve directional cloning in just 2.5 minutes after mixing the components.\n3. It is used for a wide range of applications, including gene expression, gene editing, and genome engineering.\n4. SLIC-CAGE can be used for cloning large DNA fragments, such as chromosomes or genomes.\n5. The cloning process using SLIC-CAGE is performed at room temperature.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a cloning method that involves a single step of cloning.",
      "This method can achieve directional cloning in just 2.5 minutes after mixing the components.",
      "It is used for a wide range of applications, including gene expression, gene editing, and genome engineering.",
      "SLIC-CAGE can be used for cloning large DNA fragments, such as chromosomes or genomes.",
      "The cloning process using SLIC-CAGE is performed at room temperature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While SLIC-CAGE is a rapid cloning method, the specific time period required is not commonly cited as 2.5 minutes. The process could generally be quick but might vary depending on various factors. The exact time for the reaction should be confirmed from a reliable source.\n3. TRUE\n4. FALSE [correction]: SLIC-CAGE is indeed a cloning method, but it is generally used for inserting smaller fragments of DNA into vectors. Cloning entire chromosomes or genomes typically requires more complex techniques that can handle such large DNA fragments.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the roles of LEM-3 are:\n1. DNase activity: LEM-3 contains a LEM domain and a GIY nuclease domain, which suggests that it has DNase activity in vitro.\n2. DNA damage response: LEM-3 mutants are hypersensitive to various types of DNA damage, including ionizing radiation, UV-C light, and crosslinking agents.\n3. Mitotic defects: Embryos from irradiated LEM-3 mutants display severe defects during cell division, including chromosome mis-segregation and anaphase bridges.\n4. Interaction with other DNA damage response proteins: LEM-3 interacts with the other two C. elegans LEM domain proteins, LEM-2 and EMR-1, and loss of LEM-3 sensitizes baf-1 mutants even in the absence of DNA damage.\n5. Promoting the reorganization of damaged chromatin: Our data suggest that BAF-1, together with the LEM domain proteins, plays an important role following DNA damage - possibly by promoting the reorganization of damaged chromatin.\nIn summary, LEM-3 plays a role in the DNA damage response pathway in C. elegans, specifically in the repair of DNA damage and the reorganization of damaged chromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 contains a LEM domain and a GIY nuclease domain, indicating it has DNase activity in vitro.\n2. LEM-3 mutants demonstrate hypersensitivity to various types of DNA damage, such as ionizing radiation, UV-C light, and crosslinking agents.\n3. Embryos from irradiated LEM-3 mutants exhibit severe cell division defects, including chromosome mis-segregation and anaphase bridges.\n4. LEM-3 interacts with other LEM domain proteins in C. elegans, LEM-2 and EMR-1, and the interaction affects the sensitivity of baf-1 mutants to DNA damage.\n5. LEM-3, along with BAF-1 and other LEM domain proteins, is suggested to have a role in promoting the reorganization of damaged chromatin following DNA damage.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 contains a LEM domain and a GIY nuclease domain, indicating it has DNase activity in vitro.",
      "LEM-3 mutants demonstrate hypersensitivity to various types of DNA damage, such as ionizing radiation, UV-C light, and crosslinking agents.",
      "Embryos from irradiated LEM-3 mutants exhibit severe cell division defects, including chromosome mis-segregation and anaphase bridges.",
      "LEM-3 interacts with other LEM domain proteins in C. elegans, LEM-2 and EMR-1, and the interaction affects the sensitivity of baf-1 mutants to DNA damage.",
      "LEM-3, along with BAF-1 and other LEM domain proteins, is suggested to have a role in promoting the reorganization of damaged chromatin following DNA damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The statement incorrectly refers to \"baf-1\" mutants as being affected by the interaction between LEM-3 and other LEM domain proteins. To be correct, the statement should refer to the sensitivity of \"LEM-3\" mutants to DNA damage, not \"baf-1\" mutants, unless there is documented evidence that baf-1 is a related pathway or protein affected by LEM-3. However, without specific context or details from the passage indicating this relationship, the statement as given is deemed false.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of the Tendyne device are as follows:\n1. Compasionate use at a single center\n2. 18-month/two-year outcomes of the five first-in-man patients undergoing chronic TMVR with the Tendyne device.\nIt is important to note that the document does not provide information on any other releases of the Tendyne device beyond these two mentions.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no specific database of somatic mutations in normal cells. The document focuses on the detection of somatic mutations in tumor samples using a method that does not require matched normal samples. The method involves filtering out inherited variants and technical artifacts, and comparing the detected mutations to those detected using a \"gold-standard\" tumor/normal approach. While the document mentions the use of population variation datasets to remove inherited variants, it does not provide information on the availability of such datasets for normal cells. Therefore, I cannot provide a database of somatic mutations in normal cells based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are graph kernel libraries available implemented in Java. One such library is the GraphKernel library, which is a Java implementation of graph kernel methods for graph classification. The library provides a set of algorithms for computing graph kernels, including the graph diffusion kernel, which is similar to the technique described in the paper you provided.\nThe GraphKernel library is available on GitHub and can be easily integrated into Java-based applications. It provides a simple API for computing graph kernels and can be used for a variety of graph-related tasks, including graph classification, graph similarity search, and graph clustering.\nAnother Java library for graph kernel methods is the GraphKernel++ library, which is an extension of the original GraphKernel library. It provides additional features, such as support for weighted graphs and graph-based semi-supervised learning.\nBoth of these libraries are actively maintained and have been used in a variety of applications, including social network analysis, recommendation systems, and bioinformatics.\nIn summary, yes, there are graph kernel libraries available implemented in Java, and they can be used for a variety of graph-related tasks, including graph classification.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GraphKernel library is a Java implementation of graph kernel methods for graph classification.\n2. The GraphKernel library includes algorithms for computing graph kernels, such as the graph diffusion kernel.\n3. The GraphKernel library can be found on GitHub.\n4. The GraphKernel++ library is an extension of the GraphKernel library and supports weighted graphs and graph-based semi-supervised learning.\n5. Both libraries are used in applications such as social network analysis, recommendation systems, and bioinformatics.",
    "llama-2-7b-chat-hf_fact": [
      "The GraphKernel library is a Java implementation of graph kernel methods for graph classification.",
      "The GraphKernel library includes algorithms for computing graph kernels, such as the graph diffusion kernel.",
      "The GraphKernel library can be found on GitHub.",
      "The GraphKernel++ library is an extension of the GraphKernel library and supports weighted graphs and graph-based semi-supervised learning.",
      "Both libraries are used in applications such as social network analysis, recommendation systems, and bioinformatics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without detailed information provided about the \"GraphKernel\" library such as its official documentation or a trustworthy source, the truthfulness of this statement cannot be verified.\n2. UNKNOWN: As with the first statement, without access to specific details about the algorithms included in the \"GraphKernel\" library, this statement's truthfulness cannot be ascertained.\n3. UNKNOWN: The availability of the \"GraphKernel\" library on GitHub cannot be confirmed without access to its repository URL or other definitive information.\n4. UNKNOWN: Similar to the previous statements, without further information, it cannot be confirmed if \"GraphKernel++\" is an actual extension of the \"GraphKernel\" library or if it supports the features mentioned.\n5. UNKNOWN: The use of both libraries in specific applications requires substantiation through user documentation, research papers, or other authoritative sources. Without such evidence, this statement remains unverifiable.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the four advances integrated into the SHERLOCKv2 platform are:\n1. Integration of Java Molecular Viewer (JMV) with virtual reality display environments: SHERLOCKv2 has adapted JMV to display molecular structures in virtual reality, allowing for a more immersive and interactive experience.\n2. Overlay of phylogenetic information onto molecule structures: SHERLOCKv2 allows for the overlay of phylogenetic information, such as temporal information, onto molecule structures in real-time, providing a dynamic and visual representation of the relationships between molecules.\n3. Handling of an infinite number of objects in the same display: SHERLOCKv2 can display an infinite number of molecules in the same display, allowing for a more comprehensive view of complex molecular systems.\n4. Six degrees of freedom manipulation of objects: SHERLOCKv2 allows for the manipulation of molecules in six degrees of freedom, including translation, rotation, and scaling, providing a high level of control and flexibility in the visualization and analysis of molecular structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 has incorporated the Java Molecular Viewer (JMV) to display molecular structures in virtual reality.\n2. SHERLOCKv2 has the capability to overlay phylogenetic information onto molecule structures in real-time.\n3. The platform can handle the display of an infinite number of molecules simultaneously.\n4. SHERLOCKv2 provides six degrees of freedom manipulation of molecules, including translation, rotation, and scaling.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 has incorporated the Java Molecular Viewer (JMV) to display molecular structures in virtual reality.",
      "SHERLOCKv2 has the capability to overlay phylogenetic information onto molecule structures in real-time.",
      "The platform can handle the display of an infinite number of molecules simultaneously.",
      "SHERLOCKv2 provides six degrees of freedom manipulation of molecules, including translation, rotation, and scaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: It is technically impossible for any platform to handle the display of an infinite number of molecules simultaneously due to limitations in processing power and memory.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a simulation model used to study the interactions between agents and their environment in relation to drinking behavior. The model is based on a 1-dimensional lattice, where agents move left or right in single steps at each iteration. In the second generation of the model, a \"bar\" is added to the lattice to attract drinkers.\nThe model demonstrates that changes in drinking status propagate through the agent population based on probabilities of conversion, rates of contact, and contact time. The critical speed of population mixing beyond which the conversion rate of susceptible nondrinkers is saturated is also observed. Additionally, the bar both enhances and buffers the rate of propagation, changing the model dynamics.\nIn essence, the bartender algorithm is a tool for understanding how social influences shape drinking behavior and how the characteristics of drinking environments can impact these influences. By simulating the interactions between agents and their environment, the model can help researchers and policymakers better understand the factors that contribute to drinking behavior and develop strategies to promote healthier drinking habits.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm is a simulation model used to study the interactions between agents and their environment in relation to drinking behavior.\n2. The model uses a 1-dimensional lattice where agents move left or right in single steps.\n3. In the second generation of the bartender algorithm, a \"bar\" is added to the lattice.\n4. The bartender algorithm observes the critical speed of population mixing that affects the conversion rate of susceptible nondrinkers.\n5. The model aims to help researchers and policymakers understand and develop strategies to promote healthier drinking habits.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm is a simulation model used to study the interactions between agents and their environment in relation to drinking behavior.",
      "The model uses a 1-dimensional lattice where agents move left or right in single steps.",
      "In the second generation of the bartender algorithm, a \"bar\" is added to the lattice.",
      "The bartender algorithm observes the critical speed of population mixing that affects the conversion rate of susceptible nondrinkers.",
      "The model aims to help researchers and policymakers understand and develop strategies to promote healthier drinking habits."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided suggest a specific algorithm related to social simulations or behavioral studies, but without a reliable source or further context, it is impossible to confirm the accuracy of the details given about the \"bartender algorithm\". As such, all statements remain unknown as they pertain to a specific model or theory that is not widely recognized or standard without additional context or information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several web-based pedigree editors available, including:\n1. Pelican: A lightweight graphical pedigree editor developed by the Wellcome Trust Sanger Institute, which allows users to rapidly construct linkage pedigree files and diagrams. The software is available for free and can be accessed through a Java Web Start launch or by downloading the class files, demonstration applet, source code, and documentation from the website.\nOther web-based pedigree editors that may be of interest include:\n2. Pedigree Editor: A web-based tool that allows users to create and edit pedigrees, including the ability to add and remove individuals, edit relationships, and save the pedigree as a text file.\n3. Family Tree Builder: A free online tool that allows users to create and edit family trees, including the ability to add and remove individuals, edit relationships, and save the tree as a PDF or GEDCOM file.\n4. GenoPro: A professional-grade genealogy software that includes a web-based pedigree editor, allowing users to create and edit large family trees with ease.\n5. Legacy Family Tree: A popular genealogy software that includes a web-based pedigree editor, allowing users to create and edit family trees, including the ability to add and remove individuals, edit relationships, and save the tree as a GEDCOM file.\nIt's important to note that the availability and features of these web-based pedigree editors may change over time, so it's always a good idea to check the website for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pelican is developed by the Wellcome Trust Sanger Institute.\n2. Pelican can be accessed through Java Web Start or by downloading various files from the website.\n3. Family Tree Builder is an online tool that allows saving trees as PDF or GEDCOM file.\n4. GenoPro includes a web-based pedigree editor for creating and editing large family trees.\n5. Legacy Family Tree's software includes a web-based pedigree editor that can save trees as GEDCOM files.",
    "llama-2-7b-chat-hf_fact": [
      "Pelican is developed by the Wellcome Trust Sanger Institute.",
      "Pelican can be accessed through Java Web Start or by downloading various files from the website.",
      "Family Tree Builder is an online tool that allows saving trees as PDF or GEDCOM file.",
      "GenoPro includes a web-based pedigree editor for creating and editing large family trees.",
      "Legacy Family Tree's software includes a web-based pedigree editor that can save trees as GEDCOM files."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: GenoPro includes a pedigree editor for creating and editing large family trees, but it is not web-based; it is a desktop application.\n5. FALSE [correction]: Legacy Family Tree is a desktop application, not a web-based editor. It can save trees as GEDCOM files.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several curated databases of spider-venom toxins that have been identified and characterized through transcriptomic and genomic analyses of various arachnid species. These include:\n1. VenomDB: This database contains a comprehensive collection of venom-related sequences from various animal species, including spiders, scorpions, and insects. As of 2019, VenomDB contains over 10,000 venom-related sequences from over 100 species.\n2. ToxinDB: This database is a comprehensive collection of toxin-related sequences from various animal species, including spiders, scorpions, and insects. As of 2019, ToxinDB contains over 15,000 toxin-related sequences from over 100 species.\n3. Arachnid Venom Database (AVD): This database is specifically focused on the venom of arachnids, including spiders, scorpions, and ticks. As of 2019, AVD contains over 5,000 venom-related sequences from over 100 species.\n4. Spider Venom Database (SVD): This database is dedicated to the venom of spiders, and contains a comprehensive collection of venom-related sequences from various species of spiders. As of 2019, SVD contains over 3,000 venom-related sequences from over 100 species.\nIt is important to note that these databases are constantly updated and expanded as new research is published, so the number of sequences and species represented may change over time. Additionally, these databases often include information on the functional and structural properties of the venom components, as well as their evolutionary relationships and distribution across different species.",
    "llama-2-7b-chat-hf_fact_raw": "1. VenomDB is a database that includes venom-related sequences from various animal species and contained over 10,000 sequences from over 100 species as of 2019.\n2. ToxinDB is a database that compiles toxin-related sequences from different animal species and had over 15,000 sequences from over 100 species as of 2019.\n3. The Arachnid Venom Database (AVD) is focused on arachnid venom and had over 5,000 venom-related sequences from over 100 species as of 2019.\n4. The Spider Venom Database (SVD) specializes in spider venom and contained over 3,000 venom-related sequences from various species of spiders as of 2019.\n5. The databases mentioned provide not only sequences but also information on venom components' functional and structural properties, evolutionary relationships, and species distribution.",
    "llama-2-7b-chat-hf_fact": [
      "VenomDB is a database that includes venom-related sequences from various animal species and contained over 10,000 sequences from over 100 species as of 2019.",
      "ToxinDB is a database that compiles toxin-related sequences from different animal species and had over 15,000 sequences from over 100 species as of 2019.",
      "The Arachnid Venom Database (AVD) is focused on arachnid venom and had over 5,000 venom-related sequences from over 100 species as of 2019.",
      "The Spider Venom Database (SVD) specializes in spider venom and contained over 3,000 venom-related sequences from various species of spiders as of 2019.",
      "The databases mentioned provide not only sequences but also information on venom components' functional and structural properties, evolutionary relationships, and species distribution."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nPlease note that while the first and last statements are accurate in general terms regarding the purpose of venom databases, I labeled the specific size and species information for VenomDB, ToxinDB, the Arachnid Venom Database (AVD), and the Spider Venom Database (SVD) as UNKNOWN, due to the lack of specificity in your prompt and the changing nature of databases. The number of sequences and species they contain can increase over time, and without updated information, the provided numbers cannot be verified as accurate or current as of the present day.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no conclusive evidence to suggest that Axitinib prolongs the survival of Pancreatic Cancer patients. The document presents the results of a clinical trial that compared the safety and efficacy of gemcitabine plus Axitinib to gemcitabine alone in patients with unresectable, locally advanced, or metastatic pancreatic cancer. The trial found that the median overall survival was longer with gemcitabine plus Axitinib than with gemcitabine alone, but the difference was not statistically significant.\nThe document states that the hazard ratio for survival with gemcitabine plus Axitinib versus with gemcitabine alone, adjusted for stratification factors, was 0.71 (95% CI 0.44-1.13). While this suggests that gemcitabine plus Axitinib may have a slight benefit in terms of overall survival, the difference is not large enough to be considered statistically significant.\nTherefore, based on the information provided in the document, it cannot be concluded that Axitinib prolongs the survival of Pancreatic Cancer patients. Further research is needed to confirm or refute this hypothesis in a larger and more robust study.",
    "llama-2-7b-chat-hf_fact_raw": "1. The document discussed relates to a clinical trial comparing gemcitabine plus Axitinib to gemcitabine alone in patients with unresectable, locally advanced, or metastatic pancreatic cancer.\n2. The trial found longer median overall survival for the combination of gemcitabine plus Axitinib compared to gemcitabine alone.\n3. However, the difference in median overall survival between gemcitabine plus Axitinib and gemcitabine alone was not statistically significant.\n4. The reported hazard ratio for survival with the combination of gemcitabine plus Axitinib versus gemcitabine alone was 0.71, with a 95% confidence interval of 0.44-1.13.\n5. The document concludes that further research is needed to confirm any potential benefit of Axitinib in prolonging the survival of pancreatic cancer patients.",
    "llama-2-7b-chat-hf_fact": [
      "The document discussed relates to a clinical trial comparing gemcitabine plus Axitinib to gemcitabine alone in patients with unresectable, locally advanced, or metastatic pancreatic cancer.",
      "The trial found longer median overall survival for the combination of gemcitabine plus Axitinib compared to gemcitabine alone.",
      "However, the difference in median overall survival between gemcitabine plus Axitinib and gemcitabine alone was not statistically significant.",
      "The reported hazard ratio for survival with the combination of gemcitabine plus Axitinib versus gemcitabine alone was 0.71, with a 95% confidence interval of 0.44-1.13.",
      "The document concludes that further research is needed to confirm any potential benefit of Axitinib in prolonging the survival of pancreatic cancer patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the provided statements, there is not enough context or detailed information to determine the veracity of the claims. Only the document itself or additional specific information related to the trial results could validate these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MLP regulates F-actin dynamics through protein interaction with the 120,000 and 80,000/77,000 polypeptides in the calspectin/actin complex. These polypeptides are detected in the brain complex and crossreact with anti-protein 4.1 antibody, indicating that they are involved in the regulation of the calspectin-F-actin interaction in a Ca2+- and calmodulin-dependent manner, as demonstrated in the reconstitution system including purified calspectin, calmodulin and F-actin. Therefore, MLP regulates F-actin dynamics through this protein interaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through interaction with the 120,000 and 80,000/77,000 polypeptides.\n2. The 120,000 and 80,000/77,000 polypeptides are part of the calspectin/actin complex and are detected in the brain complex.\n3. These polypeptides crossreact with anti-protein 4.1 antibody.\n4. The regulation of the calspectin-F-actin interaction is Ca2+- and calmodulin-dependent.\n5. The interaction dynamics were demonstrated in a reconstitution system with purified calspectin, calmodulin, and F-actin.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through interaction with the 120,000 and 80,000/77,000 polypeptides.",
      "The 120,000 and 80,000/77,000 polypeptides are part of the calspectin/actin complex and are detected in the brain complex.",
      "These polypeptides crossreact with anti-protein 4.1 antibody.",
      "The regulation of the calspectin-F-actin interaction is Ca2+- and calmodulin-dependent.",
      "The interaction dynamics were demonstrated in a reconstitution system with purified calspectin, calmodulin, and F-actin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the technical and specific nature of these statements, they appear to be scientifically accurate statements likely sourced from a study or scientific literature discussing the molecular interactions involving MLP (Muscle LIM protein), F-actin (filamentous actin), calspectin (a membrane-associated cytoskeletal spectrin), and the role of calcium and calmodulin in regulating these interactions. However, without the exact context or reference, the veracity of the statements is assumed to be correct based on their technical accuracy and consistency within the realm of cell biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are approximately 15 residues in the main immunogenic region (MIR) of the acetylcholine receptor (AChR) alpha-subunit that are considered to be important for antigenicity. These residues are located in the sequence alpha 68-74, with particular emphasis on residues alpha 68-71. However, it is important to note that the exact number of pseudokinases in the human kinome is not explicitly stated in the document, and I cannot provide an answer to this question based solely on the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are three apoE mimetics:\n1. 1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane: This compound was shown to have a similar behavior to apoE in terms of its ability to mimic beta-adrenergic receptors, as described by Hoefle [8].\n2. 1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride: This compound exhibited a particularly strong and long-lasting sympathicomimetic effect, which is a characteristic of apoE.\n3. 1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride: This compound reduced the beta-adrenergic blockade and suppressed the sympathicomimetic action, which is similar to the action of apoE.\nIt is important to note that these compounds are not apoE itself, but rather mimetics that mimic the action of apoE on beta-adrenergic receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. 1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane is an apoE mimetic that behaves similarly to apoE in mimicking beta-adrenergic receptors.\n2. 1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic with strong and long-lasting sympathicomimetic effects.\n3. 1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that reduced beta-adrenergic blockade and suppressed sympathicomimetic action.",
    "llama-2-7b-chat-hf_fact": [
      "1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane is an apoE mimetic that behaves similarly to apoE in mimicking beta-adrenergic receptors.",
      "1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic with strong and long-lasting sympathicomimetic effects.",
      "1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that reduced beta-adrenergic blockade and suppressed sympathicomimetic action."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The chemical name given here does not specify a known apoE mimetic compound or its function relating to beta-adrenergic receptors.\n2. UNKNOWN: The given chemical name is highly specific and without additional context or reference to verified chemical databases, it is not possible to determine the accuracy of the statement regarding its functions as an apoE mimetic or its sympathicomimetic effects.\n3. UNKNOWN: Similar to the previous statement, without additional context, scientific literature, or access to databases detailing the compound's properties and functions, the truth of the statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several sex differences in SAMHD1 activity in adult SHRs:\n1. Sexually mature female SHRs have greater NOS activity in the renal inner medulla compared to age-matched males.\n2. The increase in NOS activity in sexually mature female SHRs is dependent on female sex hormones and age-related increases in blood pressure.\n3. NOS3 expression is greater in 5-week-old than 13-week-old SHRs regardless of sex.\n4. Ovariectomy (OVX) decreases NOS activity and NOS1 expression in female SHRs.\nTherefore, the answer to the user's question is that there are sex differences in SAMHD1 activity in adult SHRs, with sexually mature female SHRs having greater NOS activity and NOS1 expression compared to age-matched males, and this difference is mediated by female sex hormones and age-related increases in blood pressure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Sexually mature female SHRs exhibit greater NOS activity in the renal inner medulla than age-matched males.\n2. The increase in NOS activity in sexually mature female SHRs is associated with female sex hormones and higher blood pressure due to age.\n3. NOS3 expression is higher in 5-week-old SHRs than in 13-week-old SHRs, regardless of gender.\n4. Ovariectomy decreases both NOS activity and NOS1 expression in female SHRs.",
    "llama-2-7b-chat-hf_fact": [
      "Sexually mature female SHRs exhibit greater NOS activity in the renal inner medulla than age-matched males.",
      "The increase in NOS activity in sexually mature female SHRs is associated with female sex hormones and higher blood pressure due to age.",
      "NOS3 expression is higher in 5-week-old SHRs than in 13-week-old SHRs, regardless of gender.",
      "Ovariectomy decreases both NOS activity and NOS1 expression in female SHRs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\n[Explanation]: Without specific Context or reference to what SHRs are (presumably Spontaneously Hypertensive Rats based on typical usage, but not confirmed here), or details about the specific studies or sources of information that these statements are derived from, it is not possible to confirm the accuracy of these scientific claims. Additionally, without expertise in the specific area of biology or medicine related to NOS (Nitric Oxide Synthase) activity, expression, and the effects of sex hormones on these, the truth or falsity of these statements cannot be determined from the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that RUNX2 does not inhibit astrocyte differentiation. In fact, the document suggests that endothelial cells, which express LIF mRNA, play a role in inducing astrocyte differentiation. The study shows that purified endothelial cells strongly induce the differentiation of purified astrocyte precursor cells into astrocytes in vitro, and that this induction is prevented by a neutralizing anti-LIF antiserum. These findings suggest that endothelial cells may play a role in regulating astrocyte differentiation, and that RUNX2 is not involved in this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 does not inhibit astrocyte differentiation.\n2. Endothelial cells express LIF mRNA.\n3. Endothelial cells induce the differentiation of astrocyte precursor cells into astrocytes in vitro.\n4. Induction of astrocyte differentiation by endothelial cells can be prevented by a neutralizing anti-LIF antiserum.\n5. RUNX2 is not involved in the process of astrocyte differentiation according to the study.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 does not inhibit astrocyte differentiation.",
      "Endothelial cells express LIF mRNA.",
      "Endothelial cells induce the differentiation of astrocyte precursor cells into astrocytes in vitro.",
      "Induction of astrocyte differentiation by endothelial cells can be prevented by a neutralizing anti-LIF antiserum.",
      "RUNX2 is not involved in the process of astrocyte differentiation according to the study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Contrary to this statement, RUNX2 has been shown to play a role in the process of astrocyte differentiation, and the statement that RUNX2 is not involved in the process of astrocyte differentiation according to the study may not be accurate without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Cobb-Stainsby excision arthroplasty would typically be performed in the knee joint. The document mentions that the procedure is used to remove osteophytic bone from the anterior aspect of the tibia and anterior talus, which are both bones located in the knee joint. The procedure involves using arthroscopic instruments to excise, debride, and/or abrade the osteophytic bone, and reshaping the anterior tibia and/or talus to avoid impingement of the joint space and scuffing of adjacent articular cartilage. Therefore, the Cobb-Stainsby excision arthroplasty is typically performed in the knee joint to address the pathology of osteophytes in this area.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a procedure performed in the knee joint.\n2. The procedure involves the removal of osteophytic bone from the anterior aspect of the tibia.\n3. The Cobb-Stainsby excision arthroplasty also targets the removal of osteophytic bone from the anterior talus.\n4. The procedure utilizes arthroscopic instruments for excising, debriding, and/or abrading osteophytic bone.\n5. The goal of the Cobb-Stainsby excision arthroplasty is to reshape the anterior tibia and/or talus to avoid impingement of the joint space and prevent scuffing of adjacent articular cartilage.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a procedure performed in the knee joint.",
      "The procedure involves the removal of osteophytic bone from the anterior aspect of the tibia.",
      "The Cobb-Stainsby excision arthroplasty also targets the removal of osteophytic bone from the anterior talus.",
      "The procedure utilizes arthroscopic instruments for excising, debriding, and/or abrading osteophytic bone.",
      "The goal of the Cobb-Stainsby excision arthroplasty is to reshape the anterior tibia and/or talus to avoid impingement of the joint space and prevent scuffing of adjacent articular cartilage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a procedure performed in the toe joint, specifically the hallux (big toe), not the knee joint.\n2. UNKNOWN\n3. FALSE [correction]: The procedure targets the metatarsophalangeal joint of the hallux (big toe), not the anterior talus.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that GRHL2 over-expression does lead to EMT. The document states that GRHL2 and ESRP1 are strongly correlated with CDH1 in cancer cell lines and also correlate with CDH1 at the protein level in breast cancer specimens. Additionally, the document finds that high GRHL2 expression is highly correlated with worse relapse-free survival in all four subtypes of breast cancer. These findings suggest that GRHL2 plays a role in the process of EMT, which is a critical step in the progression of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression leads to epithelial-mesenchymal transition (EMT).\n2. GRHL2 and ESRP1 show a strong correlation with CDH1 in cancer cell lines.\n3. GRHL2 correlates with CDH1 at the protein level in breast cancer specimens.\n4. High GRHL2 expression is highly correlated with worse relapse-free survival in all four subtypes of breast cancer.\n5. GRHL2 is suggested to play a role in the process of EMT, which is important in the progression of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression leads to epithelial-mesenchymal transition (EMT).",
      "GRHL2 and ESRP1 show a strong correlation with CDH1 in cancer cell lines.",
      "GRHL2 correlates with CDH1 at the protein level in breast cancer specimens.",
      "High GRHL2 expression is highly correlated with worse relapse-free survival in all four subtypes of breast cancer.",
      "GRHL2 is suggested to play a role in the process of EMT, which is important in the progression of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GRHL2 over-expression is known to lead to epithelial-mesenchymal transition (EMT), a process where epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties.\n2. UNKNOWN: Without specific data from studies, it is not possible to confirm whether GRHL2 and ESRP1 show a strong correlation with CDH1 in cancer cell lines.\n3. UNKNOWN: Similarly, without specific data or research findings, it is impossible to confirm whether GRHL2 correlates with CDH1 at the protein level in breast cancer specimens.\n4. FALSE [correction]: High GRHL2 expression is generally associated with better relapse-free survival in certain subtypes of breast cancer, particularly the luminal subtype, not worse.\n5. TRUE: GRHL2 is indeed suggested to play a role in the process of EMT, which is important in the progression and metastasis of cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in lung cancer:\n1. uc.306: The document states that this macrophage-derived T-UCR is upregulated in M1 cells and is involved in the Wnt pathway. Low expression of uc.306 was significantly associated with a shorter overall survival in HBV-related HCC.\nIt is important to note that this study focused on the prognosis of HBV-related HCC, and the findings may not necessarily apply to lung cancer. Further research is needed to determine the role of T-UCRs in lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, GPR151 is an orphan receptor that is part of the melatonin receptor subfamily, but it does not bind melatonin or respond to it in various signaling assays. Despite this, GPR151 shows spontaneous ligand-independent activities on cAMP, inositol phosphate, and arrestin pathways, with distinct pathway-specific profiles. Additionally, co-expression of GPR151 with the melatonin binding MT2 receptor leads to the formation of receptor heteromers, inhibition of melatonin-induced arrestin recruitment to MT2, and decreased cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR151. These findings suggest that GPR151 is unable to bind melatonin, but has a reciprocal regulatory interaction with MT2 receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor that is part of the melatonin receptor subfamily.\n2. GPR151 does not bind melatonin nor respond to it in various signaling assays.\n3. GPR151 exhibits spontaneous ligand-independent activities on the cAMP, inositol phosphate, and arrestin pathways.\n4. Co-expression of GPR151 with the MT2 receptor leads to the formation of receptor heteromers.\n5. The co-expression of GPR151 with the MT2 receptor results in inhibition of melatonin-induced arrestin recruitment to MT2 and a decrease in cAMP levels upon melatonin stimulation.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor that is part of the melatonin receptor subfamily.",
      "GPR151 does not bind melatonin nor respond to it in various signaling assays.",
      "GPR151 exhibits spontaneous ligand-independent activities on the cAMP, inositol phosphate, and arrestin pathways.",
      "Co-expression of GPR151 with the MT2 receptor leads to the formation of receptor heteromers.",
      "The co-expression of GPR151 with the MT2 receptor results in inhibition of melatonin-induced arrestin recruitment to MT2 and a decrease in cAMP levels upon melatonin stimulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GPR151 is not part of the melatonin receptor subfamily but rather an orphan G protein-coupled receptor (GPCR) that does not belong to any specific subfamily.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction of the first statement is based on the current classification of GPCRs where GPR151 is not categorized under the melatonin receptor subfamily. The truth value of statements 4 and 5 would require more specific knowledge or research on the interactions between GPR151 and the MT2 receptor, which is beyond general knowledge and not provided in the context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n* Reassortant B/USSR/60/69-based vaccine influenza viruses Victoria and Yamagata.\nThese are the two attenuated live viruses that are included in the quadrivalent LAIV (qLAIV) vaccine. The vaccine is safe and reactogenic in adult volunteers, and it induces an immune response to both the Victoria and Yamagata lineages following administration.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus is the 5.5 kb NcoI fragment. The study found that the frequency of this fragment was significantly higher in SLE patients compared to normal controls, suggesting that the polymorphic TNF genes, including the TNFR2 gene, may play a role in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 5.5 kb NcoI fragment of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. In a study, the frequency of the 5.5 kb NcoI fragment was significantly higher in SLE patients than in normal controls.\n3. Polymorphic TNF genes, including the TNFR2 gene, may be involved in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The 5.5 kb NcoI fragment of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "In a study, the frequency of the 5.5 kb NcoI fragment was significantly higher in SLE patients than in normal controls.",
      "Polymorphic TNF genes, including the TNFR2 gene, may be involved in the pathogenesis of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, there is currently no vaccine available for peanut allergy. The article states that oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. The authors of the article conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo for peanut allergy. The results of the review showed that oral immunotherapy increased the risk of anaphylaxis, anaphylaxis frequency, and epinephrine use, but also increased the risk of serious adverse events and non-anaphylactic reactions. The article concludes that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitization.\nTherefore, based on the information provided in the article, it appears that there is currently no vaccine available for peanut allergy, and that oral immunotherapy is the only experimental treatment available, but its benefits and harms are still unclear and require further evaluation.",
    "llama-2-7b-chat-hf_fact_raw": "1. As of the information provided, there is no vaccine available for peanut allergy.\n2. Oral immunotherapy is an emerging experimental treatment for peanut allergy.\n3. The authors conducted a systematic review and meta-analysis of randomized controlled trials on oral immunotherapy for peanut allergy.\n4. Oral immunotherapy increased the risk of anaphylaxis, anaphylaxis frequency, and epinephrine use compared to allergen avoidance or placebo.\n5. Oral immunotherapy also increased the risk of serious adverse events and non-anaphylactic reactions for peanut allergy.",
    "llama-2-7b-chat-hf_fact": [
      "As of the information provided, there is no vaccine available for peanut allergy.",
      "Oral immunotherapy is an emerging experimental treatment for peanut allergy.",
      "The authors conducted a systematic review and meta-analysis of randomized controlled trials on oral immunotherapy for peanut allergy.",
      "Oral immunotherapy increased the risk of anaphylaxis, anaphylaxis frequency, and epinephrine use compared to allergen avoidance or placebo.",
      "Oral immunotherapy also increased the risk of serious adverse events and non-anaphylactic reactions for peanut allergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (Based on the information provided, it is suggested that there is no vaccine available for peanut allergy. However, my knowledge only goes up until early 2023, and if this has changed meanwhile, my information might be outdated.)\n2. TRUE\n3. TRUE (Assuming the statement is based on a specific study or collection of studies that the respondent is aware of within the context.)\n4. TRUE (This statement seems to be a finding from the mentioned systematic review and meta-analysis, and it is consistent with known outcomes from oral immunotherapy research.)\n5. TRUE (Like statement 4, this seems to be a finding from the systematic review and meta-analysis and aligns with known potential side effects of oral immunotherapy.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mouse Fxy gene is located on the Y chromosome. Specifically, it is located in the sex-determining region of the Y chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the Y chromosome.\n2. It is situated in the sex-determining region of the Y chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the Y chromosome.",
      "It is situated in the sex-determining region of the Y chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse Fxy gene, sometimes called Fx, is not located on the Y chromosome; it is located on the X chromosome.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of the enzyme DNase I and the synthetic molecule methidium-propyl-EDTA (MPE) for partial cleavage of ligand-protected DNA restriction fragments, followed by Maxam-Gilbert sequencing gel methods of analysis. DNase I footprinting and MPE.Fe (II) footprinting are the two methods used in MPE-seq.\nDNase I footprinting employs the enzyme DNase I as the DNA cleaving agent, which cleaves the DNA at the binding sites of the protein of interest. This method reports larger binding site sizes than MPE.Fe (II) footprinting. DNase I footprinting appears more sensitive for weakly bound sites.\nMPE.Fe (II) footprinting, on the other hand, uses the synthetic molecule MPE to cleave the DNA at the binding sites of the protein of interest. This method appears more accurate in determining the actual size and location of the binding sites for small molecules on DNA, especially in cases where several small molecules are closely spaced on the DNA. MPE.Fe (II) footprinting reports the same sequence and binding site size for lac repressor protein on operator DNA as DNase I footprinting.\nIn summary, the MPE-seq method combines the advantages of both DNase I footprinting and MPE.Fe (II) footprinting to provide a more accurate and comprehensive understanding of the binding sites of proteins on DNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method uses the enzyme DNase I and the synthetic molecule methidium-propyl-EDTA (MPE) for partial cleavage of DNA.\n2. Following partial cleavage by MPE-seq, Maxam-Gilbert sequencing gel methods are used for analysis.\n3. DNase I footprinting, part of the MPE-seq method, uses the enzyme DNase I to cleave DNA at protein binding sites and tends to report larger binding site sizes.\n4. MPE.Fe (II) footprinting, another component of MPE-seq, employs the synthetic molecule MPE to cleave DNA at protein binding sites and is more accurate in determining actual size and location of binding sites.\n5. MPE.Fe (II) footprinting reports the same sequence and binding site size for lac repressor protein on operator DNA as does DNase I footprinting.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method uses the enzyme DNase I and the synthetic molecule methidium-propyl-EDTA (MPE) for partial cleavage of DNA.",
      "Following partial cleavage by MPE-seq, Maxam-Gilbert sequencing gel methods are used for analysis.",
      "DNase I footprinting, part of the MPE-seq method, uses the enzyme DNase I to cleave DNA at protein binding sites and tends to report larger binding site sizes.",
      "MPE.Fe (II) footprinting, another component of MPE-seq, employs the synthetic molecule MPE to cleave DNA at protein binding sites and is more accurate in determining actual size and location of binding sites.",
      "MPE.Fe (II) footprinting reports the same sequence and binding site size for lac repressor protein on operator DNA as does DNase I footprinting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: DNase I footprinting is a technique that involves the enzyme DNase I to cleave DNA at random locations rather than just at protein binding sites. This method results in a pattern that can be used to infer the location of protein binding sites because they will be protected from DNase I cleavage, but it doesn't inherently cleave DNA at protein binding sites and it may report larger binding site sizes if the protein protects a larger area of DNA.\n4. TRUE\n5. FALSE [correction]: MPEFe(II) footprinting and DNase I footprinting may not always report the same sequence and binding site size for protein-DNA interactions such as the lac repressor protein on operator DNA. MPEFe(II) is often more precise in pinpointing the location of the binding sites due to the different cleavage properties of MPE compared to DNase I, which can lead to differences in reported sizes of protected regions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the programming language used for implementing GWAR is Perl. The document mentions that G-language GAE has an interface as a set of Perl libraries for software development, which suggests that Perl is the primary language used for the development of GWAR.",
    "llama-2-7b-chat-hf_fact_raw": "1. Perl has been used for implementing GWAR.\n2. G-language GAE provides an interface as a set of Perl libraries for software development.",
    "llama-2-7b-chat-hf_fact": [
      "Perl has been used for implementing GWAR.",
      "G-language GAE provides an interface as a set of Perl libraries for software development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no conclusive evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS). The document discusses the effects of xaliproden on allodynia induced by chemotherapeutic agents in mice, but does not mention anything about ALS.\nALS is a progressive neurological disease that affects the nerve cells responsible for controlling voluntary muscle movement. It is characterized by muscle weakness, atrophy, and twitching, and eventually leads to paralysis and death. There is currently no cure for ALS, and the available treatments only provide temporary relief from symptoms.\nWhile the document does mention that paclitaxel, vincristine, and oxaliplatin are chemotherapeutic agents that can induce allodynia in mice, there is no evidence to suggest that xaliproden has any effect on ALS. The document only discusses the effects of xaliproden on allodynia induced by these chemotherapeutic agents, and does not provide any information about its potential effect on ALS.\nTherefore, based on the information provided in the document, it can be concluded that xaliproden does not improve the prognosis of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no conclusive evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. The document mentions that xaliproden has effects on allodynia induced by chemotherapeutic agents in mice.\n3. Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects nerve cells responsible for controlling voluntary muscle movement.\n4. ALS is characterized by muscle weakness, atrophy, twitching, and eventually leads to paralysis and death.\n5. There is currently no cure for ALS, and available treatments only provide temporary relief from symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "There is no conclusive evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "The document mentions that xaliproden has effects on allodynia induced by chemotherapeutic agents in mice.",
      "Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects nerve cells responsible for controlling voluntary muscle movement.",
      "ALS is characterized by muscle weakness, atrophy, twitching, and eventually leads to paralysis and death.",
      "There is currently no cure for ALS, and available treatments only provide temporary relief from symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: As of my last update, there was no conclusive evidence that xaliproden significantly improves the prognosis of ALS. Clinical trials have yielded mixed results, and the drug has not been widely adopted for this purpose.\n2. UNKNOWN: Without the specific document referenced, it is not possible to confirm whether it mentions effects of xaliproden on allodynia induced by chemotherapeutic agents in mice.\n3. TRUE: Amyotrophic lateral sclerosis (ALS) is indeed a progressive neurological disease that primarily affects motor neurons responsible for controlling voluntary muscles.\n4. TRUE: ALS is characterized by the symptoms mentioned: muscle weakness, atrophy, twitching, and eventual paralysis. These symptoms are indicative of the progressive nature of the disease.\n5. FALSE [correction]: There is currently no cure for ALS, which is true, but available treatments such as Riluzole and Edaravone can slow disease progression, and other interventions can help manage symptoms. Thus, treatments do not just provide temporary relief from symptoms but can also have an impact on the disease course.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the transgenes were inserted into the following chromosomes:\n* Tg 74: Chromosome 7\n* Tg 174: Chromosome 13\n* Tg 171: Chromosome 18\nTherefore, the answer to the user's question is: The LiPS-A3S line has transgenes inserted into chromosomes 7, 13, and 18.",
    "llama-2-7b-chat-hf_fact_raw": "1. In the LiPS-A3S line, transgenes were inserted into chromosome 7.\n2. In the LiPS-A3S line, transgenes were inserted into chromosome 13.\n3. In the LiPS-A3S line, transgenes were inserted into chromosome 18.",
    "llama-2-7b-chat-hf_fact": [
      "In the LiPS-A3S line, transgenes were inserted into chromosome 7.",
      "In the LiPS-A3S line, transgenes were inserted into chromosome 13.",
      "In the LiPS-A3S line, transgenes were inserted into chromosome 18."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific context or documented evidence provided to verify the location of the transgene insertion for the LiPS-A3S line, it is not possible to determine the truth of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several deep learning tools that can be used for predicting drug synergy:\n1. Deep Belief Network (DBN): The document mentions DBN as the novel method used for predicting drug synergy. DBN is a type of deep learning algorithm that can learn complex patterns in data and make predictions based on those patterns.\n2. Convolutional Neural Networks (CNNs): CNNs are a type of deep learning algorithm that can be used for image recognition tasks, but they can also be used for predicting drug synergy. CNNs can learn patterns in gene expression data and predict drug synergy based on those patterns.\n3. Recurrent Neural Networks (RNNs): RNNs are a type of deep learning algorithm that can be used for time series data, such as gene expression data. RNNs can learn patterns in gene expression data and predict drug synergy based on those patterns.\n4. Long Short-Term Memory (LSTM) Networks: LSTM is a type of RNN that can learn long-term dependencies in time series data. LSTM networks can be used for predicting drug synergy based on gene expression data.\n5. Generative Adversarial Networks (GANs): GANs are a type of deep learning algorithm that can be used for generating new data that is similar to a given dataset. GANs can be used for predicting drug synergy by generating new drug combinations based on the patterns learned from the existing data.\nThese are some of the deep learning tools that can be used for predicting drug synergy, based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deep Belief Networks (DBNs) are described as a type of deep learning algorithm for predicting drug synergy.\n2. Convolutional Neural Networks (CNNs) can be utilized for predicting drug synergy by learning patterns in gene expression data.\n3. Recurrent Neural Networks (RNNs) can predict drug synergy by analyzing time series data like gene expression data.\n4. Long Short-Term Memory (LSTM) networks are a form of RNN that can handle long-term dependencies in time series data for predicting drug synergy.\n5. Generative Adversarial Networks (GANs) can generate new drug combinations for predicting drug synergy by learning from existing data patterns.",
    "llama-2-7b-chat-hf_fact": [
      "Deep Belief Networks (DBNs) are described as a type of deep learning algorithm for predicting drug synergy.",
      "Convolutional Neural Networks (CNNs) can be utilized for predicting drug synergy by learning patterns in gene expression data.",
      "Recurrent Neural Networks (RNNs) can predict drug synergy by analyzing time series data like gene expression data.",
      "Long Short-Term Memory (LSTM) networks are a form of RNN that can handle long-term dependencies in time series data for predicting drug synergy.",
      "Generative Adversarial Networks (GANs) can generate new drug combinations for predicting drug synergy by learning from existing data patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deep Belief Networks (DBNs) are a type of deep learning algorithm, but they are not described specifically for predicting drug synergy; they are a more general-purpose algorithm that can be used in various applications including feature learning and classification tasks.\n2. TRUE: Convolutional Neural Networks (CNNs) can indeed be utilized for predicting drug synergy by learning patterns in gene expression data, among other applications.\n3. TRUE: Recurrent Neural Networks (RNNs) are well-suited for time series data analysis and hence can be used to predict drug synergy, if the gene expression data is presented as a time series.\n4. TRUE: Long Short-Term Memory (LSTM) networks are a specialized form of RNN designed to handle long-term dependencies, and they are suitable for tasks involving sequences like time series data, which can be relevant for predicting drug synergy.\n5. TRUE: Generative Adversarial Networks (GANs) are capable of generating new drug combinations for predicting drug synergy, as they can learn to mimic the distribution of the input data and create new, plausible examples of data that could be potential drug combinations.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cloud-based platform that has been developed for comparing GWAS is BlueSNP. According to the document, BlueSNP is a R package that implements GWAS statistical tests in the R programming language and executes the calculations across computer clusters configured with Apache Hadoop, a de facto standard framework for distributed data processing using the MapReduce formalism. This allows for computationally intensive analyses, such as estimating empirical p-values via data permutation and searching for expression quantitative trait loci over thousands of genes, to be performed on large genotype-phenotype datasets. The BlueSNP package is available for implementation at the following URL: <http://github.com/ibm-bioinformatics/bluesnp>.",
    "llama-2-7b-chat-hf_fact_raw": "1. BlueSNP is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies).\n2. BlueSNP is an R package that implements GWAS statistical tests.\n3. BlueSNP executes calculations across computer clusters configured with Apache Hadoop.\n4. Apache Hadoop is used for distributed data processing within the BlueSNP platform.\n5. The BlueSNP package is available at the URL: http://github.com/ibm-bioinformatics/bluesnp.",
    "llama-2-7b-chat-hf_fact": [
      "BlueSNP is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies).",
      "BlueSNP is an R package that implements GWAS statistical tests.",
      "BlueSNP executes calculations across computer clusters configured with Apache Hadoop.",
      "Apache Hadoop is used for distributed data processing within the BlueSNP platform.",
      "The BlueSNP package is available at the URL: http://github.com/ibm-bioinformatics/bluesnp."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or a source, it's impossible to confirm the accuracy of this statement as \"BlueSNP\" is not a well-known term in the public domain.\n2. FALSE [correction]: BlueSNP is an R package, but it's specifically designed for performing analyses on genotypic and phenotypic data in cloud environments, rather than implementing GWAS statistical tests.\n3. TRUE: BlueSNP is designed to execute calculations across computer clusters, and it's reasonable for it to use Apache Hadoop, given that it's a common framework for distributed computing.\n4. TRUE: Given that BlueSNP is designed for computation across computer clusters and Apache Hadoop is a platform that allows for distributed data processing, it's logical that Hadoop would be utilized within BlueSNP.\n5. UNKNOWN: Without current internet access to verify the provided URL, the accuracy of this statement cannot be confirmed. URLs are subject to change and may have been correct at the time of writing but may not be so presently, or the URL could have been incorrect from the start.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 may not be effective against sarcomas. The document mentions that ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice bearing sarcomas, including sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma. Additionally, the drug was found to exert its maximum effect when given on days -2 to +2 relative to antigenic stimulus, suggesting that it interferes with the afferent limb of the immune response. These findings suggest that CMB305 may have similar limitations in its ability to treat sarcomas as ZIMET 3164. Therefore, it is unlikely that CMB305 would be effective against sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 may not be effective against sarcomas.\n2. ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice with sarcomas.\n3. The types of sarcomas in the study with ZIMET 3164 included sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.\n4. ZIMET 3164 had its maximum effect when administered between days -2 and +2 relative to antigenic stimulus.\n5. ZIMET 3164 appears to interfere with the afferent limb of the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 may not be effective against sarcomas.",
      "ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice with sarcomas.",
      "The types of sarcomas in the study with ZIMET 3164 included sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.",
      "ZIMET 3164 had its maximum effect when administered between days -2 and +2 relative to antigenic stimulus.",
      "ZIMET 3164 appears to interfere with the afferent limb of the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is not enough context to confirm whether CMB305 is effective against sarcomas or not.\n2. UNKNOWN: Without additional context or study data, it cannot be determined whether ZIMET 3164 was successful in prolonging the survival time of mice with sarcomas.\n3. UNKNOWN: Without access to the study or its results, the types of sarcomas used in the experiments cannot be confirmed.\n4. UNKNOWN: The effectiveness and timing of ZIMET 3164's maximum effect relative to antigenic stimulus cannot be verified without additional information.\n5. UNKNOWN: It's not possible to confirm whether ZIMET 3164 interferes with the afferent limb of the immune response without more detailed information or research data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the manifestations of the Saint's Triad in Filippino Lippi's Magrini Altarpiece (c. 1482) are:\n1. St Rocco and St Sebastian, the two young saints on the left side of the altarpiece, have hand deformities, such as swelling and twisting of the fingers, which are more significant than those of the older man and young woman on the right side.\n2. The artist may have deliberately chosen to depict the young male saints' hands in this way to emphasize both their aristocratic standing and the role of suffering and martyrdom in their traditional biographies.\nIt is worth noting that the artist, Filippino Lippi, was known for his realistic depiction of human anatomy, and it is possible that he based the hand deformities on observations of people with arthritis or other hand deformities.",
    "llama-2-7b-chat-hf_fact_raw": "1. St Rocco and St Sebastian are depicted on the left side of Filippino Lippi's Magrini Altarpiece, which dates around 1482.\n2. These two saints are shown with hand deformities, including swelling and twisting of the fingers.\n3. Filippino Lippi was recognized for his realistic portrayal of human anatomy.\n4. It is suggested that Lippi may have depicted the deformities to reflect the saints' aristocratic status and the concept of suffering and martyrdom in their stories.\n5. The artist may have drawn inspiration for the hand deformities from actual observations of people with arthritis or other similar conditions.",
    "llama-2-7b-chat-hf_fact": [
      "St Rocco and St Sebastian are depicted on the left side of Filippino Lippi's Magrini Altarpiece, which dates around 1482.",
      "These two saints are shown with hand deformities, including swelling and twisting of the fingers.",
      "Filippino Lippi was recognized for his realistic portrayal of human anatomy.",
      "It is suggested that Lippi may have depicted the deformities to reflect the saints' aristocratic status and the concept of suffering and martyrdom in their stories.",
      "The artist may have drawn inspiration for the hand deformities from actual observations of people with arthritis or other similar conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: St Roch (Rocco) and St Sebastian are depicted on the right side of Filippino Lippi's Magrini Altarpiece.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, overexpression of LY6K is associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients. The study found that high levels of LY6K expression were detected in 25.9% of NSCLC tissues, and patients with overexpression of LY6K had a poorer overall survival rate compared to those with low expression. Specifically, the patients with Nek2 overexpression had the most negative prognosis. These findings suggest that LY6K may represent a new potential target for NSCLC therapeutic intervention. Therefore, the answer to the user's question is yes, overexpression of LY6K is associated with a poorer prognosis for NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression were detected in 25.9% of NSCLC tissues.\n3. Patients with overexpression of LY6K had a poorer overall survival rate compared to those with low expression.\n4. Patients with Nek2 overexpression had the most negative prognosis among the study subjects.\n5. LY6K is suggested as a potential target for therapeutic intervention in NSCLC.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression were detected in 25.9% of NSCLC tissues.",
      "Patients with overexpression of LY6K had a poorer overall survival rate compared to those with low expression.",
      "Patients with Nek2 overexpression had the most negative prognosis among the study subjects.",
      "LY6K is suggested as a potential target for therapeutic intervention in NSCLC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Overexpression of LY6K has been reported in literature to be associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients.\n2. UNKNOWN: Without the specific study or statistical data referenced, it's not possible to confirm the percentage of NSCLC tissues with high levels of LY6K expression.\n3. TRUE: It is consistent with the statement in 1, as overexpression leading to a poorer prognosis would logically be associated with a poorer overall survival rate.\n4. UNKNOWN: The statement about Nek2 overexpression and its prognostic implications in the study subjects cannot be confirmed without the specific study or context.\n5. TRUE: It is common for overexpressed oncogenes, such as LY6K in certain cancers, to be investigated as potential targets for therapeutic intervention.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the CDK targets that are dephosphorylated during cytokinesis:\n1. Aip1\n2. Ede1\n3. Inn1\nThese targets are identified through phosphoproteome analysis of mitotic exit and further confirmed through the use of a new tool to generate conditionally phosphorylated proteins. The study suggests that the dephosphorylation of these CDK targets is required for cytokinesis to occur properly.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aip1 is dephosphorylated during cytokinesis.\n2. Ede1 is dephosphorylated during cytokinesis.\n3. Inn1 is dephosphorylated during cytokinesis.\n4. The dephosphorylation of CDK targets such as Aip1, Ede1, and Inn1 is required for proper cytokinesis.\n5. Phosphoproteome analysis of mitotic exit was used to identify CDK targets that are dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Aip1 is dephosphorylated during cytokinesis.",
      "Ede1 is dephosphorylated during cytokinesis.",
      "Inn1 is dephosphorylated during cytokinesis.",
      "The dephosphorylation of CDK targets such as Aip1, Ede1, and Inn1 is required for proper cytokinesis.",
      "Phosphoproteome analysis of mitotic exit was used to identify CDK targets that are dephosphorylated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided require specialized knowledge in the field of cell biology and a specific understanding of the proteins involved in the process of cytokinesis. Without the specific passage or additional scientific context, it is not possible to accurately determine the truthfulness of these statements. Therefore, the accuracy of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Xanamem is not a specific binding partner of collapsin response mediator protein 2 (CRMP-2). The study found that LCM, a drug used as an adjunctive treatment for partial-onset seizures, does not specifically bind to CRMP-2 using various drug binding methods such as radioligand binding experiments and surface plasmon resonance measurements. The results of the study suggest that LCM does not have an additional mode of action by binding to CRMP-2.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the role of the Hof1-Cyk3 interaction in yeast is to form a complex called the HICS (Hof1-Inn1-Cyk3-Sho1) complex. This complex is involved in connecting the membrane with the actin-myosin ring during cytokinesis. The HICS complex is formed through interactions between three SH3 domains located in Cyk3p, Hof1p, and Sho1p, and five acceptor sites found in Cyk3p, Hof1p, and Inn1p. The HICS complex is described as an ensemble of isomeric interaction states that precisely coordinate the different functions of the interactors during cytokinesis. In other words, the Hof1-Cyk3 interaction plays a crucial role in connecting the actin-myosin ring to the membrane during cell division in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast forms a complex called the HICS (Hof1-Inn1-Cyk3-Sho1) complex.\n2. The HICS complex is involved in connecting the membrane with the actin-myosin ring during cytokinesis in yeast.\n3. The HICS complex is formed through interactions between three SH3 domains located in Cyk3p, Hof1p, and Sho1p.\n4. There are five acceptor sites found in Cyk3p, Hof1p, and Inn1p that contribute to the formation of the HICS complex.\n5. The HICS complex represents an ensemble of isomeric interaction states that help coordinate the functions of the interactors during cytokinesis in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast forms a complex called the HICS (Hof1-Inn1-Cyk3-Sho1) complex.",
      "The HICS complex is involved in connecting the membrane with the actin-myosin ring during cytokinesis in yeast.",
      "The HICS complex is formed through interactions between three SH3 domains located in Cyk3p, Hof1p, and Sho1p.",
      "There are five acceptor sites found in Cyk3p, Hof1p, and Inn1p that contribute to the formation of the HICS complex.",
      "The HICS complex represents an ensemble of isomeric interaction states that help coordinate the functions of the interactors during cytokinesis in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Hof1-Cyk3 interaction in yeast forms a complex called the \"CHS\" (Cyk3-Hof1-Sho1) complex, not HICS.\n2. TRUE\n3. FALSE [correction]: The HICS (should be CHS) complex is formed through interactions between SH3 domains; however, the specific number of SH3 domains and their exact locations would need verification, as only Hof1p and Cyk3p were mentioned in the original statement, not Sho1p.\n4. UNKNOWN: Without specific literature on the acceptor sites in the proteins mentioned, it's difficult to confirm the number of acceptor sites and in which proteins they are found.\n5. TRUE: Complexes like CHS often represent an ensemble of isomeric interaction states to coordinate functions during processes such as cytokinesis, but the statement could be more specific to be accurately assessed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in gastric cancer:\n1. None. The document states that TGF-beta 1RII mutations were not found in any of the 61 stable or unstable gastric or esophageal cancers evaluated.\nTherefore, the answer to the user's question is: None.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE) in patients, including those with mesenteric vasculitis (LMV). The LSI is a composite score that takes into account various organ involvement, disease activity, and severity of symptoms. The score ranges from 0 to 100, with higher scores indicating more severe disease.\nIn the case of LMV, the LSI can help clinicians identify patients who are at high risk of developing severe complications, such as bowel obstruction, perforation, or ischemia. The LSI can also help guide treatment decisions, as more severe scores may indicate a need for more aggressive therapy, such as corticosteroids, immunosuppressants, or biologic agents.\nIn the study described in the passage, the authors used the LSI to assess the severity of SLE in five patients aged 14 to 21 years old who were diagnosed with LMV. The LSI score was calculated based on the patients' clinical presentation, laboratory results, and imaging findings, and was found to be useful in predicting the severity of disease and guiding treatment decisions.\nOverall, the LSI is a valuable tool for assessing the severity of SLE in patients with LMV, and can help clinicians provide more effective and targeted treatment to improve outcomes for these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE) in patients.\n2. The LSI score is a composite score that considers various organ involvement, disease activity, and severity of symptoms.\n3. The LSI score ranges from 0 to 100, with higher scores indicating more severe disease.\n4. Higher LSI scores may indicate a need for more aggressive therapy in SLE patients, such as corticosteroids, immunosuppressants, or biologic agents.\n5. The study mentioned used the LSI to assess the severity of SLE in patients aged 14 to 21 years old diagnosed with mesenteric vasculitis (LMV).",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE) in patients.",
      "The LSI score is a composite score that considers various organ involvement, disease activity, and severity of symptoms.",
      "The LSI score ranges from 0 to 100, with higher scores indicating more severe disease.",
      "Higher LSI scores may indicate a need for more aggressive therapy in SLE patients, such as corticosteroids, immunosuppressants, or biologic agents.",
      "The study mentioned used the LSI to assess the severity of SLE in patients aged 14 to 21 years old diagnosed with mesenteric vasculitis (LMV)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE (Generally, as scores that measure disease severity increase, they may indicate a need for more aggressive therapy, although professional judgment is always required.)\n5. FALSE [correction]: It's unclear without additional context whether the study used the LSI or if it focused specifically on patients aged 14 to 21 with mesenteric vasculitis. Mesenteric vasculitis (LMV) should also be clarified if it refers to lupus mesenteric vasculitis, as \"LMV\" does not inherently indicate \"lupus.\" If it does, the statement still needs correction for clarity and verification regarding the age range and specific use of the LSI.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, de novo mutations in the ZSWIM6 gene have been associated with the following disorders:\n1. Amyotrophic lateral sclerosis (ALS): The document mentions that de novo mutations in the FUS gene (which is also known as ZSWIM6) have been found in approximately 1% to 2% of sporadic ALS cases, highlighting the importance of screening ALS patients for FUS mutations.\nTherefore, based on the information provided, de novo mutations in ZSWIM6 have been linked to ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene are associated with Amyotrophic lateral sclerosis (ALS).\n2. De novo mutations in the FUS gene, known as ZSWIM6, have been found in approximately 1% to 2% of sporadic ALS cases.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene are associated with Amyotrophic lateral sclerosis (ALS).",
      "De novo mutations in the FUS gene, known as ZSWIM6, have been found in approximately 1% to 2% of sporadic ALS cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in the ZSWIM6 gene are not associated with Amyotrophic lateral sclerosis (ALS); they have been associated with developmental disorders such as intellectual disability and autism.\n2. FALSE [correction]: De novo mutations in the FUS gene, which is not known as ZSWIM6, have been found in approximately 1% to 2% of sporadic ALS cases. ZSWIM6 and FUS are two different genes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is \"cytologic findings\". The passage highlights the limitations of the Papanicolaou classification for interpreting cytologic findings and suggests that a more descriptive approach, such as the Koos Classification, may be more appropriate.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the in vivo effects of AZD8601 (a MEK1/2 inhibitor) include:\n1. Safety and tolerability: AZD8601 was generally well-tolerated in patients with advanced malignancies, with the most common adverse events being acneiform dermatitis, fatigue, diarrhea, and vomiting. Four patients experienced dose-limiting toxicities, including mental status changes and rash.\n2. Pharmacokinetics: AZD8601 exposure increased proportionally with dose across the dose range of 0.5-60 mg orally once daily (OD) or twice daily (BID).\n3. Pharmacodynamics: Dose-dependent modulation of phosphorylated ERK in peripheral blood mononuclear cells (PBMCs) was observed at doses greater than 3 mg.\n4. Antitumor activity: One patient with malignant melanoma had a partial response, and 32 patients (39%) had stable disease, with a duration of greater than 3 months in 22 patients, as assessed by Response Evaluation Criteria in Solid Tumors.\nOverall, the in vivo effects of AZD8601 suggest that it has a manageable toxicity profile and target inhibition in PBMCs, with potential antitumor activity in patients with advanced malignancies.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 was generally well-tolerated in patients with advanced malignancies.\n2. The most common adverse events for patients taking AZD8601 were acneiform dermatitis, fatigue, diarrhea, and vomiting.\n3. AZD8601 exposure increased proportionally with the dose across the range of 0.5-60 mg orally once or twice daily.\n4. Dose-dependent modulation of phosphorylated ERK in peripheral blood mononuclear cells was observed at doses greater than 3 mg.\n5. One patient with malignant melanoma had a partial response, and 32 patients had stable disease for more than 3 months as assessed by Response Evaluation Criteria in Solid Tumors with AZD8601 treatment.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 was generally well-tolerated in patients with advanced malignancies.",
      "The most common adverse events for patients taking AZD8601 were acneiform dermatitis, fatigue, diarrhea, and vomiting.",
      "AZD8601 exposure increased proportionally with the dose across the range of 0.5-60 mg orally once or twice daily.",
      "Dose-dependent modulation of phosphorylated ERK in peripheral blood mononuclear cells was observed at doses greater than 3 mg.",
      "One patient with malignant melanoma had a partial response, and 32 patients had stable disease for more than 3 months as assessed by Response Evaluation Criteria in Solid Tumors with AZD8601 treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about AZD8601 being \"generally well-tolerated in patients with advanced malignancies\" can't be verified without specific clinical trial data or research findings. More context is needed to evaluate the veracity of this statement.\n\n2. UNKNOWN: Information about common adverse events for patients taking AZD8601 would require access to clinical trial data or official drug information which is not provided. More context is needed to assess this statement.\n\n3. UNKNOWN: The statement regarding the proportionality of AZD8601 exposure to the dosage requires pharmacokinetic data to verify. Without this data, the truth of the statement cannot be confirmed.\n\n4. UNKNOWN: The dose-dependent modulation of phosphorylated ERK is a specific pharmacodynamic effect that would need to be confirmed with scientific evidence. Without access to the relevant study or data, it is not possible to verify this statement.\n\n5. UNKNOWN: Information about patient responses to AZD8601, including the patient with malignant melanoma who had a partial response and those with stable disease, necessitates clinical trial results or detailed study data for confirmation. The statement cannot be validated without this information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the SAHFS (Streptomyces aromatic hydrocarbon receptor fusion protein) is created through the following steps:\n1. Bioinformatics analysis: The researchers used bioinformatics tools to identify a putative type II polyketide synthase (PKS) gene cluster (sah) in the genome of Streptomyces sahachiroi ATCC 33158.\n2. Cloning and functional analysis: The researchers cloned the sah cluster and performed functional analyses, including gene knockout and heterologous expression, to determine the biological function of the cluster.\n3. Identification of involved genes: Annotation of the predicted open reading frames (ORFs) revealed that the sah cluster is highly homologous with the spore-pigment biosynthetic cluster (whiE) in S. coelicolor A3, except for an additional O-methyltransferase gene (sahI). Three genes of the sah cluster, sahG, sahH, and sahI, were found to be involved in post-PKS modifications.\n4. Deletion of genes: The researchers deleted the three genes of the sah cluster by double crossover, resulting in mutant strains with changed spore colors.\n5. Heterologous expression: The researchers expressed the sah-minimal PKS gene and the whiE-minimal PKS gene in S. lividans ZX1, which produced the same hydrophilic red pigments.\nBased on these findings, the researchers concluded that the sah cluster is responsible for the spore-pigment biosynthesis of S. sahachiroi ATCC 33158 and catalyzes the formation of polyketides with the same core structures as the whiE cluster.",
    "llama-2-7b-chat-hf_fact_raw": "1. A putative type II polyketide synthase gene cluster (sah) was identified in the genome of Streptomyces sahachiroi ATCC 33158 using bioinformatics tools.\n2. The sah cluster was cloned and subjected to functional analysis including gene knockout and heterologous expression by researchers.\n3. Annotation of the predicted open reading frames revealed that the sah cluster is highly homologous to the spore-pigment biosynthetic cluster (whiE) in Streptomyces coelicolor A3, with an additional gene, sahI.\n4. Deletion of three genes (sahG, sahH, sahI) from the sah cluster led to mutant strains with altered spore colors.\n5. Heterologous expression of the sah-minimal PKS gene and the whiE-minimal PKS gene in Streptomyces lividans ZX1 produced hydrophilic red pigments.",
    "llama-2-7b-chat-hf_fact": [
      "A putative type II polyketide synthase gene cluster (sah) was identified in the genome of Streptomyces sahachiroi ATCC 33158 using bioinformatics tools.",
      "The sah cluster was cloned and subjected to functional analysis including gene knockout and heterologous expression by researchers.",
      "Annotation of the predicted open reading frames revealed that the sah cluster is highly homologous to the spore-pigment biosynthetic cluster (whiE) in Streptomyces coelicolor A3, with an additional gene, sahI.",
      "Deletion of three genes (sahG, sahH, sahI) from the sah cluster led to mutant strains with altered spore colors.",
      "Heterologous expression of the sah-minimal PKS gene and the whiE-minimal PKS gene in Streptomyces lividans ZX1 produced hydrophilic red pigments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are all related to specific scientific research findings. Without access to the original publication or findings related to Streptomyces sahachiroi and its polyketide synthase gene cluster, it is not possible to determine the veracity of these statements. They are highly specialized and would require expertise in microbial genetics and biochemistry, plus the actual research data, to confirm or refute.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the PDZ domain in SATB1 is to provide scaffolds for membrane-associated protein complexes by binding to the cytosolic, C-terminal fragments of receptors, channels, and other integral membrane proteins. The PDZ domain of SATB1 can bind to peptides corresponding to the C-termini of syndecan, neurexin, and ephrin B, with the PDZ2 domain binding these peptides in a canonical fashion, and the PDZ1 domain requiring a noncanonical conformation for binding. These findings suggest that SATB1 may preferentially bind to dimeric and clustered targets, and provide a mechanistic explanation for the previously reported cooperative ligand binding by SATB1's two PDZ domains.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 provides scaffolds for membrane-associated protein complexes.\n2. It binds to the cytosolic, C-terminal fragments of receptors, channels, and other integral membrane proteins.\n3. The PDZ domain of SATB1 can bind to peptides corresponding to the C-termini of syndecan, neurexin, and ephrin B.\n4. The PDZ2 domain of SATB1 binds peptides in a canonical fashion.\n5. The PDZ1 domain of SATB1 requires a noncanonical conformation for binding.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 provides scaffolds for membrane-associated protein complexes.",
      "It binds to the cytosolic, C-terminal fragments of receptors, channels, and other integral membrane proteins.",
      "The PDZ domain of SATB1 can bind to peptides corresponding to the C-termini of syndecan, neurexin, and ephrin B.",
      "The PDZ2 domain of SATB1 binds peptides in a canonical fashion.",
      "The PDZ1 domain of SATB1 requires a noncanonical conformation for binding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is a common structural domain found in signaling proteins, but SATB1 (Special AT-rich sequence-binding protein 1) is a matrix-attachment region (MAR)-binding protein that does not have a PDZ domain.\n2. TRUE: Generally, PDZ domains bind to the cytosolic, C-terminal fragments of receptors, channels, and other integral membrane proteins.\n3. UNKNOWN: Without specific information on the PDZ domain interactions of SATB1, which is incorrect as SATB1 doesn't have a PDZ domain, we cannot verify the truth of the statement. However, in general, PDZ domains can bind to C-termini of various proteins, which might include proteins like syndecan, neurexin, and ephrin B.\n4. FALSE [correction]: Since SATB1 does not contain a PDZ domain, it does not have a PDZ2 domain that could bind peptides in any fashion, canonical or otherwise.\n5. FALSE [correction]: Similarly, as SATB1 does not have a PDZ domain, it cannot have a PDZ1 domain that requires any conformation for binding.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is based on a symbolic and graphical language that was developed by Tony O'Donnell after his stroke 15 years ago. The language has been used with various clinical populations, including people with severe aphasia, and has been found to be meaningful to them when spoken and written English is not easily accessible. The BLISS technique is an adapted version of this language, which was specifically designed for people with severe aphasia.\nThe basis of the BLISS technique is to use symbolic and graphical representations to communicate meaningful concepts and ideas. The language consists of a set of symbols, each representing a specific concept or idea, and a set of rules for combining these symbols to form more complex messages. The use of symbols and rules allows individuals with severe aphasia to communicate more effectively and efficiently, as they can bypass the language processing difficulties that are often associated with this condition.\nThe study you mentioned investigated the validity and generality of O'Donnell's adapted BLISS system by assessing the ability of individuals without aphasia to match BLISS symbols to pictures. The results showed that individuals without aphasia were able to match the BLISS symbols to the pictures without any training, but there was considerable individual variation in their performance. The study also highlighted the benefits of collaborative research involving researchers with and without aphasia, as it provided a more comprehensive understanding of the research process and the experiences of all involved.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique was developed by Tony O'Donnell after his stroke 15 years ago.\n2. The BLISS technique is based on a symbolic and graphical language designed for people with severe aphasia.\n3. The language used in the BLISS technique includes a set of symbols, each representing a specific concept or idea.\n4. The BLISS technique has rules for combining symbols to form more complex messages.\n5. Research has shown that individuals without aphasia can match BLISS symbols to pictures without training, although with individual variation.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique was developed by Tony O'Donnell after his stroke 15 years ago.",
      "The BLISS technique is based on a symbolic and graphical language designed for people with severe aphasia.",
      "The language used in the BLISS technique includes a set of symbols, each representing a specific concept or idea.",
      "The BLISS technique has rules for combining symbols to form more complex messages.",
      "Research has shown that individuals without aphasia can match BLISS symbols to pictures without training, although with individual variation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS technique, also known as Blissymbols, was developed by Charles K. Bliss, not Tony O'Donnell, and it originated in the 1940s, not 15 years ago.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are 3 NK3R antagonists:\n1. L-659877\n2. [D-Pro4,D-Trp7,9,10]substance P\n3. GR 125963\nThese antagonists were identified in the document as being able to bind to and block the activity of NK3 receptors in rat uterus, as demonstrated through contractile and radioligand binding studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. L-659877 is identified as an NK3R antagonist.\n2. [D-Pro4,D-Trp7,9,10]substance P is identified as an NK3R antagonist.\n3. GR 125963 is identified as an NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "L-659877 is identified as an NK3R antagonist.",
      "[D-Pro4,D-Trp7,9,10]substance P is identified as an NK3R antagonist.",
      "GR 125963 is identified as an NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n\nThese statements pertain to specific compounds and their pharmacological classification concerning the neurokinin 3 receptor (NK3R). Without additional context or specific scientific references, I cannot confirm or refute the identification of L-659877 and [D-Pro4,D-Trp7,9,10]substance P as NK3R antagonists. However, GR 125963 is indeed known to be an NK3R antagonist.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is compound 33. According to the PK/PD analysis, compound 33 suppressed weight gain in rat models of obesity with a dose of 30 mg/kg. Therefore, it can be inferred that compound 33 is the first oral ghrelin receptor inverse agonist to be tested in healthy subjects and showed promising results in suppressing weight gain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Compound 33 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Compound 33 suppressed weight gain in rat models of obesity at a dose of 30 mg/kg.",
    "llama-2-7b-chat-hf_fact": [
      "Compound 33 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Compound 33 suppressed weight gain in rat models of obesity at a dose of 30 mg/kg."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nThe statements provided do not include sufficient context for me to verify as true or false. Both statements require specific scientific knowledge or evidence from the study that profiled Compound 33. Without access to the relevant research data or results, I cannot accurately validate these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the protective efficacy of Vaxchora against moderate to severe cholera is estimated to be effective. The trial conducted in 150 volunteers showed that the oral cholera chemical vaccine, Vaxchora, was both immunologically effective and safe, with no serious adverse events reported. Specifically, the results of titration of specific antitoxins and vibriocidal antibodies in the blood serum, as well as of coproantibodies, indicated that a dose of 2 tablets was the optimal dose for maximum protection.\nWhile the trial did not specifically evaluate the vaccine's efficacy against moderate to severe cholera, the results suggest that Vaxchora may provide adequate protection against the disease. The fact that the vaccine was found to be both immunologically effective and safe in a controlled trial is encouraging, and suggests that it may be a useful tool in preventing cholera in individuals at risk of infection.\nIt is important to note, however, that the protective efficacy of Vaxchora may vary depending on a number of factors, including the individual's age, health status, and exposure history. Additionally, the vaccine's efficacy may be influenced by factors such as the dose and route of administration, as well as the duration of protection provided. Further research is needed to fully understand the protective efficacy of Vaxchora against moderate to severe cholera, and to determine its place in the prevention and treatment of this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is an oral cholera vaccine.\n2. A trial was conducted with 150 volunteers to evaluate the immunological effectiveness and safety of Vaxchora.\n3. No serious adverse events were reported in the trial of Vaxchora.\n4. The trial results indicated that a dose of 2 tablets of Vaxchora was optimal for maximum protection.\n5. Vaxchora may provide adequate protection against cholera, according to the trial.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is an oral cholera vaccine.",
      "A trial was conducted with 150 volunteers to evaluate the immunological effectiveness and safety of Vaxchora.",
      "No serious adverse events were reported in the trial of Vaxchora.",
      "The trial results indicated that a dose of 2 tablets of Vaxchora was optimal for maximum protection.",
      "Vaxchora may provide adequate protection against cholera, according to the trial."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (The exact number of volunteers is not specified; it may vary between trials.)\n3. UNKNOWN (Without specific details about the trial, we cannot confirm the presence or absence of serious adverse events.)\n4. FALSE [correction]: Vaxchora is an oral vaccine, not administered in tablet form, so the optimal dose would not be measured in tablets.\n5. TRUE (This statement is generally supported by the knowledge that Vaxchora is an FDA-approved vaccine for the prevention of cholera, which implies that it is considered to provide adequate protection.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first cholera vaccine approved in the US is PXVX0200. According to the study, PXVX0200 is a single-dose cholera vaccine that elicits seroconversion of vibriocidal antibodies within 10 days of administration and provides significant vaccine efficacy against cholera challenge at both 10 days and 3 months after vaccination. The study found that the vaccine was well tolerated and there was no difference in adverse event frequency between the vaccine and placebo groups. Therefore, based on the results of this study, PXVX0200 is the first cholera vaccine approved in the US.",
    "llama-2-7b-chat-hf_fact_raw": "1. PXVX0200 is the first cholera vaccine approved in the US.\n2. PXVX0200 is a single-dose cholera vaccine.\n3. PXVX0200 elicits seroconversion of vibriocidal antibodies within 10 days of administration.\n4. The vaccine provides significant efficacy against cholera at 10 days and 3 months after vaccination.\n5. The vaccine was well tolerated with no difference in adverse event frequency when compared to the placebo group.",
    "llama-2-7b-chat-hf_fact": [
      "PXVX0200 is the first cholera vaccine approved in the US.",
      "PXVX0200 is a single-dose cholera vaccine.",
      "PXVX0200 elicits seroconversion of vibriocidal antibodies within 10 days of administration.",
      "The vaccine provides significant efficacy against cholera at 10 days and 3 months after vaccination.",
      "The vaccine was well tolerated with no difference in adverse event frequency when compared to the placebo group."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nI can confirm the approval status, dosage, and general efficacy information regarding PXVX0200 (Vaxchora) as a cholera vaccine based on my last update. However, without specific and current data or access to the relevant clinical trials, I cannot confirm the precise details about the tolerance and adverse event frequency compared to a placebo. Therefore, the last statement remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a genetic mutation that affects the immune system. The document mentions that CVID is the most common primary immunodeficiency and that a granulomatous form of the condition is recognized. It also notes that renal involvement is rare in CVID.\nThere is no specific mention of a particular monogenic cause of CVID in the document, but it is suggested that hypercalcemia in granulomatous disorders may be related to the immune system dysfunction. Therefore, based on the available information, it can be inferred that the most common monogenic cause of CVID in Europeans is likely a genetic mutation that affects the immune system, leading to dysfunction and impaired immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common Variable Immunodeficiency (CVID) is the most common primary immunodeficiency.\n2. A granulomatous form of CVID is recognized.\n3. Renal involvement is rare in CVID.\n4. Hypercalcemia in granulomatous disorders may be related to immune system dysfunction.\n\nNote: The specific gene mutation that is the most common monogenic cause of CVID in Europeans is not provided in the response, hence the lack of a directly related factual statement on this point.",
    "llama-2-7b-chat-hf_fact": [
      "Common Variable Immunodeficiency (CVID) is the most common primary immunodeficiency.",
      "A granulomatous form of CVID is recognized.",
      "Renal involvement is rare in CVID.",
      "Hypercalcemia in granulomatous disorders may be related to immune system dysfunction.",
      "te: The specific gene mutation that is the most common monogenic cause of CVID in Europeans is not provided in the response, hence the lack of a directly related factual statement on this point."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Common Variable Immunodeficiency (CVID) is indeed one of the most common primary immunodeficiencies, characterized by low antibody levels and varied immune dysfunctions.\n2. TRUE: A granulomatous form of CVID is recognized, which involves the formation of granulomas in various organs, including the lungs, liver, spleen, and lymph nodes.\n3. TRUE: Renal involvement is considered rare in individuals with CVID, although when it occurs, it can present serious complications.\n4. TRUE: Hypercalcemia in granulomatous disorders such as sarcoidosis is known to be related to immune system dysfunction. In a granulomatous form of CVID, similar mechanisms may be implicated.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is to induce Interferon-alpha (IFN-alpha) in response to elevated levels of apoptotic DNA in the splenic marginal zone. The lack of complement in lupus-susceptible, complement C4-deficient mice leads to increased intravascular levels of apoptotic DNA, which accumulates in the splenic marginal zone and induces the production of IFN-alpha. This suggests that the IFIT1 gene plays a key role in the induction of SLE through the activation of the IFN-alpha pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene induces Interferon-alpha (IFN-alpha) in response to elevated levels of apoptotic DNA in the splenic marginal zone in Systemic Lupus Erythematosus (SLE).\n2. Lupus-susceptible, complement C4-deficient mice have increased intravascular levels of apoptotic DNA.\n3. Increased levels of apoptotic DNA accumulate in the splenic marginal zone and induce the production of IFN-alpha.\n4. The lack of complement in complement C4-deficient mice is associated with the induction of Systemic Lupus Erythematosus (SLE).\n5. The IFIT1 gene is implicated in playing a key role in the induction of SLE through the activation of the IFN-alpha pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene induces Interferon-alpha (IFN-alpha) in response to elevated levels of apoptotic DNA in the splenic marginal zone in Systemic Lupus Erythematosus (SLE).",
      "Lupus-susceptible, complement C4-deficient mice have increased intravascular levels of apoptotic DNA.",
      "Increased levels of apoptotic DNA accumulate in the splenic marginal zone and induce the production of IFN-alpha.",
      "The lack of complement in complement C4-deficient mice is associated with the induction of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene is implicated in playing a key role in the induction of SLE through the activation of the IFN-alpha pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While it is known that IFN-alpha plays a significant role in SLE and that elevated levels of cytosolic DNA can trigger interferon production, the specific role of the IFIT1 gene in inducing IFN-alpha in response to DNA in the splenic marginal zone is not clearly stated as common knowledge or universally accepted.\n\n2. TRUE: Lupus-susceptible, complement C4-deficient mice are often used in research as a model for SLE. The deficiency in complement C4 is associated with increased levels of apoptotic cells and DNA due to impaired clearance.\n\n3. UNKNOWN: The statement seems plausible, as increased levels of apoptotic DNA can lead to immune activation and the production of IFN-alpha, which is relevant in the context of SLE. However, the direct induction of IFN-alpha by apoptotic DNA in the splenic marginal zone is not a universally recognized fact.\n\n4. TRUE: Complement C4 deficiency is associated with SLE, and the lack of functional complement proteins leads to impaired clearance of apoptotic cells and immune complexes, contributing to the development of the disease.\n\n5. UNKNOWN: The IFIT1 gene is involved in the response to viral infection and has been studied in connection to IFN signaling. Its key role in the induction of SLE via the IFN-alpha pathway is a topic under investigation and may not be a universally established fact. More research is needed to definitively implicate IFIT1 in the induction of SLE.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Liverpool Elbow Score is a questionnaire used to measure the patients' subjective experience of elbow surgery. It is a reliable and valid 12-item questionnaire that can be completed within several minutes by patients with elbow injuries. The questionnaire assesses the patients' experience in three domains: elbow function, pain, and social-psychological effects. The Dutch version of the Oxford Elbow Score (OES) was developed and evaluated for reliability, validity, and responsiveness in patients with elbow trauma and surgery. The study found that the Dutch OES has good internal consistency, test-retest reliability, and convergent validity with other outcome measures such as the Mayo Elbow Performance Index (MEPI), QuickDASH, and visual analogue pain scale (VAS). Therefore, the Liverpool Elbow Score is a useful tool for measuring the patients' subjective experience of elbow surgery in patients with elbow injuries.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is a questionnaire designed to measure the subjective experience of patients with elbow surgery.\n2. It consists of a 12-item questionnaire.\n3. The questionnaire covers three domains: elbow function, pain, and social-psychological effects.\n4. The Dutch version of the Oxford Elbow Score (OES) has been evaluated for reliability and validity in patients with elbow trauma and surgery.\n5. The Dutch OES demonstrates good internal consistency, test-retest reliability, and convergent validity with the Mayo Elbow Performance Index, QuickDASH, and visual analogue pain scale.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is a questionnaire designed to measure the subjective experience of patients with elbow surgery.",
      "It consists of a 12-item questionnaire.",
      "The questionnaire covers three domains: elbow function, pain, and social-psychological effects.",
      "The Dutch version of the Oxford Elbow Score (OES) has been evaluated for reliability and validity in patients with elbow trauma and surgery.",
      "The Dutch OES demonstrates good internal consistency, test-retest reliability, and convergent validity with the Mayo Elbow Performance Index, QuickDASH, and visual analogue pain scale."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score is not explicitly mentioned as a questionnaire for patients with elbow surgery. The well-known score related to elbow assessment is the Oxford Elbow Score (OES).\n2. UNKNOWN: Without specific information about the Liverpool Elbow Score, the number of items in the questionnaire cannot be determined.\n3. UNKNOWN: Again, no specific information about the Liverpool Elbow Score is provided, so the domains it covers are unknown.\n4. TRUE: This statement about the Dutch version of the Oxford Elbow Score being evaluated for reliability and validity in patients with elbow trauma and surgery is feasible, as it is common for such instruments to undergo these types of evaluations.\n5. TRUE: This statement is specific and provides details on the type of reliability and validity demonstrated by the Dutch OES, which is consistent with how clinical assessment tools are evaluated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project has made significant efforts in understanding Sarcoma, a rare and complex cancer, through the analysis of genomic data from a diverse set of individuals. The project has reconstructed the genomes of 2,504 individuals from 26 populations using a combination of whole-genome sequencing, exome sequencing, and dense microarray genotyping.\nThe analysis has identified over 88 million variants, including 84.7 million single nucleotide polymorphisms (SNPs), 3.6 million short insertions/deletions (indels), and 60,000 structural variants. These variants were phased onto high-quality haplotypes, providing valuable information for studying the genetic basis of Sarcoma.\nThe project has also characterized the distribution of genetic variation across the global sample, providing insights into the genetic diversity of Sarcoma across different populations. This information can be used to identify genetic risk factors for Sarcoma and to develop targeted therapies for this cancer.\nOverall, the 100,000 Genomes Project has made significant progress in understanding the genetic basis of Sarcoma and has provided valuable resources for researchers studying this complex cancer. The project's findings have the potential to improve the diagnosis, treatment, and prevention of Sarcoma, leading to better outcomes for patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project has analyzed genomic data from individuals to understand Sarcoma.\n2. The project has reconstructed the genomes of 2,504 individuals from 26 populations.\n3. Over 88 million variants were identified by the project, including 84.7 million single nucleotide polymorphisms (SNPs).\n4. The project found 3.6 million short insertions/deletions (indels) and 60,000 structural variants.\n5. The 100,000 Genomes Project has characterized the distribution of genetic variation of Sarcoma across different populations.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project has analyzed genomic data from individuals to understand Sarcoma.",
      "The project has reconstructed the genomes of 2,504 individuals from 26 populations.",
      "Over 88 million variants were identified by the project, including 84.7 million single nucleotide polymorphisms (SNPs).",
      "The project found 3.6 million short insertions/deletions (indels) and 60,000 structural variants.",
      "The 100,000 Genomes Project has characterized the distribution of genetic variation of Sarcoma across different populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While the 100,000 Genomes Project aims to sequence 100,000 genomes to understand rare diseases, cancer, and infectious diseases, the statement does not provide enough information to confirm whether Sarcoma specifically has been studied within this project.\n2. FALSE [correction]: The statement about reconstructing the genomes of 2,504 individuals from 26 populations refers to the 1000 Genomes Project, not the 100,000 Genomes Project.\n3. UNKNOWN: Given that the information about 88 million variants, including 84.7 million SNPs, might be conflated with data from the 1000 Genomes Project, it's unclear if this statement is accurate for the 100,000 Genomes Project specifically without additional information.\n4. UNKNOWN: Similar to statement 3, this information may also pertain to results from the 1000 Genomes Project and not the 100,000 Genomes Project, so the accuracy regarding the latter project is uncertain without further context.\n5. UNKNOWN: Without specific information or results from the 100,000 Genomes Project regarding the genetic variation of Sarcoma across different populations, it's not possible to determine the veracity of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, protein ALEX1 does not contain armadillo repeats. The document specifically mentions that armadillo repeats have been identified in proteins regulating cell junction assembly, nuclear transport, and transcription activation, but does not mention ALEX1 as one of these proteins. Therefore, it can be concluded that ALEX1 does not contain armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the following are enzymes that remove histone modifications:\n1. Histone deacetylases (HDACs): These enzymes catalyze the removal of acetyl groups from the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones. There are 18 potential HDAC enzymes in humans responsible for the removal of acetyl groups and maintenance of the equilibrium of lysine acetylation on histones.\nOther enzymes that may also remove histone modifications include:\n2. Lysine-specific demethylases (LSD1 and LSD2): These enzymes remove methyl groups from the -amino groups of histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27), respectively.\n3. Histone-modifying enzymes: Some enzymes, such as protein arginine methyltransferases (PRMTs) and SUV39H1, have been shown to modify histones, leading to changes in chromatin structure and gene expression.\nIt is important to note that the above list is not exhaustive and there may be other enzymes that remove histone modifications, as the field is constantly evolving.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones.\n2. There are 18 potential HDAC enzymes in humans.\n3. Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from specific lysine residues on histone H3.\n4. LSD1 specifically targets histone H3 lysine 4 (H3K4) for demethylation.\n5. LSD2 specifically targets histone H3 lysine 27 (H3K27) for demethylation.",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) are enzymes that remove acetyl groups from the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones.",
      "There are 18 potential HDAC enzymes in humans.",
      "Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from specific lysine residues on histone H3.",
      "LSD1 specifically targets histone H3 lysine 4 (H3K4) for demethylation.",
      "LSD2 specifically targets histone H3 lysine 27 (H3K27) for demethylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are 18 HDAC enzymes in humans, but not all of them are necessarily \"potential\" enzymes as some are well-characterized and validated.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: LSD2 specifically targets histone H3 lysine 4 (H3K4) for demethylation, not histone H3 lysine 27 (H3K27).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no conclusive evidence to suggest that head CT scans increase the risk of brain tumors. In fact, the study found that CT with and without contrast enhancement was the most accurate neurodiagnostic method employed in 2,928 patients, including 1,071 patients with intracranial tumors. While radionuclide studies and plain radiography were less accurate, they were seldom found to be positive if CT and angiography were negative.\nIt is important to note that while CT scans are a valuable tool for diagnosing and detecting brain tumors, they do involve exposure to ionizing radiation, which has been linked to an increased risk of cancer. However, the risk associated with CT scans is generally considered to be low, and the benefits of the test often outweigh the risks.\nIf you have concerns about the potential risks of head CT scans or any other medical imaging procedure, it is best to discuss them with your healthcare provider. They can provide you with more information and help you make an informed decision about whether the test is right for you.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans involve exposure to ionizing radiation.\n2. Ionizing radiation has been linked to an increased risk of cancer.\n3. The risk associated with CT scans is generally considered to be low.\n4. CT with and without contrast enhancement was found to be the most accurate neurodiagnostic method in a study of 2,928 patients.\n5. Radionuclide studies and plain radiography were found to be less accurate compared to CT and angiography in a study.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans involve exposure to ionizing radiation.",
      "Ionizing radiation has been linked to an increased risk of cancer.",
      "The risk associated with CT scans is generally considered to be low.",
      "CT with and without contrast enhancement was found to be the most accurate neurodiagnostic method in a study of 2,928 patients.",
      "Radionuclide studies and plain radiography were found to be less accurate compared to CT and angiography in a study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Otx2 is associated with induced pluripotent stem (iPS) cells. The combination of Oct4, Sox2, and Klf4 (OSK) is the minimal requirement for generating iPS cells from mouse embryonic fibroblasts, and Otx2 is one of the transcription factors involved in this process. The document states that iPS cells generated with the OSK and Tbx3 (OSKT) combination are superior in both germ-cell contribution to the gonads and germ-line transmission frequency, and that Tbx3 regulates pluripotency-associated and reprogramming factors, in addition to sharing many common downstream regulatory targets with Oct4, Sox2, Nanog, and Smad1. Therefore, Otx2 is specifically associated with iPS cells generated using the OSK and Tbx3 combination.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with induced pluripotent stem (iPS) cells.\n2. Oct4, Sox2, and Klf4 (OSK) is the minimal requirement for generating iPS cells from mouse embryonic fibroblasts.\n3. Otx2 is involved in generating iPS cells as one of the transcription factors.\n4. iPS cells generated with the combination of OSK and Tbx3 (OSKT) are considered superior in germ-cell contribution to the gonads and germ-line transmission frequency.\n5. Tbx3 regulates pluripotency-associated and reprogramming factors and shares common downstream regulatory targets with Oct4, Sox2, Nanog, and Smad1.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with induced pluripotent stem (iPS) cells.",
      "Oct4, Sox2, and Klf4 (OSK) is the minimal requirement for generating iPS cells from mouse embryonic fibroblasts.",
      "Otx2 is involved in generating iPS cells as one of the transcription factors.",
      "iPS cells generated with the combination of OSK and Tbx3 (OSKT) are considered superior in germ-cell contribution to the gonads and germ-line transmission frequency.",
      "Tbx3 regulates pluripotency-associated and reprogramming factors and shares common downstream regulatory targets with Oct4, Sox2, Nanog, and Smad1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Otx2 is a homeobox transcription factor that has been associated with the development and maintenance of induced pluripotent stem (iPS) cells.\n2. TRUE: Oct4, Sox2, and Klf4 (often along with c-Myc, making the acronym OSKM) are known as the Yamanaka factors, after Shinya Yamanaka who discovered that the introduction of these factors could reprogram somatic cells into iPS cells. However, there have been variations demonstrated where c-Myc is not strictly necessary, so in some contexts OSK alone can indeed be sufficient for generating iPS cells from mouse embryonic fibroblasts.\n3. FALSE [correction]: While Otx2 plays a role in the development and maintenance of iPS cells, it is not typically listed among the core set of transcription factors (Oct4, Sox2, Klf4, and sometimes c-Myc) used to induce pluripotency. Otx2's precise role in generating iPS cells might therefore be as a supportive or secondary factor, not one of the primary reprogramming factors.\n4. UNKNOWN: The statement about iPS cells generated with OSKT being superior in germ-cell contribution to the gonads and germ-line transmission frequency requires specific scientific evidence to verify its accuracy, and without such context, it isn't possible to ascertain its truthfulness.\n5. UNKNOWN: Tbx3 is involved in pluripotency and reprogramming, but the specific claim that it shares common downstream regulatory targets with Oct4, Sox2, Nanog, and Smad1 requires detailed knowledge on recent research findings to confirm or refute, and thus cannot be determined without supporting scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 4 DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 4 DNaseI hypersensitive sites marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact": [
      "There are 4 DNaseI hypersensitive sites marking the murine beta globin locus region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout further context or specific reference to scientific literature that specifies the number of DNaseI hypersensitive sites within the murine beta globin locus region, I cannot determine the truthfulness of this statement. Identification of such sites is subject to research methods and findings, which may have changed or been refined up to the knowledge cutoff date in 2023.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, here are some European influenza vaccines that are mentioned or can be inferred:\n1. Pandemrix (A/California/7/09-like strain): This vaccine is produced by GlaxoSmithKline and is the most widely used influenza vaccine in Europe.\n2. Fluarix (A/Brisbane/10/2007-like strain): This vaccine is produced by Sanofi Pasteur and is also widely used in Europe.\n3. Aggrivax (A/Brisbane/10/2007-like strain): This vaccine is produced by Novartis and is specifically designed for use in children and adolescents.\n4. Fluvirin (A/Brisbane/10/2007-like strain): This vaccine is produced by Novartis and is another widely used influenza vaccine in Europe.\n5. FluMist (A/Brisbane/10/2007-like strain): This vaccine is produced by MedImmune and is an intranasal vaccine that is administered through the nose.\n6. Vaxigrip (A/California/7/09-like strain): This vaccine is produced by Sanofi Pasteur and is a quadrivalent vaccine that protects against four strains of the influenza virus.\n7. Celvapan (A/Perth/16/2009-like strain): This vaccine is produced by Sanofi Pasteur and is a quadrivalent vaccine that protects against four strains of the influenza virus.\n8. Focetria (A/Brisbane/10/2007-like strain): This vaccine is produced by Novartis and is a quadrivalent vaccine that protects against four strains of the influenza virus.\nIt's important to note that the availability and composition of these vaccines may vary by country and region within Europe, and this list is not exhaustive. Additionally, new vaccines may have been developed or approved since the data in",
    "llama-2-7b-chat-hf_fact_raw": "1. Pandemrix is an influenza vaccine produced by GlaxoSmithKline.\n2. Fluarix is an influenza vaccine produced by Sanofi Pasteur.\n3. Aggrivax is an influenza vaccine designed for use in children and adolescents, produced by Novartis.\n4. Fluvirin is an influenza vaccine produced by Novartis.\n5. FluMist is an intranasal influenza vaccine administered through the nose, produced by MedImmune.",
    "llama-2-7b-chat-hf_fact": [
      "Pandemrix is an influenza vaccine produced by GlaxoSmithKline.",
      "Fluarix is an influenza vaccine produced by Sanofi Pasteur.",
      "Aggrivax is an influenza vaccine designed for use in children and adolescents, produced by Novartis.",
      "Fluvirin is an influenza vaccine produced by Novartis.",
      "FluMist is an intranasal influenza vaccine administered through the nose, produced by MedImmune."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Fluarix is an influenza vaccine produced by GlaxoSmithKline.\n3. FALSE [correction]: There is no vaccine known as 'Aggrivax'. Novartis' influenza vaccines have included brands like Fluvirin and Flucelvax.\n4. FALSE [correction]: Fluvirin was an influenza vaccine produced by Novartis, but as of my knowledge cutoff date, influenza vaccine production from Novartis' vaccines division has been acquired by CSL's Seqirus.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nThe document explains that negative-strand RNA viruses, including the Paramyxoviridae family, encode their own polymerases to perform the processes of duplicating their genomes and producing virus-specific mRNAs. The L protein from members of the Paramyxoviridae family, including vesicular stomatitis virus, shares sequence and predicted secondary structure homology with the L proteins from other viral families, including the Rhabdoviridae and Filoviridae. The N-terminal domain of the L protein from vesicular stomatitis virus, which is conserved among members of the Paramyxoviridae family, is essential to viral transcription and shares structural homology with polymerases from other viral families, including segmented negative-strand RNA and double-stranded RNA (dsRNA) viruses.\nTherefore, based on the information provided in the document, the Paramyxovirus geneome is segmented, negative-sense RNA, and the L protein from members of the Paramyxoviridae family plays a crucial role in the replication cycle of these viruses.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. The Paramyxovirus genome is segmented.\n3. Members of the Paramyxoviridae family encode their own polymerases for genome duplication and virus-specific mRNA production.\n4. The L protein is conserved among members of the Paramyxoviridae family.\n5. The N-terminal domain of the L protein is essential to viral transcription in vesicular stomatitis virus, a member of the Paramyxoviridae family.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "The Paramyxovirus genome is segmented.",
      "Members of the Paramyxoviridae family encode their own polymerases for genome duplication and virus-specific mRNA production.",
      "The L protein is conserved among members of the Paramyxoviridae family.",
      "The N-terminal domain of the L protein is essential to viral transcription in vesicular stomatitis virus, a member of the Paramyxoviridae family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Paramyxovirus genome is non-segmented.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The vesicular stomatitis virus is not a member of the Paramyxoviridae family; it belongs to the Rhabdoviridae family. The N-terminal domain of the L protein (the large polymerase protein) is indeed critical for viral transcription, but this statement incorrect in linking vesicular stomatitis virus to the Paramyxoviridae family.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, roflumilast cream is effective in treating exercise-induced asthma. The study showed that roflumilast significantly reduced the percentage fall of forced expiratory volume in 1 second (FEV1) after exercise compared to placebo, indicating improved lung function. Additionally, roflumilast treatment was associated with a decrease in tumor necrosis factor alpha (TNF-alpha) levels ex vivo, which suggests inhibition of inflammatory cell activation. Therefore, the answer to the user's question is: Roflumilast cream is effective in treating exercise-induced asthma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used in the treatment of exercise-induced asthma.\n2. The study showed that roflumilast significantly reduced the percentage fall of forced expiratory volume in 1 second (FEV1) after exercise.\n3. Roflumilast has a positive effect on improving lung function for patients with exercise-induced asthma.\n4. Roflumilast treatment was associated with a decrease in tumor necrosis factor alpha (TNF-alpha) levels ex vivo.\n5. The reduction of TNF-alpha levels suggests inhibition of inflammatory cell activation by roflumilast.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used in the treatment of exercise-induced asthma.",
      "The study showed that roflumilast significantly reduced the percentage fall of forced expiratory volume in 1 second (FEV1) after exercise.",
      "Roflumilast has a positive effect on improving lung function for patients with exercise-induced asthma.",
      "Roflumilast treatment was associated with a decrease in tumor necrosis factor alpha (TNF-alpha) levels ex vivo.",
      "The reduction of TNF-alpha levels suggests inhibition of inflammatory cell activation by roflumilast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is not a cream and is typically used in the treatment of severe chronic obstructive pulmonary disease (COPD), not specifically for exercise-induced asthma. It is an oral medication in pill form.\n2. UNKNOWN: Without specific data from the referred study, it is impossible to confirm the effect of roflumilast on FEV1 after exercise.\n3. UNKNOWN: While roflumilast improves lung function in COPD patients, its effect on exercise-induced asthma is not well established without specific clinical study results.\n4. UNKNOWN: The statement about roflumilast's effect on TNF-alpha levels is specific, and without access to the study's findings or relevant research, it's impossible to confirm its accuracy.\n5. UNKNOWN: This is a conclusion based on the stated reduction of TNF-alpha levels, which would be logical if roflumilast were indeed shown to reduce such levels; however, without confirming statement 4, the truth of statement 5 is also unknown.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, several tools have been developed for identifying and visualizing ncRNA promoters:\n1. Rfam lncRNA families: The Rfam database is a comprehensive collection of non-coding RNA (ncRNA) families, including lncRNAs. The database contains a wide range of ncRNAs from various organisms, including bacteria, archaea, and eukaryotes.\n2. HLRF (High-throughput LncRNA Finder): This tool is a genome-wide ncRNA classification framework that was developed to identify known and novel ncRNAs in a wide variety of organisms, including bacteria, archaea, and eukaryotes. HLRF uses a random forest (RF) classifier to identify ncRNA sequences and features, and it can also visualize the predicted ncRNA promoters.\n3. SCORE (Structural and Sequence-based feature for long ncRNA Elements): This feature is a new proposed feature that was developed to improve the identification of long ncRNA (lncRNA) elements. SCORE combines five significant features, including structure, sequence, modularity, structural robustness, and coding potential, to enable improved characterization of lncRNA elements.\n4. NCNN (Non-coding RNA Network): This tool is a web-based platform that allows users to search for and visualize ncRNAs in a variety of organisms, including humans. NCNN uses a combination of machine learning algorithms and structural bioinformatics tools to predict ncRNA structures and functions.\n5. RNAhybrid: This tool is a web-based platform that allows users to predict the secondary and tertiary structure of RNA molecules, including ncRNAs. RNAhybrid uses a combination of machine learning algorithms and structural bioinformatics tools to predict the structure of RNA molecules and identify potential ncRNA promoters.\nIn summary, these tools have been developed to identify and visualize ncRNA promoters by using a combination of machine learning algorithms, structural bioinformatics tools, and feature-based approaches.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Rfam database contains non-coding RNA (ncRNA) families, including lncRNAs from various organisms such as bacteria, archaea, and eukaryotes.\n2. HLRF (High-throughput LncRNA Finder) is a tool that identifies both known and novel ncRNAs across a range of organisms, including bacteria, archaea, and eukaryotes, using a random forest classifier.\n3. SCORE (Structural and Sequence-based feature for long ncRNA Elements) is a feature that improves the identification of long ncRNA (lncRNA) elements by combining five significant features.\n4. NCNN (Non-coding RNA Network) is a web-based platform that predicts ncRNA structures and functions for various organisms, including humans.\n5. RNAhybrid is a web-based platform that predicts the secondary and tertiary structure of RNA molecules, including ncRNAs, and identifies potential ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "The Rfam database contains non-coding RNA (ncRNA) families, including lncRNAs from various organisms such as bacteria, archaea, and eukaryotes.",
      "HLRF (High-throughput LncRNA Finder) is a tool that identifies both known and novel ncRNAs across a range of organisms, including bacteria, archaea, and eukaryotes, using a random forest classifier.",
      "SCORE (Structural and Sequence-based feature for long ncRNA Elements) is a feature that improves the identification of long ncRNA (lncRNA) elements by combining five significant features.",
      "NCNN (Non-coding RNA Network) is a web-based platform that predicts ncRNA structures and functions for various organisms, including humans.",
      "RNAhybrid is a web-based platform that predicts the secondary and tertiary structure of RNA molecules, including ncRNAs, and identifies potential ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN  While \"SCORE\" likely stands for some computational method or tool involving feature integration for ncRNA identification, without additional context, it is not possible to accurately assess the correctness of the statement, particularly what the five significant features are and how they improve lncRNA element identification.\n4. FALSE [correction]: NCNN (Non-coding RNA Network) is not well-known as a standard term in the context of ncRNA research databases or platforms. This means that, without additional context, the description and existence of \"NCNN\" as stated cannot be confirmed. However, there are several databases and platforms meant for predicting ncRNA structures and functions, and they might have functions as described but with different names.\n5. FALSE [correction]: RNAhybrid is a tool designed to find the minimum free energy hybridization of a long and a short RNA. It is used to predict potential microRNA target sites within a longer RNA sequence and is not directly used to predict secondary and tertiary structures of RNA molecules, nor is it used to identify ncRNA promoters. Secondary and tertiary RNA structures are usually predicted using different tools, such as RNAfold or 3dRNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, SWIM tool has identified several down-regulated genes in glioblastoma, including:\n1. TP53: A tumor suppressor gene that is commonly mutated in glioblastoma.\n2. CDKN2A: A gene that encodes a cyclin-dependent kinase inhibitor and is frequently mutated or deleted in glioblastoma.\n3. STK11: A gene that encodes a serine/threonine kinase and is associated with Peutz-Jeghers syndrome, a rare genetic disorder that is also seen in glioblastoma.\n4. PTEN: A gene that encodes a phosphatase and tensin homolog deleted on chromosome 10 (PTEN), which is a tumor suppressor that is frequently mutated or lost in glioblastoma.\n5. APC: A gene that encodes adenomatous polyposis coli, a tumor suppressor that is frequently mutated in glioblastoma.\n6. MSH2: A gene that encodes a mismatch repair protein and is frequently mutated in glioblastoma.\n7. MLH1: A gene that encodes a mismatch repair protein and is frequently mutated in glioblastoma.\n8. MSH6: A gene that encodes a mismatch repair protein and is frequently mutated in glioblastoma.\n9. PML: A gene that encodes a protein that is involved in the regulation of apoptosis and is frequently mutated in glioblastoma.\n10. TARDBP: A gene that encodes a protein that is involved in the regulation of RNA metabolism and is frequently mutated in glioblastoma.\nIt is important to note that these genes are not the only down-regulated genes in glioblastoma, and the list may not be exhaustive. The study used a specific methodology to identify dysregulated genes in glioblastoma, and the results may not be generalizable to all glioblastoma tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified TP53 as a down-regulated gene in glioblastoma.\n2. The CDKN2A gene, which encodes a cyclin-dependent kinase inhibitor, is frequently mutated or deleted in glioblastoma.\n3. STK11, a gene associated with Peutz-Jeghers syndrome, is implicated in glioblastoma.\n4. The PTEN gene, coding for a tumor suppressor, is often mutated or lost in glioblastoma cases.\n5. APC, a gene that encodes adenomatous polyposis coli, a tumor suppressor, is frequently mutated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified TP53 as a down-regulated gene in glioblastoma.",
      "The CDKN2A gene, which encodes a cyclin-dependent kinase inhibitor, is frequently mutated or deleted in glioblastoma.",
      "STK11, a gene associated with Peutz-Jeghers syndrome, is implicated in glioblastoma.",
      "The PTEN gene, coding for a tumor suppressor, is often mutated or lost in glioblastoma cases.",
      "APC, a gene that encodes adenomatous polyposis coli, a tumor suppressor, is frequently mutated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific study results or additional context, it's difficult to verify the assertion about the SWIM tool's identification of TP53 status in glioblastoma.\n2. TRUE: The CDKN2A gene, encoding a cyclin-dependent kinase inhibitor, is indeed frequently mutated or deleted in glioblastoma.\n3. UNKOWN: While STK11 is linked to Peutz-Jeghers syndrome, its direct implication in glioblastoma is specific and would require validation from scientific literature or study data.\n4. TRUE: The PTEN gene, which codes for a tumor suppressor, is often found to be mutated or lost in glioblastoma cases.\n5. FALSE [correction]: The APC gene is most famously associated with colorectal cancer, particularly familial adenomatous polyposis (FAP). It is not frequently mutated in glioblastoma; other genes such as TP53, EGFR, and CDKN2A are more commonly implicated in glioblastoma.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several R packages that have been developed for studying TADs (Tissue-Associated DNA):\n1. TADseq: This package provides a comprehensive workflow for the analysis of TADs, including the detection of TADs, the estimation of TAD boundaries, and the analysis of TAD-related genomic features.\n2. TissueGen: This package provides a framework for the analysis of genomic and transcriptomic data from tissue samples, including the detection of TADs and the analysis of gene expression.\n3. TADtrack: This package provides a tool for the visualization and analysis of TADs in 3D genomic data, including the detection of TADs, the analysis of TAD-related genomic features, and the visualization of TADs in 3D.\n4. TAD-seq: This package provides a workflow for the analysis of TADs in sequencing data, including the detection of TADs, the estimation of TAD boundaries, and the analysis of TAD-related genomic features.\n5. Tissue-RNA: This package provides a framework for the analysis of RNA sequencing data from tissue samples, including the detection of TADs and the analysis of gene expression.\nThese packages can be used to analyze TADs in various tissue types, including those affected by RDS, PDA, and/or BPD, as mentioned in the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADseq is an R package developed for the analysis of TADs which includes detection and estimation of TAD boundaries.\n2. TissueGen is an R package that facilitates analysis of genomic and transcriptomic data including TAD detection.\n3. TADtrack is an R package designed for visualization and analysis of TADs in 3D genomic data.\n4. TAD-seq is an R package that presents a workflow for TAD analysis in sequencing data.\n5. Tissue-RNA is an R package for analyzing RNA sequencing data from tissue samples, including TAD detection.",
    "llama-2-7b-chat-hf_fact": [
      "TADseq is an R package developed for the analysis of TADs which includes detection and estimation of TAD boundaries.",
      "TissueGen is an R package that facilitates analysis of genomic and transcriptomic data including TAD detection.",
      "TADtrack is an R package designed for visualization and analysis of TADs in 3D genomic data.",
      "TAD-seq is an R package that presents a workflow for TAD analysis in sequencing data.",
      "Tissue-RNA is an R package for analyzing RNA sequencing data from tissue samples, including TAD detection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TADseq is not known as an R package but rather a method for identifying topologically associating domains (TADs) using sequencing data.\n2. UNKNOWN: Without more information on \"TissueGen,\" it is unclear whether this is an actual R package and whether it includes TAD detection in its functionalities.\n3. UNKNOWN: \"TADtrack\" might not be the correct name or may not exist as a well-known R package for TAD analysis in 3D genomic data.\n4. FALSE [correction]: TAD-seq itself is not an R package. It is a method for high-throughput identification of chromatin domain boundaries. There might be confusion with R packages that can analyze TADs identified by TAD-seq or similar technologies, but TAD-seq itself is not an R package.\n5. FALSE [correction]: There is no known R package by the name \"Tissue-RNA.\" However, there are R packages for analyzing RNA-sequencing data; their primary focus is transcriptomic analysis, not typically including TAD detection.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is likely \"population control\" circuit. This tool is a synthetic circuit that regulates cell density through a feedback mechanism based on quorum sensing, which was observed in the microfluidic bioreactor using Escherichia coli. The ability to monitor the dynamics of bacterial populations over hundreds of hours in a controlled environment suggests that this tool can provide valuable insights into the regulation of bacterial behavior and the interactions between bacteria and their environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. The tool is likely called \"population control\" circuit.\n3. The \"population control\" circuit uses a feedback mechanism based on quorum sensing.\n4. The circuit's functionality was observed in a microfluidic bioreactor using Escherichia coli.\n5. The tool allows monitoring of bacterial populations over hundreds of hours in a controlled environment.",
    "llama-2-7b-chat-hf_fact": [
      "There is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "The tool is likely called \"population control\" circuit.",
      "The \"population control\" circuit uses a feedback mechanism based on quorum sensing.",
      "The circuit's functionality was observed in a microfluidic bioreactor using Escherichia coli.",
      "The tool allows monitoring of bacterial populations over hundreds of hours in a controlled environment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There are several bioconductor tools developed for various biological analyses, including the access to bacterial regulatory networks.\n2. FALSE [correction]: The tool for accessing bacterial regulatory networks would not typically be called \"population control\" circuit; this sounds more like a description of a feature within synthetic biology rather than a bioinformatics tool. A more appropriate name for a tool in the Bioconductor project would likely be more technical and less metaphorical.\n3. UNKNOWN: Without specific context or reference to a particular study or project, it is impossible to confirm whether a tool or circuit named \"population control\" utilizes a feedback mechanism based on quorum sensing.\n4. UNKNOWN: Again, without a specific reference or detailed information, it cannot be confirmed whether the functionality of a so-called \"population control\" circuit was observed in a microfluidic bioreactor using Escherichia coli.\n5. UNKNOWN: The statement regarding the tool allowing monitoring of bacterial populations over hundreds of hours in a controlled environment is plausible, as this describes a common goal in microbial research and synthetic biology, but without more context or a specific reference, the truth of the statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the end products of the shikimate pathway are:\n1. Shikimate-3-phosphate (5-membered ring analogues)\nThe document shows that cyclopentylidenes 1 and 2, as well as cyclopentenes 3 and 4, are processed by shikimate kinase to give phosphates 1-P, 2-P, and 3-P as five-membered ring analogues of shikimate-3-phosphate. Enzymatic studies show that analogue 1 is converted by the enzyme at a rate only 3.5-fold slower than that of the native substrate, while analogue 3 binds to shikimate kinase with an apparent Km of 1.7 mM, compared to 0.14 mM for shikimate.\nTherefore, the end products of the shikimate pathway are shikimate-3-phosphate and its five-membered ring analogues, which are produced through the action of shikimate kinase.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shikimate-3-phosphate is an end product of the shikimate pathway.\n2. Cyclopentylidenes and cyclopentenes are processed by shikimate kinase to give phosphate analogues of shikimate-3-phosphate.\n3. Enzymatic studies have shown that analogue 1 of the shikimate pathway is converted by the enzyme at a rate slower than the native substrate.\n4. Analogue 3 of the shikimate pathway binds to shikimate kinase with an apparent Km of 1.7 mM.\n5. The native substrate of the shikimate pathway has an apparent Km value of 0.14 mM when binding to shikimate kinase.",
    "llama-2-7b-chat-hf_fact": [
      "Shikimate-3-phosphate is an end product of the shikimate pathway.",
      "Cyclopentylidenes and cyclopentenes are processed by shikimate kinase to give phosphate analogues of shikimate-3-phosphate.",
      "Enzymatic studies have shown that analogue 1 of the shikimate pathway is converted by the enzyme at a rate slower than the native substrate.",
      "Analogue 3 of the shikimate pathway binds to shikimate kinase with an apparent Km of 1.7 mM.",
      "The native substrate of the shikimate pathway has an apparent Km value of 0.14 mM when binding to shikimate kinase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shikimate-3-phosphate is not an end product of the shikimate pathway; it is an intermediate compound in the pathway.\n2. UNKNOWN: The processing of cyclopentylidenes and cyclopentenes by shikimate kinase to give phosphate analogues of shikimate-3-phosphate is not a standard known reaction, and without specific research or context, it's not possible to verify this statement.\n3. TRUE: This statement is reasonable assuming \"analogue 1\" refers to a chemical analogue of a substrate in the shikimate pathway, as analogues often have different conversion rates when processed by enzymes.\n4. UNKNOWN: Specific details such as binding affinities of analogues to enzymes require empirical data or published research to verify, and without that, this statement cannot be evaluated with certainty.\n5. UNKNOWN: The Km value of the native substrate for shikimate kinase cannot be verified without access to specific experimental data or literature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated. In a case series of nine patients with severe Cushing's syndrome of ectopic or occult origin, cabergoline was used in combination with steroidogenesis inhibitors and showed rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases. While the literature review found only 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, 10 of these cases responded. Therefore, based on the available evidence, it is possible that cabergoline may be effective in the treatment of Nelson's syndrome, a rare and severe form of Cushing's syndrome. However, further research is needed to confirm this conclusion.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease.\n2. In a case series of nine patients with severe Cushing's syndrome of ectopic or occult origin, cabergoline was used in combination with steroidogenesis inhibitors.\n3. Three out of nine cases in the case series showed rapid withdrawal of steroidogenesis inhibitors and long-term control of hypercortisolism after being treated with cabergoline.\n4. A literature review found 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, with 10 responding to the treatment.\n5. Nelson's syndrome is a rare and severe form of Cushing's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease.",
      "In a case series of nine patients with severe Cushing's syndrome of ectopic or occult origin, cabergoline was used in combination with steroidogenesis inhibitors.",
      "Three out of nine cases in the case series showed rapid withdrawal of steroidogenesis inhibitors and long-term control of hypercortisolism after being treated with cabergoline.",
      "A literature review found 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, with 10 responding to the treatment.",
      "Nelson's syndrome is a rare and severe form of Cushing's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Cabergoline, a dopamine receptor agonist, has been used in the treatment of Cushing's disease with some reported effectiveness, especially in cases with mild or moderate symptoms.\n2. UNKNOWN: Without the specific details of the study or case series to confirm this statement, it is difficult to determine the accuracy. Various treatments can be used in severe cases of Cushing's syndrome, and combinations with steroidogenesis inhibitors are possible.\n3. UNKNOWN: Similarly, without access to the case series data, the outcome of the described treatment cannot be confirmed.\n4. UNKNOWN: The success rate mentioned hinges on the specifics of the literature review, which is not provided here. Therefore, I cannot verify the accuracy of the statement.\n5. FALSE [correction]: Nelson's syndrome is not a form of Cushing's syndrome; it is a complication that can occur in patients who undergo bilateral adrenalectomy (removal of both adrenal glands) for the treatment of Cushing's disease and describes the rapid growth of an existing pituitary adenoma due to the lack of cortisol feedback inhibition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the paper, the main manifestation of Liebenberg syndrome is the transformation of the upper limbs to reflect lower limb characteristics. This is evident from the radiological features in the upper limbs of all affected members of the family, which are almost identical to the phenotype in the mouse model with ectopic expression of Pitx1 in the forelimbs. The authors suggest that the area of deletion contains a regulatory sequence that suppresses the expression of PITX1 in the upper limb buds, leading to the transformation of the upper limbs to resemble the lower limbs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by the transformation of the upper limbs to reflect lower limb characteristics.\n2. Radiological features in the upper limbs of individuals affected by Liebenberg syndrome are similar to the phenotype in a mouse model with ectopic expression of Pitx1.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by the transformation of the upper limbs to reflect lower limb characteristics.",
      "Radiological features in the upper limbs of individuals affected by Liebenberg syndrome are similar to the phenotype in a mouse model with ectopic expression of Pitx1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the following are orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605: As mentioned in the document, this purine-based lead compound has been optimized for its biological activity, novelty, selectivity, and oral bioavailability.\n2. MPS1 inhibitor 1: The document mentions that efforts were made to optimize the biochemical activity and cytotoxicity of MPS1 inhibitors in the HCT-116 cell line. While the specific compound used in the study is not mentioned, it is likely that this compound is an MPS1 inhibitor with improved oral bioavailability.\n3. MPS1 inhibitor 2: Similarly, the document mentions that another MPS1 inhibitor was optimized for its oral bioavailability in mice. While the name of this compound is not provided, it is likely to be another orally bioavailable MPS1 inhibitor.\nIt is important to note that these are the only MPS1 kinase inhibitors mentioned in the document, and there may be other compounds with similar properties that have not been disclosed. Additionally, the document does not provide detailed information on the chemical structures of these compounds, so further research would be needed to confirm their identity and properties.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.\n2. MPS1 inhibitor 1 has been optimized for improved oral bioavailability.\n3. MPS1 inhibitor 2 has been optimized for its oral bioavailability in mice.\n4. MPI-0479605 is a purine-based lead compound.\n5. MPI-0479605 was optimized for selectivity and biological activity.",
    "llama-2-7b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.",
      "MPS1 inhibitor 1 has been optimized for improved oral bioavailability.",
      "MPS1 inhibitor 2 has been optimized for its oral bioavailability in mice.",
      "MPI-0479605 is a purine-based lead compound.",
      "MPI-0479605 was optimized for selectivity and biological activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no evidence to suggest that golimumab was tested for diabetes. The document is focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis (RA), and does not mention anything about diabetes. Therefore, I must conclude that golimumab has not been tested for diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab was not tested for diabetes according to the provided document.\n2. The provided document is focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab was not tested for diabetes according to the provided document.",
      "The provided document is focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout the provided document, it is not possible to verify the accuracy of the statements related to golimumab.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it is likely that progeria is caused by an autosomal recessive gene. The document states that mutations in the lamin A/C gene lead to the expression of a truncated, farnesylated prelamin A variant called progerin, which accumulates at the nuclear envelope and causes mis-shapen nuclei and progeroid syndromes. The document also mentions that blocking farnesylation of prelamin A ameliorates the nuclear shape abnormalities, and that an inhibitor of farnesyl diphosphate synthase, N6-isopentenyladenosine, impedes the farnesylation of prelamin A and improves nuclear shape abnormalities in fibroblast cell lines from atypical progeria patients. These findings suggest that the accumulation of progerin at the nuclear envelope is caused by a mutation in the lamin A/C gene, which is inherited in an autosomal recessive manner.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is likely caused by a mutation in the lamin A/C gene.\n2. A mutated form of prelamin A, called progerin, accumulates at the nuclear envelope and is associated with progeroid syndromes.\n3. Blocking the farnesylation of prelamin A can ameliorate nuclear shape abnormalities.\n4. N6-isopentenyladenosine is an inhibitor of farnesyl diphosphate synthase that can improve nuclear shape abnormalities in cell lines from atypical progeria patients.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is likely caused by a mutation in the lamin A/C gene.",
      "A mutated form of prelamin A, called progerin, accumulates at the nuclear envelope and is associated with progeroid syndromes.",
      "Blocking the farnesylation of prelamin A can ameliorate nuclear shape abnormalities.",
      "N6-isopentenyladenosine is an inhibitor of farnesyl diphosphate synthase that can improve nuclear shape abnormalities in cell lines from atypical progeria patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThese statements are consistent with scientific understanding regarding progeria and cellular mechanisms related to laminopathies, although the specifics of the fourth statement would require data from peer-reviewed research to confirm its accuracy. However, based on the general knowledge that inhibitors of farnesyl diphosphate synthase can affect nuclear shape abnormalities through the modification of progerin's processing, the statement could be considered true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the common variants at 12q14 and 12q24 associated with prostate cancer risk are:\n* The rs1447295 SNP in 8q24, which is associated with an increased risk of prostate cancer in Korean men.\n* The [AGC] and [CTA] haplotypes in 8q24, which are associated with a significantly increased risk of prostate cancer compared to the [CTC] haplotype.\nIt is important to note that these findings are based on a study conducted in Korean men, and the results may not be generalizable to other populations. Additionally, while this study found an association between these genetic variants and prostate cancer risk, it does not establish a causal relationship. Further research is needed to confirm these findings and to better understand the underlying mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The rs1447295 SNP in 8q24 is associated with an increased risk of prostate cancer in Korean men.\n2. The [AGC] and [CTA] haplotypes in 8q24 are associated with a significantly increased risk of prostate cancer compared to the [CTC] haplotype.\n3. The study mentioned was conducted specifically in Korean men.\n4. The study does not establish a causal relationship between the genetic variants and prostate cancer risk.\n5. Further research is acknowledged as necessary to confirm the findings related to these genetic variants and prostate cancer risk.",
    "llama-2-7b-chat-hf_fact": [
      "The rs1447295 SNP in 8q24 is associated with an increased risk of prostate cancer in Korean men.",
      "The [AGC] and [CTA] haplotypes in 8q24 are associated with a significantly increased risk of prostate cancer compared to the [CTC] haplotype.",
      "The study mentioned was conducted specifically in Korean men.",
      "The study does not establish a causal relationship between the genetic variants and prostate cancer risk.",
      "Further research is acknowledged as necessary to confirm the findings related to these genetic variants and prostate cancer risk."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The rs1447295 SNP in 8q24 has been reported in multiple studies to be associated with an increased risk of prostate cancer, and some studies have considered populations including Korean men.\n\n2. UNKNOWN: Without specific study data or results, it is not possible to verify the association of the [AGC] and [CTA] haplotypes with prostate cancer risk, especially compared to the [CTC] haplotype.\n\n3. UNKNOWN: Without additional context, it is not possible to confirm whether the mentioned study was conducted specifically in Korean men, although statement 1 implies this could be the case.\n\n4. TRUE: Typically, genetic association studies identify correlations between genetic variants and disease risk but do not by themselves establish a direct causal relationship. This statement aligns with common scientific consensus regarding genetic association studies.\n\n5. TRUE: It is a standard scientific practice to acknowledge that findings need further research for confirmation, especially in the field of genetics and disease association studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the ligands of the Roundabout (Robo) receptors are Slit proteins. Specifically, the document states that Robo4Fc, a soluble extracellular domain of the Robo4 receptor, inhibits angiogenesis in vivo and in vitro by interacting with Slit proteins. Recombinant Slits-1, -2, and -3 were shown to bind to Robo1, but not Robo4, suggesting that Slit proteins are the ligands of the Robo receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Slit proteins are the ligands of the Roundabout (Robo) receptors.\n2. Robo4Fc, a soluble extracellular domain of the Robo4 receptor, can inhibit angiogenesis by interacting with Slit proteins.\n3. Recombinant Slits-1, -2, and -3 proteins can bind to Robo1. \n4. Slits-1, -2, and -3 proteins do not bind to Robo4.",
    "llama-2-7b-chat-hf_fact": [
      "Slit proteins are the ligands of the Roundabout (Robo) receptors.",
      "Robo4Fc, a soluble extracellular domain of the Robo4 receptor, can inhibit angiogenesis by interacting with Slit proteins.",
      "Recombinant Slits-1, -2, and -3 proteins can bind to Robo1.",
      "Slits-1, -2, and -3 proteins do not bind to Robo4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Slits-1, -2, and -3 proteins can bind to Robo4, although they often show different binding affinities to different Robo receptors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no direct role for TFII-I in megakaryopoiesis. The document discusses the function of TFIIIC, a transcription factor that plays a crucial role in the initiation of transcription in eukaryotic cells, particularly in the synthesis of transfer RNA (tRNA) genes. While TFIIIC is involved in various cellular processes, including cell viability, there is no mention of its involvement in megakaryopoiesis, which is the process of blood cell formation in the bone marrow.\nMegakaryopoiesis is a complex process that involves the coordinated action of multiple transcription factors, including GATA1, GATA2, and KLF1, among others. These transcription factors regulate the expression of genes involved in platelet production and function, including genes involved in the synthesis of platelet-specific proteins and the regulation of platelet activation and aggregation.\nIn summary, while TFIIIC is an important transcription factor involved in various cellular processes, there is no direct role for TFII-I in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I does not have a direct role in megakaryopoiesis.\n2. TFIIIC is a transcription factor that plays a crucial role in the initiation of transcription in eukaryotic cells.\n3. TFIIIC is specifically involved in the synthesis of transfer RNA (tRNA) genes.\n4. Megakaryopoiesis is the process of blood cell formation in the bone marrow.\n5. The transcription factors GATA1, GATA2, and KLF1 are involved in regulating platelet production and function during megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I does not have a direct role in megakaryopoiesis.",
      "TFIIIC is a transcription factor that plays a crucial role in the initiation of transcription in eukaryotic cells.",
      "TFIIIC is specifically involved in the synthesis of transfer RNA (tRNA) genes.",
      "Megakaryopoiesis is the process of blood cell formation in the bone marrow.",
      "The transcription factors GATA1, GATA2, and KLF1 are involved in regulating platelet production and function during megakaryopoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Megakaryopoiesis is the process of megakaryocyte formation, which are cells responsible for the production of platelets (thrombocytes), not all blood cells, in the bone marrow.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, atenolol is metabolized by CYP2D6. The study found that the peak concentration of the d-enantiomer of atenolol was greater than the peak concentration of the l-enantiomer, and the renal clearance of the d-enantiomer was not significantly different from the l-enantiomer. However, the AUC and the amount excreted unchanged in the urine in 24 hours were significantly greater for the d-enantiomer than for the l-enantiomer. These findings suggest that CYP2D6 is involved in the metabolism of atenolol, with the d-enantiomer being more susceptible to metabolism by this enzyme. Therefore, the answer to the user's question is yes, atenolol is metabolized by CYP2D6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the enzyme CYP2D6.\n2. The peak concentration of the d-enantiomer of atenolol is greater than that of the l-enantiomer.\n3. The renal clearance of the d-enantiomer of atenolol is not significantly different from that of the l-enantiomer.\n4. The Area Under the Curve (AUC) for the d-enantiomer of atenolol is significantly greater than for the l-enantiomer.\n5. The amount of d-enantiomer of atenolol excreted unchanged in the urine over 24 hours is significantly greater than that for the l-enantiomer.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the enzyme CYP2D6.",
      "The peak concentration of the d-enantiomer of atenolol is greater than that of the l-enantiomer.",
      "The renal clearance of the d-enantiomer of atenolol is not significantly different from that of the l-enantiomer.",
      "The Area Under the Curve (AUC) for the d-enantiomer of atenolol is significantly greater than for the l-enantiomer.",
      "The amount of d-enantiomer of atenolol excreted unchanged in the urine over 24 hours is significantly greater than that for the l-enantiomer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver, including the CYP2D6 enzyme. It is excreted primarily unchanged in the urine.\n2. UNKNOWN: The available literature does not provide clear information on the peak concentration comparison between the d-enantiomer and the l-enantiomer of atenolol. This would require specific pharmacokinetic studies comparing the two.\n3. TRUE: Generally, the renal clearance of both enantiomers of atenolol should be very similar, as the drug is excreted primarily unchanged in the urine and is not significantly metabolized.\n4. UNKNOWN: The AUC for the d-enantiomer versus the l-enantiomer of atenolol would require specific pharmacokinetic data to compare, which is not commonly provided in general information about the drug.\n5. UNKNOWN: As with point 4, specific quantitative data comparing the amount of each enantiomer excreted unchanged in the urine is not typically included in general descriptions of atenolol's pharmacokinetics. This would require detailed study results for confirmation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the versions of ExpansionHunter:\n1. ExonHunter (version unknown) - This is the new and comprehensive gene finding system presented in the document, which outperforms existing systems and features several new ideas and approaches.\n2. ROSETTA (version unknown) - This is one of the existing gene finders compared to ExonHunter in the document, which performs significantly worse than ExonHunter on a commonly used test set.\n3. SLAM (version unknown) - This is another existing gene finder compared to ExonHunter in the document, which also performs significantly worse than ExonHunter on the test set.\n4. TWINSCAN (version unknown) - This is another existing gene finder compared to ExonHunter in the document, which also performs significantly worse than ExonHunter on the test set.\nIt is not specified in the document what versions of these gene finders are being compared to ExonHunter, but it is clear that ExonHunter is a more recent and improved version of these existing systems.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Adamts18 plays a role in hormone receptor signaling by being involved in the shedding of the epidermal growth factor receptor (EGFR) ligand TGF. The study found that a constitutively active form of Src, as well as v-Src, can enhance ADAM17-mediated shedding of TGF. Additionally, the study showed that inhibition of Src can reduce constitutive shedding of TGF in several cell lines. These findings suggest that ADAM17 is the principal TGF sheddase that is activated by Src in a manner that does not require its cytoplasmic domain. Furthermore, the study found that stimulation of ADAM17 by Src leads to enhanced paracrine signaling via the release of EGFR ligands into the culture supernatant, which could contribute to tumorigenesis by enhancing signaling via the EGFR and ERK in an autocrine and paracrine manner. Therefore, Adamts18 plays a role in hormone receptor signaling by being involved in the shedding of EGFR ligands, which can affect signaling via the EGFR and ERK pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in the shedding of the epidermal growth factor receptor (EGFR) ligand TGF.\n2. A constitutively active form of Src and v-Src can enhance ADAM17-mediated shedding of TGF.\n3. Inhibition of Src reduces constitutive shedding of TGF in several cell lines.\n4. ADAM17 is activated by Src in a manner that does not require its cytoplasmic domain.\n5. Stimulation of ADAM17 by Src leads to enhanced paracrine signaling via the release of EGFR ligands, which could contribute to tumorigenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in the shedding of the epidermal growth factor receptor (EGFR) ligand TGF.",
      "A constitutively active form of Src and v-Src can enhance ADAM17-mediated shedding of TGF.",
      "Inhibition of Src reduces constitutive shedding of TGF in several cell lines.",
      "ADAM17 is activated by Src in a manner that does not require its cytoplasmic domain.",
      "Stimulation of ADAM17 by Src leads to enhanced paracrine signaling via the release of EGFR ligands, which could contribute to tumorigenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ADAMTS18 is not known to be involved in the shedding of EGFR ligands. It is ADAM17 that is more commonly associated with the shedding of EGFR ligands such as transforming growth factor-alpha (TGF-).\n2. TRUE: Src kinase can enhance ADAM-mediated shedding, including ADAM17, which is known to shed EGFR ligands like TGF-.\n3. TRUE: It is reported in scientific literature that inhibition of Src kinase can reduce the shedding of various substrates, including EGFR ligands.\n4. TRUE: Src can activate ADAM17 independently of its cytoplasmic domain, meaning that the phosphorylation by Src that contributes to ADAM17 activation can occur outside of this domain.\n5. TRUE: Activation of ADAM17 by Src does lead to increased shedding of EGFR ligands, contributing to enhanced paracrine signaling. This process can contribute to tumorigenesis because it promotes cellular proliferation and survival.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Thiazovivin's mode of action appears to be related to its effectiveness in reducing the duration of maximal electroshock seizures in albino rats. Specifically, the document states that Thiazovivin produced a significant dose-dependent decrease in the duration of the tonic extensor phase of hind legs in these rats. This suggests that Thiazovivin may work by reducing the severity or frequency of seizures, rather than completely preventing them.\nIt is worth noting that the document also mentions that Thiazovivin was found to be effective against PTZ-induced convulsions, but the effectiveness was dose-dependent. This suggests that Thiazovivin may have a complex mode of action that involves multiple mechanisms, including the reduction of seizure duration and the prevention of convulsions.\nOverall, based on the information provided, it can be inferred that Thiazovivin's mode of action is likely related to its ability to reduce the duration and severity of seizures in albino rats, possibly by modulating the excitability of neurons or the activity of neurotransmitters involved in seizure propagation. However, further research is needed to fully understand the mechanisms underlying Thiazovivin's anticonvulsant effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin decreases the duration of the tonic extensor phase of hind legs in albino rats in a dose-dependent manner.\n2. Thiazovivin was found to be effective against PTZ-induced convulsions in a dose-dependent manner.\n3. Thiazovivin's mode of action may involve reducing the severity or frequency of seizures.\n4. Thiazovivin's anticonvulsant effects might be through modulating the excitability of neurons or the activity of neurotransmitters.\n5. Further research is needed to fully understand the mechanisms underlying Thiazovivin's anticonvulsant effects.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin decreases the duration of the tonic extensor phase of hind legs in albino rats in a dose-dependent manner.",
      "Thiazovivin was found to be effective against PTZ-induced convulsions in a dose-dependent manner.",
      "Thiazovivin's mode of action may involve reducing the severity or frequency of seizures.",
      "Thiazovivin's anticonvulsant effects might be through modulating the excitability of neurons or the activity of neurotransmitters.",
      "Further research is needed to fully understand the mechanisms underlying Thiazovivin's anticonvulsant effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements regarding thiazovivin and its effects on albino rats, PTZ-induced convulsions, and its mode of action are too specific without additional context or source material. Since I don't have the necessary information to verify these claims, they are labeled as UNKNOWN.\n\nThe last statement can be considered generally true since most scientific statements regarding the effects of a substance like thiazovivin would conclude with an acknowledgment that more research is needed to fully understand the mechanisms of action.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  }
]